

EXHIBIT B

**(SECOND SUPPLEMENTAL AFFIDAVIT
OF ERIC M. GAIER, Ph.D.)**

(N.D.N.Y. No. 05-CV-00088))
<i>County of Tompkins v. Abbott Labs., et al.</i>)
(N.D.N.Y. No. 05-CV-00397))
<i>County of Cayuga v. Abbott Labs., et al.</i>)
(N.D.N.Y. No. 05-CV-00423))
<i>County of Madison v. Abbott Labs., et al.</i>)
(N.D.N.Y. No. 05-CV-00714))
<i>County of Cortland v. Abbott Labs., et al.</i>)
(N.D.N.Y. No. 05-CV-00881))
<i>County of Herkimer v. Abbott Labs. et al.</i>)
(N.D.N.Y. No. 05-CV-00415))
<i>County of Oneida v. Abbott Labs., et al.</i>)
(N.D.N.Y. No. 05-CV-00489))
<i>County of Fulton v. Abbott Labs., et al.</i>)
(N.D.N.Y. No. 05-CV-00519))
<i>County of St. Lawrence v. Abbott Labs., et al.</i>)
(N.D.N.Y. No. 05-CV-00479))
<i>County of Jefferson v. Abbott Labs., et al.</i>)
(N.D.N.Y. No. 05-CV-00715))
<i>County of Lewis v. Abbott Labs., et al.</i>)
(N.D.N.Y. No. 05-CV-00839))
<i>County of Chautauqua v. Abbott Labs., et al.</i>)
(W.D.N.Y. No. 05-CV-06204))
<i>County of Allegany v. Abbott Labs., et al.</i>)
(W.D.N.Y. No. 05-CV-06231))
<i>County of Cattaraugus v. Abbott Labs., et al.</i>)
(W.D.N.Y. No. 05-CV-06242))
<i>County of Genesee v. Abbott Labs., et al.</i>)
(W.D.N.Y. No. 05-CV-06206))
<i>County of Wayne v. Abbott Labs., et al.</i>)
(W.D.N.Y. No. 05-CV-06138))
<i>County of Monroe v. Abbott Labs., et al.</i>)
(W.D.N.Y. No. 05-CV-06148))
<i>County of Yates v. Abbott Labs., et al.</i>)
(W.D.N.Y. No. 05-CV-06172))
<i>County of Niagara v. Abbott Labs., et al.</i>)
(W.D.N.Y. No. 05-CV-06296))
<i>County of Seneca v. Abbott Labs., et al.</i>)
(W.D.N.Y. No. 05-CV-06370))
<i>County of Orleans v. Abbott Labs., et al.</i>)
(W.D.N.Y. No. 05-CV-06371))
<i>County of Ontario v. Abbott Labs., et al.</i>)
(W.D.N.Y. No. 05-CV-06373))
<i>County of Schuyler v. Abbott Labs, et al.</i>)
(W.D.N.Y. No. 05-CV-06387))

<i>County of Steuben v. Abbott Labs., et al.</i>)
(W.D.N.Y. No. 05-CV-06223))
<i>County of Chemung v. Abbott Labs., et al.</i>)
(W.D.N.Y. No. 05-CV-06744))
AND)
<i>County of Nassau v. Abbott Labs., et al.</i>)
(E.D.N.Y. No. 04-CV-5126))

City of Washington)

:ss:

District of Columbia)

Eric M. Gaier, Ph.D., being duly sworn, deposes and says:

I. Introduction

- (1) On November 24, 2008, I offered an Affidavit (“Gaier Affidavit”) in support of Defendant SmithKline Beecham Corporation’s, d/b/a GlaxoSmithKline’s (“GSK’s”) Motion for Partial Summary Judgment in the above-captioned New York County cases.¹ In that Affidavit, I reported the results of certain WAC test and “spread” calculations I performed for relevant GSK NDCs at the request of Counsel for GSK.²
- (2) On March 4, 2009, I offered a Supplemental Affidavit (“Gaier Supplemental Affidavit”) in which I responded to several criticisms of my analysis raised by plaintiffs’ expert Harris Devor in his February 11, 2009 Affidavit (“Devor Affidavit”). Among other things, I concluded:
 - Mr. Devor was incorrect (1) in his assertion that price concessions generated by chargeback contracts between GSK and certain purchasers should be accounted for as price concessions to *wholesalers* (rather than price concessions to the *providers* who actually received the discount, which was my approach), and (2) in his assertion that chargebacks, which occur only for certain sales, should be accounted for in a way that reduces the overall “average” price paid on all sales to or through wholesalers rather than just reducing the price paid on the sales associated with the chargebacks.³ I concluded that Mr. Devor’s method of accounting for chargebacks was inconsistent with the way the WAC test was performed and relied upon by this Court in the “Track One” MDL trial, makes no sense, and was

¹ I have previously summarized my qualifications to this Court and I will not repeat them here. See Gaier Affidavit, p. 3.

² As I previously stated, the calculations were performed for the period January 1, 1997 to December 31, 2005, the same time period for which discovery in this matter has been permitted.

³ As discussed further below, Mr. Devor has now changed his recommended method of allocating chargebacks and treating wholesaler sales under the WAC test so that it is very similar to mine.

inconsistent with the economics of GSK's pricing, the drug distribution system, and undisputed testimony from wholesalers.

- Utilization-based rebates to payors, which include PBMs and third-party payors ("TPPs"), were properly excluded from my analysis of the net price paid by a purchaser for purposes of the WAC test, since such rebates have no effect on what drug purchasers pay for GSK drugs. However, I further concluded that, even if I apply utilization-based rebates to PBMs and TPPs in a manner consistent with Mr. Devor's original assertion that "...only those rebates attributable to PBM Mail Order operations would properly be included," it makes virtually no difference to the results under the WAC test as applied to the 208 GSK NDCs at issue—that is, 207 of them would still pass the test.⁴

- (3) On June 16, 2009, Mr. Devor offered a Second Supplemental Affidavit ("Devor 2nd Supplemental Affidavit") in which, for the first time, he has attempted to apply fully the WAC test to the 208 NDCs at issue in GSK's motion. In addition, although I understand that GSK has not moved based on the AWP Spread Test, Mr. Devor has now also presented a second version of his application of the AWP Spread Test that is quite different from his first.

II. Overview of flaws concerning rebates in Mr. Devor's new WAC test application

- (4) In Mr. Devor's current application of the WAC test to the GSK NDCs at issue, he has essentially conceded the issue previously in dispute concerning how chargebacks and wholesaler sales should be treated. That is, based on my review of the computer programs Mr. Devor used and my ability to replicate his results, I have concluded that he is now appropriately considering price concessions generated by chargeback contracts with providers *separately* from prices paid by wholesalers for units not subject to a chargeback contract. Therefore, the fundamental remaining difference between the WAC test calculations currently offered by Mr. Devor and the calculations I offered in my Supplemental Affidavit ("alternative calculations") concerns a relatively simple question: should all utilization-based rebates to PBMs and TPPs be included in determining the relevant net sales price or not? Mr. Devor's original answer *was* no⁵—as is mine—but he has now changed his answer to yes. Below, I explain why my treatment of PBM and TPP rebates in my previous affidavit (my

⁴ Gaier Supplemental Affidavit, pp. 9-11. As explained in my Supplemental Affidavit, I also addressed Mr. Devor's original concerns related to rebates to GPOs and other classes of trade, as well as his complaint about my assumption concerning the 2% prompt-pay discount for a relatively small volume of GSK sales. As explained in my Supplemental Affidavit, I presented "alternative calculations" that accounted for these issues and again it made no difference in the results except for one NDC.

⁵ Mr. Devor previously stated, unequivocally, that "It is not my position that all PBM rebates should be included. Rather, only those rebates attributable to PBM Mail Order operations would properly be included." Devor Affidavit, February 11, 2009, p. 10, footnote 2.

“alternative calculations”) was appropriate, if not conservative. I also explain why Mr. Devor’s new WAC test calculations, which inappropriately now incorporate *all* utilization-based rebates to PBMs and TPPs, are inconsistent with the purposes of the WAC test and fundamental economics because they (1) fail to recognize that rebates to payors (such as PBMs, when they reimburse providers, and other TPPs) are fundamentally different from rebates to drug purchasers (such as wholesalers and providers), and (2) his calculations again miss the point of the WAC test because they effectively allocate PBM and TPP rebates to retail pharmacies who did not get them. I then demonstrate the singular importance of the remaining “rebate” issue by showing that if the rebates paid to PBMs and TPPs are properly accounted-for and allocated, it makes no difference whether Mr. Devor’s methodology for performing the WAC test is employed or whether my methodology is used. Either way, once the rebates are properly treated, a minimum of 205 of the 208 GSK NDCs at issue still pass the test.

A. My appropriate application of the WAC test, which is designed to compare published WACs to net prices paid by drug purchasers

- (5) The principle underlying the WAC test as articulated by the FTC (and relied on by this Court) is that “a list price ‘will not be deemed fictitious if it is the price at which substantial (that is, not isolated or insignificant) sales are made,’” which was deemed by this Court to be satisfied for a given NDC if more than 50% of the sales were within 5% of the published WAC.⁶ As I discussed in my Supplemental Affidavit, as a matter of economics, one should evaluate a “sale” at the last purchaser of a drug in the distribution chain for which GSK determines the price and compare the net purchase price paid by that customer to the published WAC. This is what my methodology does.
- (6) In applying the WAC test for GSK’s NDCs at issue, I calculate the net price paid by each drug purchaser, which is what should be compared to the published WAC, by including all credits, discounts, and rebates that could reasonably be said to reduce the net price paid by the purchaser, including any up-front discounts, chargebacks, distribution allowance adjustments, buy-in credits, prompt-payment discounts,⁷ and rebates paid to the purchaser (referred to in GSK’s data as “purchase-based rebates”). The main types of drug purchasers that could receive any of these price concessions are set forth on the left side of the graphic designated as Exhibit 24 to the deposition of

⁶ *In Re Pharmaceutical Industry Average Wholesale Price Litigation*, Findings of Fact and Conclusions of Law in the “Track One” MDL Trial of Class 2 and Class 3 Claims, June 21, 2007, slip op. at p. 167.

⁷ As I note in my original Affidavit, prompt-payment discounts are earned discounts associated with financing terms. As such, including these discounts, as I have, is conservative since they are not intended to reduce the provider’s purchase price. See Gaier Affidavit, p. 5.

David Brown, GSK's recently-deposed Rule 30(b)(6) witness on rebate issues. For ease of reference, I have attached that graphic as Attachment A.⁸ As shown, drug purchasers are broken into the categories of wholesalers, retail pharmacies, PBM-owned mail-order pharmacies, "contract sales" (e.g., hospitals and government purchasers that generate chargebacks), and direct purchasers (e.g., retail chains). In performing my WAC test calculations, I have included all of the price concessions listed above, all of which could arguably affect the net price of a drug paid by a drug purchaser, for all of these types of drug purchasers.

- (7) Not all manufacturer rebates, however, are paid to drug purchasers—a critical fact that is now being obfuscated by Plaintiffs. Substantial rebates are paid to "payors," including payors that do not purchase drugs at all but merely *reimburse* providers—the actual drug purchasers.⁹ GSK's data refers to such rebates as "utilization rebates." The most significant of these rebates are the rebates paid to Medicaid, which are utilization-based rebates that Mr. Devor and plaintiffs concede should not be included in applying the WAC test. The fundamental remaining difference between the parties, however, concerns whether to include the *other* utilization-based rebates paid to payors—namely those paid to TPPs and PBMs (in the latter case, when they have not purchased drugs but are merely reimbursing for drugs purchased by an independent purchaser on behalf of their TPP clients).
- (8) In my opinion, these utilization-based rebates should *not* be included in any attempt to determine the net price paid by a drug purchaser, because (among other reasons) these rebates *simply do not affect the net price of a drug that is paid by any wholesaler or provider, i.e., by any drug purchaser*. The evidence is clear that such utilization-based rebates are *not shared* with drug purchasers such as wholesalers, retail pharmacies (whether they purchase directly from GSK or from wholesalers), hospitals, or other providers. Moreover, in the case of utilization-based rebates paid to PBMs because of sales made through their PBM mail-order pharmacies, the rebates are most often *not retained* by the PBM that owns the mail order pharmacy, but rather are passed on to the PBM's TPP client. Nevertheless, as I described in my Supplemental Affidavit, in order to be very conservative I have included such PBM "mail-order rebates" in my WAC test analysis as if they *were all* retained by the PBM and as if they therefore *did* reduce the mail-order operation's drug purchase price.

⁸ I note that Mr. Brown succinctly explains each portion of Attachment A (the graphic) at pages 166-182 of his June 3, 2009 deposition, which is attached hereto as Attachment B for the Court's convenience.

⁹ In other words, these rebates are paid *to* the very "payors" that have filed AWP lawsuits, such as insurance companies, employee health plans, and Medicaid programs.

- (9) The fact that utilization-based rebates to PBMs and TPPs are not passed on to purchasers of GSK's drugs, including retail pharmacies, is explicitly documented in a study by the Department of Health and Human Services ("HHS") and is supported by the testimony of Mr. Brown. In its April 2000 report to the President, HHS succinctly and unequivocally states that a rebate "paid directly from the manufacturer to the PBM...does not affect the price paid by a wholesaler to a manufacturer for the drug, the price paid by a retail pharmacy to the wholesaler, or the price paid by the PBM to the pharmacy."¹⁰ Similarly, Mr. Brown testified:

Q All right. Now, with respect to utilization rebates that go to either PBMs or third-party payors, do any of those rebates get passed on in any way to actual purchasers of the drug?

A They do not.

Q Do they get passed on to wholesalers?

A They do not.

Q Do they get passed on to retail pharmacies?

A They do not.

Q Do they get passed on to any of the purchasing entities illustrated in this graphic [referring to the document now attached hereto as Attachment A]?

A My opinion, No.

Q Do utilization rebates of the kind we have been discussing to PBMs or third-party payers have any effect on the purchase price paid by any purchaser for a drug?

A They do not.¹¹

Based on my review of Mr. Brown's deposition and the graphic attached as Attachment A hereto, I understand that the green lines marked with green squares that extend from the manufacturer to the PBMs and TPPs represent the flow of utilization-based rebates. Importantly, this flow of rebates does not extend to any purchasers of GSK drugs, including retail pharmacy purchasers.

¹⁰ HHS report to the President, "Prescription Drug Coverage, Spending, Utilization, and Prices," April 2000, Chapter 3, p. 7. This Report is available on the Internet at <http://aspe.hhs.gov/health/reports/drugstudy/chap03.htm>

¹¹ Brown deposition, p. 175.

- (10) In fact, as I explained in my Supplemental Affidavit and as demonstrated by the dashed green line on the right side of the graphic in Attachment A, a significant portion of utilization-based rebates paid to PBMs is passed on to the PBMs' health plan clients and is therefore not retained by the PBMs.¹² In its April 2000 report to the President, HHS estimated that between 70% and 90% of utilization-based rebates paid to PBMs are passed on to the PBM's clients, that is, to insurers or employer health plans that *reimburse* for drugs, but do not purchase them.¹³ At any rate, regardless of the percentage of these utilization-based rebates that was shared by PBMs with their TPP clients, it makes no logical or economic sense to allocate the utilization-based rebates paid to PBMs and TPPs to drug *purchasers* that never received them. This flawed logic is exhibited by Mr. Devor's most recent calculations in a desperate attempt to fail GSK NDCs under the Court's WAC test.

B. Mr. Devor's inappropriate inclusion of all utilization-based rebates to PBMs and TPPs in his new WAC Test

- (11) Mr. Devor's new WAC test calculations now incorporate *all* utilization-based rebates paid by GSK to PBMs and TPPs. Doing so is inconsistent with the purpose of the WAC test—to compare the published WAC to the net purchase price paid by each purchaser. As I explained above, utilization-based rebates paid to payors such as TPPs and PBMs (particularly when they act on behalf of TPPs by reimbursing providers) simply have no effect on any purchaser's net price.¹⁴ Thus, the only conceivable way a utilization-based rebate to a PBM or TPP could reduce a net *purchase* price is if it was (1) paid to a PBM or TPP that also owns a mail-order pharmacy through which it purchases drugs and (2) not passed on from the PBM or TPP to its health plan customers. I have included all such potential rebates in my "alternative calculations," but Mr. Devor now includes billions of dollars of *additional* utilization-based rebates in determining net price under the WAC test. He does so even though, as I noted above, Mr. Devor himself previously conceded, "It is not my position that all PBM rebates should be included. Rather, only those rebates attributable to PBM Mail Order operations would properly be included." Despite this statement and without explanation, Mr. Devor now inappropriately includes *all* utilization-based rebates to PBMs and TPPs, the vast majority of which

¹² See Gaier Supplemental Affidavit, p. 10 and footnote 20.

¹³ HHS report to the President, "Prescription Drug Coverage, Spending, Utilization, and Prices," April 2000, Chapter 3, p. 8. I understand that the same 70% to 90% estimate was previously made by this Court in another opinion in the AWP litigation. See 230 F.R.D. 61 at 73.

¹⁴ As I previously stated, "because utilization rebates are not intended to reduce the price of pharmaceutical products *purchased by providers*, they are properly excluded from analysis of sales at or about WAC." Gaier Supplemental Affidavit, p. 9.

have no relationship to drugs *purchased* by their mail-order pharmacies and therefore could have no effect on the drug's purchase price.

- (12) To make matters worse, after inappropriately including utilization-based rebates that have no effect on the net price paid by any drug purchaser, Mr. Devor then effectively “allocates” those rebates to entities *that never received them*. In other words, after inflating the number of rebates by including rebates to PBMs and TPPs (not purchasers), Mr. Devor attributes *to retail pharmacy purchasers* the vast majority of the utilization-based rebates that GSK paid to PBMs and TPPs.¹⁵ The result is that units sold to retail pharmacy purchasers are failed in the WAC test because of the utilization-based rebates that GSK paid to the payors—rebates that the retail pharmacy purchasers did not receive. In other words, Mr. Devor's methodology allows the rebates to PBM and TPPs to fail units bought by retail pharmacy purchasers with no contract with GSK (who simply purchased GSK drugs through wholesalers at prices near WAC), thereby inappropriately failing a significant number of sales units purchased at or about WAC.
- (13) Ironically, this flawed approach is similar to the flawed approach that Mr. Devor originally took, but has now abandoned, with respect to discounted contract sales to providers that involved wholesaler “chargebacks”—where he misallocated chargebacks across all sales to or through wholesalers, including non-contract sales not associated with chargebacks, and calculated an “average” wholesaler's price that caused all wholesaler sales to fail the WAC test. Mr. Devor's “allocation” of PBM and TPP utilization-based rebates to retail pharmacies that did not get them constitutes yet another flawed approach that is inconsistent with the purpose of the WAC test and makes no economic sense.

C. Results of my “alternative calculations” and my adjustment to Mr. Devor's new WAC test methodology to account for his inappropriate treatment of utilization-based rebates to PBMs and TPPs

- (14) While I do not agree that any utilization-based rebates should be included in the WAC test, as I described above and in my Supplemental Affidavit, I previously performed a set of “alternative calculations” that includes utilization-based rebates paid to PBM and TPP mail-order pharmacies. As stated in my Supplemental Affidavit, 207 of 208 of the GSK NDCs at issue passed the WAC test

¹⁵ Specifically, Mr. Devor allocates ORS utilization-based rebate dollars across all units of utilization that generated the rebates, regardless of whether those units were dispensed by a PBM or TPP mail-order operation (on the one hand) or (on the other hand) by a retail pharmacy provider that is not owned by the PBM or TPP and is completely independent from the PBM or TPP (*i.e.*, a retail pharmacy that was simply reimbursed by a PBM or TPP). See Devor 2nd Supplement Affidavit, pp. 5-6.

under those alternative calculations. In addition, since receiving Plaintiffs' Sur-Reply Memorandum of Law dated March 18, 2009, I performed a "sensitivity analysis" of my alternative calculations to make sure I have properly addressed all of the concerns raised by plaintiffs' counsel in that Memorandum.¹⁶ The results are set forth in Attachment C hereto. As shown in Attachment C, 206 of the 208 GSK NDCs at issue continue to pass the WAC test even after taking into account all of the technical concerns previously expressed by plaintiffs' counsel, so that the only remaining issue is not a technical one but is the PBM and TPP rebate issue I discussed above. The 206 NDCs that pass after implementing these refinements account for \$2.098 billion or 97.9% of plaintiffs' alleged reimbursements for all of the GSK drugs at issue in the litigation. Attachment D reports the year-by-year results for the 208 NDCs placed at issue in GSK's Motion for Partial Summary Judgment.

- (15) In fact, in an effort to see whether it is the PBM and TPP utilization-based rebate issue or a technical data issue that is causing the differences in results between my WAC test analysis and Mr. Devor's, I also performed another sensitivity analysis. Specifically, I replicated Mr. Devor's WAC test analysis by using the data and computer programs he used when he attempted to run the test (which were produced by plaintiffs' counsel). Then, using his method of analysis, I included only the portion of disputed PBM and TPP utilization-based rebates conceivably related to purchases by PBM and TPP mail-order pharmacies, as I previously agreed to do in my "alternative calculations" for purposes of the WAC test motion only, and I allocated those rebates to the correct entity (i.e., the PBM or TPP

¹⁶ To address these concerns, I refined the WAC test calculations I presented in my Supplemental Affidavit as follows:

- Instead of relying on publicly available PBM 10-K reports and other documents, I use rebate utilization data that was recently produced by GSK to determine, for each GSK NDC, the percentage of utilization-based rebates conceivably related to PBM and TPP mail-order operations. I note that, according to the GSK data manual produced in this litigation, utilization-based rebates loaded to the old SmithKline Beecham IMHC system before its 2001 merger with Glaxo Wellcome were not recorded on an NDC level in some instances, but rather were allocated to a single NDC in a product family. My refined WAC test calculations account for this issue by allocating such rebates within a drug family to all rebated NDCs in the drug family, pro-rated by sales. See *Confidential Stipulation of Facts Concerning GSK Sales Datasets and Data Systems*, November 9, 2005, p. 13.
- By relying on the recently produced GSK utilization data, I am able to arrive at a mail-order penetration rate without relying on a count of "net claims," which plaintiffs' counsel criticized.
- I have allocated the relevant mail order utilization-based rebates to the GSK drug sales that, according to wholesaler data, actually went to PBM/TPP mail order entities. The data shows that PBM and TPP mail-order pharmacies (with few exceptions) purchased GSK drugs from wholesalers and without any contract with GSK. I have therefore allocated the utilization-based rebates paid due to GSK drug purchases by PBM and TPP mail-order pharmacies to the sales that the wholesaler data show to have gone from them to such entities. I have determined which sales by wholesalers qualify by conducting a customer-by-customer, NDC-by-NDC review of the wholesaler sales data. Specifically, I have searched the wholesaler sales data for the top 65 utilization-rebate earners, which together account for over 98% of all of GSK's utilization-based rebates. Thus, I have now accounted for the wholesaler classes of trade that plaintiffs' counsel argue should have been included in my prior "alternative" analysis.

mail-order pharmacy—not retail pharmacies that did not receive the rebate). The results were nearly identical to the results of my own most recent application of the test. The “adjusted” Devor results are shown in Attachment E. Specifically, 205 of the 208 GSK NDCs at issue pass the WAC test after making only the adjustments to his treatment of PBM and TPP utilization-based rebates described above.¹⁷ These 205 NDCs account for \$2.100 billion or 98.0% of plaintiffs’ alleged reimbursements for the GSK drugs at issue in the litigation. Now, the only fundamental difference that remains between our calculations concerns the treatment of utilization-based rebates to PBMs and TPPs.¹⁸

- (16) Finally, using my latest, most refined methodology for applying the test, I further tested what would happen if *all* utilization-based rebates to PBMs and TPPs were, *contrary to the purpose of the test and economic logic*, nevertheless *included* as if they were purchased-based rebates, but correctly *allocated* so that only the GSK drug *purchases* that were *actually made by PBM and TPP-owned mail-order pharmacies* would be affected by the rebates. Even with this extreme approach, I found that 205 of the 208 GSK NDCs at issue in GSK’s Motion continue to pass the WAC test. These 205 NDCs, which I have identified with a “†” in Attachment C, account for \$2.098 billion or 97.9% of plaintiffs’ alleged reimbursements for the challenged GSK drugs.

D. The results of the WAC test when properly applied are consistent with the basic economics of brand-name drug pricing

- (17) Using the results from my most refined WAC test calculations, counsel for GSK have asked me to quantify the size of each of the following channels of GSK sales, expressed as a percentage of total GSK sales evaluated at WAC, for the 208 NDCs at issue in GSK’s Motion: (1) direct sales to non-wholesalers such as major retail chain pharmacies, (2) non-contract sales to wholesalers not associated with mail-order operations, most of which are then sold by wholesalers to retail pharmacies, (3) non-contract sales to wholesalers where the drugs are then purchased by PBM or TPP-owned mail-order pharmacy operations, and (4) sales through wholesalers pursuant to a chargeback contract (e.g., to hospitals and government entities). I present these statistics in Table 1 below across the 208 NDCs at issue. In addition, I have annotated the graphic attached as Attachment

¹⁷ I have included the results only for the 208 NDCs at issue in GSK’s Motion, not all 262 GSK NDCs at issue in the case. Attachment F reports the year-by-year results of adjusting Mr. Devor’s calculations for the 208 NDCs at issue in GSK’s Motion.

¹⁸ As stated above, based on my analysis of Mr. Devor’s computer programs and my ability to reconcile differences in our results by adjusting only his treatment of utilization-based rebates, I have also concluded that Mr. Devor has now conceded that I previously treated chargeback sales involving wholesalers correctly, as Mr. Devor’s WAC test calculations now appropriately consider price concessions generated by chargeback contracts with providers separately from prices paid by wholesalers for units not subject to a chargeback contract.

A by placing the relevant percentage for each provider channel into the appropriate provider box on the graphic. See Attachment G.

Table 1: GSK's sales by channel

GSK sales channel		Total dollars	Percent of total
Direct sales to non-wholesalers	Mostly to Major Retail Chain Pharmacies	\$18.0 b	17.3%
Sales through wholesalers	Sales without GSK contracts other than Mail Order Pharmacy sales (almost all to Retail Pharmacies)	\$65.3 b	62.6%
	Sales without GSK contracts to Mail Order Pharmacies	\$7.7 b	7.4%
	Sales pursuant to a GSK "chargeback" contract (e.g., to hospitals and govt. entities)	\$13.3 b	12.7%
Grand total		\$104.2 b	100%

- (18) The fundamental reason that the GSK drugs at issue pass the WAC test is that, regardless of Mr. Devor's flawed attempts to "fail" GSK NDCs at issue, the fundamental facts are that (1) 62.6% of the GSK drugs at issue in the motion are sold through wholesalers to retail pharmacies with no GSK contract, and virtually all of these sales were made within 5% of WAC,¹⁹ and (2) most of GSK's direct sales (e.g., its sales to chain pharmacies), which account for another 17.3% of GSK's sales, were also made within 5% of WAC.²⁰ That is, in the aggregate more than 75% of GSK's sales of the NDCs at issue were made through the two sales channels where there is very little discounting for brand-name drugs. No matter what discounts or rebates were provided by GSK when drugs were sold through *other* sales channels (such as sales to hospitals and entities like the V.A.), the majority of which are *not* reimbursed by Medicaid, the WAC test is easily passed because well over 50% of the sales of brand-name drugs are made with little discounting to the retail and chain pharmacy channels. That is a fundamental fact of the economics of the brand-name business model.

¹⁹ If my most recent, very conservative assumptions are used, about \$0.9 billion of these sales would fail the test due to periodic concessions to wholesalers.

²⁰ Of the \$18 billion in direct sales, about \$1.4 billion would fail the test if my most recent, very conservative assumptions are used. Thus, the direct sales that "pass" represent 15.9% of the GSK total for these NDCs, and those that fail represent 1.3% of that total.

III. Mr. Devor's inconsistent and inappropriate application of the "AWP Spread Test"

- (19) In his 2nd Supplemental Affidavit, Mr. Devor also offers revised calculations of "spreads" between "GSK's average sale price ('ASP') to providers for subject NDCs and the published AWP for corresponding GSK NDCs."²¹ These calculations (1) represent an entirely new approach to the AWP "spread" methodologies offered previously by both Mr. Devor and plaintiffs' counsel, (2) are inconsistent with the purpose of the AWP "spread" test, and (3) reflect, in my view, another desperate attempt to fail GSK's NDCs. Furthermore, nothing has been offered by plaintiffs' counsel or expert that alters my original conclusion that all but 4 of the 208 NDCs at issue pass the AWP "spread" test. See Gaier Affidavit at ¶¶ 8-9.²²
- (20) The purpose of the AWP "spread" test, as I understand it, is to measure, for each NDC, the difference between the published AWP and the average net purchase price paid by providers who dispense drugs under circumstances eligible for reimbursement by the New York Medicaid program. This is what my original methodology did. As described in my original affidavit, consistent with the "spread" methodology first described by plaintiffs' counsel in the July 11, 2007 Declaration of Joanne M. Cicala, I began my calculation of the average net purchase price paid by Medicaid providers for each NDC by using wholesaler data for the classes of trade alleged by plaintiffs' counsel to be relevant in the New York Medicaid context ("Plaintiffs' Alleged Medicaid Classes of Trade").²³ I then accounted for all discounts, rebates, and other price concessions given by GSK to the providers in the Plaintiffs' Alleged Medicaid Classes of Trade.²⁴ Because I thus focused on the net prices providers in Plaintiffs' Alleged Medicaid Classes of Trade actually paid to acquire drugs from wholesalers (and because I incorporated rebates, etc., paid to those same providers), it continues to be my opinion that my methodology satisfies the purpose of the AWP "spread" test.²⁵

²¹ Devor 2nd Supplement Affidavit, p. 2.

²² I note that the 4 NDCs at issue that do not pass the "spread" test do not exhibit the "megaspreads" that have concerned this Court. Cimetidine NDCs 58437000218 and 58437000225 have "spreads" of 51.5% and 41.4%, respectively. Lanoxin NDC 00173024255 has a "spread" of 36.6%. Because data are not available for the fourth NDC, Lanoxin NDC 00173024955, I am unable to conclude that this NDC passes the "spread" test and so have included it in the "fail" column.

²³ See Declaration of Joanne M. Cicala in Opposition to Defendants' Joint Motion to Dismiss the First Amended Consolidated Complaint, dated July 11, 2007. I note that despite plaintiffs' previous criticism (in the context of GSK's motion) of my use of wholesaler sales data to calculate "spreads," the "spread" calculations most recently offered Mr. Devor rely almost entirely on wholesaler sales data.

²⁴ Gaier Affidavit, pp. 6-7.

²⁵ In my Supplemental Affidavit, I responded to concerns raised by plaintiffs' counsel concerning my use of wholesaler data, along with other data sources, to calculate "spread." See Gaier Supplemental Affidavit, p. 13. Nothing offered by plaintiffs' counsel or expert has altered my opinion about the appropriateness of relying on wholesaler data to calculate

- (21) In contrast, each of the two AWP “spread” calculations offered by Mr. Devor to date are inconsistent with the purpose of the “spread” test and are also inconsistent with one another. In his Supplemental Affidavit, Mr. Devor offered his first “spread” calculations (“original ‘spread’ calculations”), which he says were based on GSK’s sales data and the “classes of trade [that] would appear in the data [I] used to perform [my] WAC List Price Test calculations.”²⁶ However, for this calculation, Mr. Devor excluded from his analysis all of the GSK sales to wholesalers for which there was no subsequent discount or rebate contract with any provider—that is, he excluded approximately 70% of GSK’s sales.²⁷ Given that the vast majority of the sales he excluded were sales at close to WAC with no discounting, it is entirely unsurprising that he was able to make many drugs fail the AWP “spread” test—but his results were meaningless. I note that with respect to the sales Mr. Devor did analyze in his original “spread” calculations, he at least got a few things right. That is, he did not include *any* utilization-based rebates, nor did Mr. Devor suggest anywhere in his Supplemental Affidavit that including such rebates would be appropriate. In fact, the classes of trade that Mr. Devor deemed relevant for the “spread” test in his original “spread” calculations did not include any GSK class of trade pertaining to PBM and TPP utilization-based rebates, as shown in Exhibit B of his Supplemental Affidavit.
- (22) In contrast to his original “spread” calculations, the “spread” calculations currently offered by Mr. Devor in his 2nd Supplemental Affidavit (“revised ‘spread’ calculations”) now appropriately *include* the sales to wholesalers that he previously omitted. However, Mr. Devor reverses course with respect to his position on utilization-based rebates, in that he now inappropriately *includes* the vast majority of utilization-based rebates paid to entities in the classes of trade he previously excluded. As with his application of the WAC test, his insistence on including such rebates paid to PBMs and some TPPs totally skews his analysis. As I described above in the context of the WAC test, including utilization-based rebates to PBMs or TPPs as a measure of provider acquisition cost in the AWP “spread” test simply makes no sense, as these rebates are not paid to providers who dispense drugs to New York Medicaid recipients and therefore do not reduce their net purchase price. The result is that Mr. Devor’s inclusion of utilization-based rebates obscures the purpose of the “spread” test, which is to


the relevant providers’ net prices for purposes of the AWP “spread” analysis. In order to demonstrate the insignificance of plaintiffs’ concerns, however, I performed a sensitivity of my “spread” test in which I supplement the wholesaler data with data concerning all of GSK’s direct sales to non-wholesaler customers. I found that my conclusions were unaffected by this adjustment.

²⁶ Devor Supplemental Affidavit, p. 6.

²⁷ This was clear both from my review of the computer program Mr. Devor used in his original “spread” calculations, as well as from the list of the classes of trade he, himself, said he evaluated (listed in Exhibit B to Mr. Devor’s Supplemental Affidavit)—which did not include wholesalers.


measure the average net purchase price paid by providers in the classes of trade relevant to New York Medicaid and to compare it to the published AWP. If Mr. Devor's new AWP "spread" analysis is unchanged other than to fix his error with respect to his treatment of PBM and TPP utilization-based rebates, then his AWP "spread" calculations would yield results remarkably consistent with the results of my original "spread" calculations for the GSK NDCs at issue.

This the 2nd day of July, 2009.



ERIC M. GAIER, PH.D.
BATES WHITE, LLC
AFFIANT

Sworn to and subscribed before me this
2 day of July, 2009.



Notary Public

My Commission Expires: **SHENETTA M. HARDEMAN-JONES**
NOTARY PUBLIC DISTRICT OF COLUMBIA
My Commission Expires May 14, 2014

Attachment A

**Exhibit 24 (Graphic) to the Deposition of David Brown
on June 3, 2009**

Ex. 24 to David Brown Deposition



Attachment B

Excerpts from the Deposition of David Brown, GSK's 30(b)(6) Witness on Rebate Issues

UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MASSACHUSETTS
MDL NO. 1456 CIVIL ACTION: 01-CV-12257-PBS

IN RE: PHARMACEUTICAL INDUSTRY
AVERAGE WHOLESALE PRICE LITIGATION

825 Third Avenue
New York, New York

June 3, 2009

9:45 a.m.

VIDEOTAPED DEPOSITION of DAVID B. BROWN before S.
Arielle Santos, Certified Shorthand Reporter, Certified
LiveNote Reporter and Notary Public.

HUDSON REPORTING & VIDEO

1-800-310-1769

New York
Connecticut

Hudson Reporting & Video
Nationwide 1-800-310-1769

New Jersey
Pennsylvania

Page 54

Page 56

1 DAVID B. BROWN
2 value of product purchased, formulary status or
3 predetermined market shares relative to competitors."
4 Do you see that?
5 A I do.
6 Q And is that consistent with your
7 understanding of -- of why GSK pays customer rebates
8 to the identified entities?
9 A I'm -- I'm not sure I understand some
10 of the terminology they used like value of product
11 purchased. I do go back to my statements before, we
12 compete to have -- so patients could have access to
13 our products. That is controlled mainly by
14 formulary. And then we do have performance based to
15 grow our volume consistent with good med- -- medical
16 practice through market share agreements.
17 Q Now, GSK, as we've -- as we've
18 discussed earlier, GSK does pay rebates to PBMs;
19 correct?
20 A On behalf of the third-party payers
21 that they represent, yes, we do.
22 Q GSK also pays rebates to PBMs in
23 connection with the PBMs own mail order activity,
24 does it not?
25 A We pay the rebate based on both

Page 55

1 DAVID B. BROWN
2 retail and mail order volume. We don't
3 differentiate.
4 Q And what do you mean when you refer
5 to retail volume?
6 A The PBM has a pharmacy network that
7 includes predominantly retail based pharmacies and
8 then it can or cannot have a mail order pharmacy.
9 Q And --
10 MR. HEROLD: We have been
11 going for more than an hour. Is
12 this a good time for a break?
13 MS. CICALA: As soon as we
14 finish this subject. Bear with me
15 for two minutes, Fred. Thanks.
16 BY MS. CICALA:
17 Q And are the reasons that GSK pays
18 rebates to PBMs consistent with the reasons that you
19 offered with respect to managed care and group
20 purchasing organizations?
21 A It's actually slightly different.
22 Q How so?
23 A We view as -- the PBM as a middleman
24 representing the third-party payers to us. And what
25 they are doing on behalf of the third-party payers

1 DAVID B. BROWN
2 is, again, the same thing they are looking at, the
3 efficacy and safety of our drug, doing a comparison,
4 seeing how it is effective versus the other drugs in
5 the class, and then they negotiate on half -- behalf
6 of the third-party payers to reduce the cost of the
7 drug to the third-party payers.
8 Q The rebate itself in the context of
9 the PBM is paid to the PBM; isn't that right, not the
10 third-party payer?
11 A It is paid to the PBM, but our
12 understanding is it's predominantly passed through to
13 the third-party payer.
14 Q Hm-hm. And what -- what is the basis
15 of that understanding?
16 A Basically, industry knowledge,
17 government reports where they'll cite that there may
18 be a range, but on average, 70 to 90 percent of the
19 rebate is passed onto the third-party payer.
20 Q Do -- do GSK's contract with PBM --
21 withdrawn.
22 Do you know whether GSK requires PBMs
23 to pass on the rebate it -- rebates it receives?
24 A It would be in each specific
25 contract. I would have to look at each contract.

Page 57

1 DAVID B. BROWN
2 Q Do you have any understanding one way
3 or the other whether that's an aspect of the
4 contracts, that GSK has with its PBMs?
5 A We normally don't address that, no.
6 Q Okay. Why don't we take a few minute
7 break and then we will resume.
8 THE VIDEOGRAPHER: This marks
9 the end of Videotape Number 1. The
10 time is 10:58 a.m. We are going off
11 the record.
12 (Whereupon a recess is
13 taken.)
14 THE VIDEOGRAPHER: This marks
15 the beginning of Videotape Number 2.
16 The time is 11:14 a.m. I am going
17 back on the record.
18 BY MS. CICALA:
19 Q Mr. Brown, returning to Exhibit 11,
20 the 20-F. And the second sentence -- sentence of
21 that exhibit, which reads, "These arrangements
22 require the customer to achieve certain performance
23 targets relating to value of product purchased
24 formulary status or predetermined market shares
25 relative to competitors."

15 (Pages 54 to 57)

New York
Connecticut

Hudson Reporting & Video
Nationwide 1-800-310-1769

New Jersey
Pennsylvania

<p style="text-align: right;">Page 66</p> <p>1 DAVID B. BROWN</p> <p>2 and product returns given or expected to be given,</p> <p>3 which vary by product arrangement and by buying</p> <p>4 groups."</p> <p>5 Q Do you -- do you understand that --</p> <p>6 well, withdrawn.</p> <p>7 Is -- is turnover essentially the</p> <p>8 same as revenue in the context of this 20-F?</p> <p>9 Do you know?</p> <p>10 MR. HEROLD: Objection to the</p> <p>11 form.</p> <p>12 THE WITNESS: Turnover to me</p> <p>13 are sales.</p> <p>14 BY MS. CICALA:</p> <p>15 Q Okay. And so can you explain what is</p> <p>16 meant by the sentence "Gross turnover is reduced by</p> <p>17 rebate discounts, allowances and products returns</p> <p>18 given or expected to be given, which vary by product</p> <p>19 arrangements and buying groups?</p> <p>20 MR. HEROLD: I am objecting</p> <p>21 to this. This is beyond the scope</p> <p>22 of the deposition. You're asking</p> <p>23 him now to become an accountant on</p> <p>24 net revenue issues, which is very</p> <p>25 different than what he was</p>	<p style="text-align: right;">Page 68</p> <p>1 DAVID B. BROWN</p> <p>2 items you just identified?</p> <p>3 A Including returns.</p> <p>4 Q Including returns, okay. And when</p> <p>5 GSK accrues for estimated -- do you -- do you</p> <p>6 understand the process by which GSK estimates the</p> <p>7 rebates for which it must accrue?</p> <p>8 A Again, it's pretty broad. I do have</p> <p>9 an understanding of the estimation process for</p> <p>10 rebates by customer-type purchaser, non-purchaser,</p> <p>11 the -- the like.</p> <p>12 MR. HEROLD: Are you talking</p> <p>13 about for accounting now or for --</p> <p>14 for something else? I just want to</p> <p>15 be clear.</p> <p>16 MS. CICALA: I am -- I am</p> <p>17 talking simply about the -- what</p> <p>18 information regarding rebates GSK</p> <p>19 reviews when it's accruing for them.</p> <p>20 MR. HEROLD: So accruing for</p> <p>21 account as opposed, for example,</p> <p>22 calculation of the AMPs or something</p> <p>23 else? That is what I am getting</p> <p>24 there.</p> <p>25 MS. CICALA: Yes, for</p>
<p style="text-align: right;">Page 67</p> <p>1 DAVID B. BROWN</p> <p>2 designated for.</p> <p>3 BY MS. CICALA:</p> <p>4 Q Just respond briefly. I'm -- I'm</p> <p>5 asking about the impact of rebates on revenue, which</p> <p>6 is within the scope in so far as it concerns rebates.</p> <p>7 A Could you ask me the question again?</p> <p>8 Q Sure. I would like your</p> <p>9 understanding of the second sentence that -- that</p> <p>10 begins with the word "gross turnover?"</p> <p>11 A Okay. And I will start with the word</p> <p>12 "gross turnover" to me means total sales of GSK.</p> <p>13 It's not customer specific, but it's probably product</p> <p>14 specific. And it's -- it's just all customer types,</p> <p>15 all the arrangements either direct, pretty much it's</p> <p>16 got to be direct sales. And then to get to a net</p> <p>17 number, net realized by GSK, not what we sold it at</p> <p>18 but the net realized by GSK, you would include</p> <p>19 deductions that would include rebates to purchasers</p> <p>20 and non-purchasers, chargebacks, which are basically</p> <p>21 to purchasers. There are other discount like the</p> <p>22 cash discount offered to purchasers and then</p> <p>23 allowances.</p> <p>24 Q So GS -- the -- the net amount</p> <p>25 realized by GSK would take into account all of the</p>	<p style="text-align: right;">Page 69</p> <p>1 DAVID B. BROWN</p> <p>2 accounting purposes.</p> <p>3 MR. HEROLD: For accounting?</p> <p>4 MS. CICALA: For accounting</p> <p>5 purposes.</p> <p>6 MR. HEROLD: All right.</p> <p>7 BY MS. CICALA:</p> <p>8 Q So it's -- it's -- let's -- let's</p> <p>9 talk about specific customer types.</p> <p>10 If GSK is -- is accruing for rebates</p> <p>11 paid to Staff Models -- Staff Model HMOs, what</p> <p>12 information would GSK review in order to determine</p> <p>13 how much to -- it needs to accrue for?</p> <p>14 A For Staff Model HMO?</p> <p>15 Q Yeah.</p> <p>16 A We would look at their past</p> <p>17 purchases. They are in-direct purchasers to the</p> <p>18 wholesaler, but they are on a contract price. So we</p> <p>19 do have their purchase data. We would look at the</p> <p>20 individual contract for each Staff Model including</p> <p>21 any performance conditions, and then we would</p> <p>22 estimate for the time period that we are accruing for</p> <p>23 what our expectation was of their performance.</p> <p>24 Q And if GSK is accruing for rebates</p> <p>25 paid to PBMs, what would GSK look at -- look at in</p>

18 (Pages 66 to 69)

New York
Connecticut

Hudson Reporting & Video
Nationwide 1-800-310-1769

New Jersey
Pennsylvania

<p style="text-align: right;">Page 70</p> <p>1 DAVID B. BROWN</p> <p>2 that context?</p> <p>3 MR. HEROLD: Objection. Same</p> <p>4 objection.</p> <p>5 THE WITNESS: Are you talking</p> <p>6 about for the accounting purposes?</p> <p>7 BY MS. CICALA:</p> <p>8 Q Yes.</p> <p>9 A To build -- again, with the PBM, we</p> <p>10 would look at the contract for the PBM, the</p> <p>11 third-party payers that they represent, whether they</p> <p>12 are adding third-party payers or subtracting</p> <p>13 third-party payers.</p> <p>14 Q Can you explain -- yes.</p> <p>15 Can you explain what you mean by</p> <p>16 that?</p> <p>17 A To us, again, the PBM is representing</p> <p>18 third-party payers and the volume of their -- the</p> <p>19 sales that we are talking about that we are going to</p> <p>20 look at are based on the members of the payers. The</p> <p>21 PBM doesn't have members. They represent employers,</p> <p>22 even government, private third-party payers. And in</p> <p>23 a contract cycle, they can have members be added and</p> <p>24 members go out.</p> <p>25 Q So is it fair to say, though, that</p>	<p style="text-align: right;">Page 72</p> <p>1 DAVID B. BROWN</p> <p>2 differentiate between retail and mail pharmacy. It's</p> <p>3 not the sale, it is the utilization of the members as</p> <p>4 prescriptions are being filled and accumulated.</p> <p>5 Hence, utilization rebate, that is the title usage.</p> <p>6 Q And if you're -- if GSK is accruing</p> <p>7 for rebates to be paid to -- to GPOs, what</p> <p>8 information would GSK review?</p> <p>9 MR. HEROLD: Objection to the</p> <p>10 form. He's testified that they</p> <p>11 don't pay rebates to GPS.</p> <p>12 BY MS. CICALA:</p> <p>13 Q And I -- all evidence, to the</p> <p>14 contrary, I am not trying to be slick about this.</p> <p>15 When -- when GSK is accruing for rebates paid to the</p> <p>16 GPO members, how does -- what information does GSK</p> <p>17 review?</p> <p>18 A It looks more at a Staff Model</p> <p>19 because the -- we are talking about the hospitals</p> <p>20 underneath the GPO -- the long term facility, the</p> <p>21 surgical centers, the members of the GPO who actually</p> <p>22 do take possession of our product. They are indirect</p> <p>23 purchasers to the wholesaler. So we are looking at</p> <p>24 their purchase pattern with the data we get from the</p> <p>25 wholesaler and then we look at the individual</p>
<p style="text-align: right;">Page 71</p> <p>1 DAVID B. BROWN</p> <p>2 the objective is to look at the volume of sales that</p> <p>3 are taking place?</p> <p>4 MR. HEROLD: Objection to the</p> <p>5 form.</p> <p>6 THE WITNESS: It is a -- it</p> <p>7 is a funny way to say it. It's</p> <p>8 looking at the utilization of the</p> <p>9 members of the third-party payers</p> <p>10 underneath that PBM contract. The</p> <p>11 PBM doesn't take possession. We</p> <p>12 don't sell to a PBM.</p> <p>13 BY MS. CICALA:</p> <p>14 Q Unless they have a mail-order</p> <p>15 pharmacy?</p> <p>16 A We don't sell to them either, yeah.</p> <p>17 Q Those -- those mail-order pharmacies</p> <p>18 would be indirect customers?</p> <p>19 A They are an indirect customer. They</p> <p>20 buy it through a wholesaler, correct.</p> <p>21 Q And presumably when you're accruing</p> <p>22 for rebates to be paid to PBMs you're also reviewing</p> <p>23 the sales taking place within the mail order</p> <p>24 component of the PBMs activities?</p> <p>25 A Again, we are looking -- we don't</p>	<p style="text-align: right;">Page 73</p> <p>1 DAVID B. BROWN</p> <p>2 contract. And if there are performance requirements,</p> <p>3 we will estimate where we think they are going to</p> <p>4 perform for the time period that we are accruing.</p> <p>5 Q The -- the PBM contracts may have</p> <p>6 performance requirements as -- as well; correct?</p> <p>7 A The PBM contracts do have performance</p> <p>8 -- can, yes.</p> <p>9 Q And so if -- if they have them, would</p> <p>10 that be reviewed by GSK when accruing for the rebates</p> <p>11 to the PBM as well?</p> <p>12 A We would look at the individual</p> <p>13 contracts of the PBM and try to estimate where we</p> <p>14 think the members, the utilization come in as</p> <p>15 performance requirements.</p> <p>16 Q What is the -- why does GSK pay</p> <p>17 rebates to the extent it does?</p> <p>18 Why does it pay rebates to PBMs</p> <p>19 connected with the -- with performance?</p> <p>20 MR. HEROLD: Objection to the</p> <p>21 form.</p> <p>22 THE WITNESS: We actually pay</p> <p>23 rebates so that the -- to reduce the</p> <p>24 cost of the third-party payers so</p> <p>25 their -- their members can have</p>

19 (Pages 70 to 73)

New York
Connecticut

Hudson Reporting & Video
Nationwide 1-800-310-1769

New Jersey
Pennsylvania

<p style="text-align: right;">Page 74</p> <p>1 DAVID B. BROWN</p> <p>2 access to our product. Performance</p> <p>3 takes two parts, basically access,</p> <p>4 formulary access is probably the key</p> <p>5 one. And again, it goes back to the</p> <p>6 pharmacy and therapeutic committee</p> <p>7 that looks at the safety and</p> <p>8 efficacy as we compare against the</p> <p>9 products in our class and then how</p> <p>10 the value that we bring, the cost.</p> <p>11 And then again, consistent with good</p> <p>12 medical practice in a competitive</p> <p>13 therapeutic class, we would like</p> <p>14 more of our product to be used so we</p> <p>15 will do a market share performance.</p> <p>16 BY MS. CICALA:</p> <p>17 Q To -- to encourage usage of your</p> <p>18 product?</p> <p>19 A To ensure access of our product and</p> <p>20 then to get the right economic value to the payer as</p> <p>21 far as a cost comparison to our competitors.</p> <p>22 Q Returning to -- to the 20-F under the</p> <p>23 section -- the -- the header turnover, do you see the</p> <p>24 sentence that begins with "Accruals are made at the</p> <p>25 time of sale." If you can look in the middle of that</p>	<p style="text-align: right;">Page 76</p> <p>1 DAVID B. BROWN</p> <p>2 Q Sure. In the -- for accounting</p> <p>3 purposes, is it -- is it your understanding that</p> <p>4 accruals are made at the time of sale for the</p> <p>5 estimated rebates based on available market</p> <p>6 information and historical experience?</p> <p>7 A Again, I am not an accountant but</p> <p>8 that is my understanding of it, to the best of my</p> <p>9 knowledge.</p> <p>10 Q Okay. Thank you.</p> <p>11 Now, on the same page here, the 20-F,</p> <p>12 do you see in the lower right corner there is a chart</p> <p>13 that is described as being a reconciliation of gross</p> <p>14 turnover to net turnover to the U.S. pharmaceutical</p> <p>15 business?</p> <p>16 A Up -- up on the title, it says</p> <p>17 "reconciliation," I do see that.</p> <p>18 Q Okay. And it sets forth information</p> <p>19 through the years 2005, 2004 and 2003.</p> <p>20 Do you see that?</p> <p>21 A I do.</p> <p>22 Q And focusing for a moment on 2005, I</p> <p>23 just want to make sure that we understand what this</p> <p>24 chart is representing.</p> <p>25 Do you see that -- for 2005 listed as</p>
<p style="text-align: right;">Page 75</p> <p>1 DAVID B. BROWN</p> <p>2 paragraph.</p> <p>3 A I do see that.</p> <p>4 Q Can you -- can you read that sentence</p> <p>5 into the record for me, please?</p> <p>6 A "Accruals are made at the time of</p> <p>7 sale for the estimated rebates, discounts for</p> <p>8 allowances payable or returns to be made based on</p> <p>9 available market information and historical</p> <p>10 experience."</p> <p>11 Q And with regard to rebates, is it --</p> <p>12 is it -- is that -- is that sentence consistent with</p> <p>13 your understanding of when accruals are made for</p> <p>14 rebates?</p> <p>15 MR. HEROLD: Objection unless</p> <p>16 you clarify this as for accounting</p> <p>17 purposes.</p> <p>18 MS. CICALA: For accounting</p> <p>19 purposes.</p> <p>20 THE WITNESS: Yeah. I'm --</p> <p>21 I'm sorry. I get -- I read the</p> <p>22 sentence above it, and so I got</p> <p>23 distracted. Can you ask your</p> <p>24 question again?</p> <p>25 BY MS. CICALA:</p>	<p style="text-align: right;">Page 77</p> <p>1 DAVID B. BROWN</p> <p>2 gross turnover we see 11,000,000,875 pounds?</p> <p>3 A I do see that.</p> <p>4 Q And from your earlier testimony,</p> <p>5 gross turn -- gross turnover means gross sales; is</p> <p>6 that right?</p> <p>7 A That's my understanding.</p> <p>8 Q Okay. And then the next century</p> <p>9 shows a chargeback -- a chargeback of 786 million</p> <p>10 pounds; is that right?</p> <p>11 A I am having trouble lining up the</p> <p>12 lines, but I -- I think that's right. Okay.</p> <p>13 Q And continuing, it then appears that</p> <p>14 we have U.S. government and state programs 775</p> <p>15 million pounds; is that right?</p> <p>16 A That is correct.</p> <p>17 Q And then it appears we have managed</p> <p>18 care and group purchasing organization rebates, 686</p> <p>19 million pounds; correct?</p> <p>20 A That is correct.</p> <p>21 Q And then the chart continues on the</p> <p>22 following page and has information relating to cash</p> <p>23 discounts, customer returns, prior year adjustments</p> <p>24 and other items.</p> <p>25 Do you see that?</p>

20 (Pages 74 to 77)

New York
Connecticut

Hudson Reporting & Video
Nationwide 1-800-310-1769

New Jersey
Pennsylvania

<p style="text-align: right;">Page 82</p> <p>1 DAVID B. BROWN</p> <p>2 The -- Fred, the -- the chart speaks</p> <p>3 for itself, and the chart, as the</p> <p>4 witness has agreed, indicates 686</p> <p>5 million in rebates paid to managed</p> <p>6 care and group purchasing</p> <p>7 organizations.</p> <p>8 BY MS. CICALA:</p> <p>9 Q You do see that in this chart, right,</p> <p>10 Mr. Brown?</p> <p>11 A And -- and again, we keep going</p> <p>12 around and around, around rebates paid to GPOs, me --</p> <p>13 they are not paid to the GPO, they are paid to the</p> <p>14 hospital underneath it.</p> <p>15 Q Right. We -- we have that</p> <p>16 understanding.</p> <p>17 A And then we also -- Managed Care</p> <p>18 entities are very broad, that includes predominantly</p> <p>19 third-party payers, not that -- who don't take</p> <p>20 possession.</p> <p>21 Q That is not my question. I am going</p> <p>22 to move to strike that.</p> <p>23 My question is whether the 20-F</p> <p>24 states that GSK paid \$686 million.</p> <p>25 According to GSK's own 20-F, did GSK,</p>	<p style="text-align: right;">Page 84</p> <p>1 DAVID B. BROWN</p> <p>2 expectation that it would be higher or lower than the</p> <p>3 5 to 6 percent range?</p> <p>4 A My expectation would be lower.</p> <p>5 Q And on what basis would you have that</p> <p>6 expectation?</p> <p>7 A Broadly put, our par time, as it</p> <p>8 ages, the rebates go up because we have to be more</p> <p>9 competitive. And Managed Care itself has evolved.</p> <p>10 Q In what way?</p> <p>11 A Two, when you look at, again, why we</p> <p>12 do rebating, for the safety, efficacy and the</p> <p>13 comparison of our value versus competitors in the</p> <p>14 therapeutic class. As manufacturers' products age in</p> <p>15 the therapeutic class, some go generic, and that puts</p> <p>16 pressure on the remaining products in that class to</p> <p>17 compete because of the cost differential to the</p> <p>18 payer. And then Managed Care entities themselves,</p> <p>19 because they have other alternatives in that</p> <p>20 therapeutic class, are more willing to restrict their</p> <p>21 formularies.</p> <p>22 Q And what -- and so what is GSK's</p> <p>23 response when a managed care entity is more willing</p> <p>24 to restrict its formulary?</p> <p>25 A Again, going back to why we contract,</p>
<p style="text-align: right;">Page 83</p> <p>1 DAVID B. BROWN</p> <p>2 in 2005, pay \$686 million in rebates to Managed Care</p> <p>3 and Group Purchasing Organizations?</p> <p>4 MR. HEROLD: Objection to the</p> <p>5 form.</p> <p>6 You can answer.</p> <p>7 THE WITNESS: Again, as it's</p> <p>8 defined poorly in here, we did pay</p> <p>9 686 million in rebates.</p> <p>10 BY MS. CICALA:</p> <p>11 Q You think that the 20-F is defined,</p> <p>12 the GSK rebate payments, poorly?</p> <p>13 A It doesn't define them hardly at all.</p> <p>14 It just says Managed Care entities, which is very</p> <p>15 broad and GPOs.</p> <p>16 Q Do you question that this amount was</p> <p>17 paid -- withdrawn.</p> <p>18 And I believe from your -- let me</p> <p>19 rephrase that.</p> <p>20 Do you have any understanding of what</p> <p>21 percentage of gross sales GSK paid in rebates to the</p> <p>22 entities identified in the 20-F for the years '97</p> <p>23 through '02?</p> <p>24 A I don't have that, no.</p> <p>25 Q Okay. Well, do you have any</p>	<p style="text-align: right;">Page 85</p> <p>1 DAVID B. BROWN</p> <p>2 we contract so that the patients of that third-party</p> <p>3 payer can have access to our product. We compete on</p> <p>4 the value our product brings. And so depending on</p> <p>5 the economics of the contract, it could be that we</p> <p>6 increased the discounts or the rebates offered.</p> <p>7 Q So GSK would have to increase its</p> <p>8 rebates in order to respond to a Managed Care</p> <p>9 organization, otherwise restricting its formulary?</p> <p>10 A Again, it's not a general statement.</p> <p>11 We respond to the situation that's unique to each</p> <p>12 customer and market.</p> <p>13 Q Why does GSK care if it's drugs are</p> <p>14 on the formulary or not?</p> <p>15 A We care that we want our -- the</p> <p>16 patients of that member, of that third-party payer to</p> <p>17 have access to our drug. And formulary is a list</p> <p>18 that is communicated by those pharmacies, doctors and</p> <p>19 the third-party payer that says we will reimburse.</p> <p>20 And it's very important to have your drug reimbursed</p> <p>21 so the patients can have access.</p> <p>22 Q And the -- so the rebate that you are</p> <p>23 paying in connection with this formulary placement is</p> <p>24 in part in response to competition in a therapeutic</p> <p>25 class; is that right?</p>

22 (Pages 82 to 85)

New York
Connecticut

Hudson Reporting & Video
Nationwide 1-800-310-1769

New Jersey
Pennsylvania

<p style="text-align: right;">Page 86</p> <p>1 DAVID B. BROWN</p> <p>2 A Yes.</p> <p>3 Q Has the -- in this context, has</p> <p>4 the -- has the -- has -- has the entity with</p> <p>5 formulary control informed GSK that -- that it has --</p> <p>6 that there was competition within the therapeutic</p> <p>7 class -- let me rephrase.</p> <p>8 How does GSK know whether there's</p> <p>9 competition in the therapeutic class?</p> <p>10 A A couple of ways. One, there's</p> <p>11 public data. We know what therapeutic class our</p> <p>12 products are in. We also track our competitors'</p> <p>13 products in that class, what our attributes are, what</p> <p>14 the value our product brings versus the value that</p> <p>15 our competitors' products bring.</p> <p>16 So there's internal review. And then</p> <p>17 in negotiating with either the third-party payer</p> <p>18 directly or with the PBM on behalf of the third-party</p> <p>19 payers, they will tell us that there's competition in</p> <p>20 the class.</p> <p>21 Q And they are telling you this even</p> <p>22 though -- even though the GSK product at issue is a</p> <p>23 brand drug; right?</p> <p>24 A Can you say that again? I must have</p> <p>25 missed that.</p>	<p style="text-align: right;">Page 88</p> <p>1 DAVID B. BROWN</p> <p>2 the formulary versus a competitor's?</p> <p>3 A That, actually, probably is going</p> <p>4 further than I would say. We offer rebates to the</p> <p>5 third-party payers to impact the value of our product</p> <p>6 versus competitors, reduce our costs. Mainly, we are</p> <p>7 looking for access of our product on that third-party</p> <p>8 payers formulary, and rarely is it -- have anything</p> <p>9 to do with what is the positioning of their</p> <p>10 competitor product.</p> <p>11 Q Okay. And what do you mean when you</p> <p>12 say positioning of the competitor product?</p> <p>13 A Again, maybe I used too much industry</p> <p>14 jargon. But basically, it's on the formula listed on</p> <p>15 the formulary.</p> <p>16 Q And it's correct, isn't it, that GSK</p> <p>17 will offer varying incentives depending on whether</p> <p>18 it's going to be an exclusive product within a</p> <p>19 therapeutic class or whether there will be other</p> <p>20 products listed as well?</p> <p>21 A Again, it's dependent on the</p> <p>22 negotiation with the third-party payer. You can</p> <p>23 offer for different -- and I will use the word</p> <p>24 "position" -- differently their positioning on the</p> <p>25 formulary, like it will be listed as one of two on</p>
<p style="text-align: right;">Page 87</p> <p>1 DAVID B. BROWN</p> <p>2 Q The TPP is informing GSK that there's</p> <p>3 competition in the class even though the GSK product</p> <p>4 at issue is a brand-brought product?</p> <p>5 A Correct.</p> <p>6 Q In this context, has the TPP</p> <p>7 concluded that the patient would be equally served by</p> <p>8 any of the competing products?</p> <p>9 A Their pharmacy and technology --</p> <p>10 their therapeutic committee, when they do a review,</p> <p>11 will say that there are -- I am not sure I am using</p> <p>12 the right word, but equivalent or can be used,</p> <p>13 multiple products can be used.</p> <p>14 Q So GSK has to offer a rebate or some</p> <p>15 other incentive in order for the TPP to select its</p> <p>16 product over the equivalent product; is that right?</p> <p>17 MR. HEROLD: Objection to the</p> <p>18 form.</p> <p>19 THE WITNESS: Can you restate</p> <p>20 it again? I'm sorry.</p> <p>21 BY MS. CICALA:</p> <p>22 Q When the TPP has concluded that there</p> <p>23 are equivalent products in the therapeutic class, GSK</p> <p>24 can decide to offer a rebate or some incentive to the</p> <p>25 TPP to place its version of the equivalent product on</p>	<p style="text-align: right;">Page 89</p> <p>1 DAVID B. BROWN</p> <p>2 the formulary to be covered, or one of three or even</p> <p>3 exclusive, it means it is the only product on the</p> <p>4 formulary.</p> <p>5 Q And is it fair to say that GSK will</p> <p>6 pay more of a rebate in connection with an exclusive</p> <p>7 placement in general than it would if it was one of</p> <p>8 the three?</p> <p>9 A That is fair in general.</p> <p>10 Q And is that -- sticking with that</p> <p>11 general proposition, would that hold true across the</p> <p>12 board for all the -- withdrawn.</p> <p>13 Do you know, Mr. Brown, if the data</p> <p>14 that GSK uses with it's estimating rebates for</p> <p>15 accrual purposes for -- in the -- in an accounting</p> <p>16 context is the same data that's been provided to --</p> <p>17 that's reflected in Exhibit 2 to this deposition,</p> <p>18 which is the list of the files that's been provided</p> <p>19 to plaintiffs?</p> <p>20 A Let me find it. That one. Okay.</p> <p>21 Depending on which table you are</p> <p>22 talking about, but if you're talking to where you</p> <p>23 have got it at, the holder level and it's got the</p> <p>24 utilization -- and again, it depends on which type of</p> <p>25 contract you are talking about. Purchasers, it will</p>

23 (Pages 86 to 89)

New York
Connecticut

Hudson Reporting & Video
Nationwide 1-800-310-1769

New Jersey
Pennsylvania

<p style="text-align: right;">Page 166</p> <p>1 DAVID B. BROWN</p> <p>2 Q Good afternoon, Mr. Brown.</p> <p>3 Fred Herold for GSK.</p> <p>4 A Okay.</p> <p>5 Q Now, Mr. Brown, you testified earlier</p> <p>6 today that you have examined the partial summary</p> <p>7 judgment motion that's been filed as well as certain</p> <p>8 court opinions relating to what we call the "WAC list</p> <p>9 price test"; is that right?</p> <p>10 MS. CICALA: Objection.</p> <p>11 Leading.</p> <p>12 THE WITNESS: Yes.</p> <p>13 BY MR. HEROLD:</p> <p>14 Q Do you have an understanding based on</p> <p>15 that review of what the WAC list price test is</p> <p>16 designed to examine?</p> <p>17 A Yes.</p> <p>18 Q And what is that understanding?</p> <p>19 A Percent of our sales, the purchasers</p> <p>20 that are at or near WAC, wholesale acquisition cost.</p> <p>21 Q Okay. Now, is there a difference</p> <p>22 between drug purchasers who buy and take possession</p> <p>23 of the drug and payers who later reimburse for the</p> <p>24 drug?</p> <p>25 MS. CICALA: Objection.</p>	<p style="text-align: right;">Page 168</p> <p>1 DAVID B. BROWN</p> <p>2 MR. HEROLD: I understand</p> <p>3 your position, but it is -- is about</p> <p>4 rebates. Because there is a</p> <p>5 difference in the types of rebates</p> <p>6 and this is foundation for that.</p> <p>7 BY MR. HEROLD:</p> <p>8 Q You can answer.</p> <p>9 A You have to repeat the question.</p> <p>10 MR. HEROLD: Can you read it</p> <p>11 back, please?</p> <p>12 (Whereupon Record is Read</p> <p>13 Back.)</p> <p>14 THE WITNESS: Wholesalers,</p> <p>15 retail chains, retail pharmacies,</p> <p>16 mail order, hospitals, government</p> <p>17 entities.</p> <p>18 BY MR. HEROLD:</p> <p>19 Q What about Staff Model HMOs?</p> <p>20 A Staff Model HMOs, correct.</p> <p>21 Q And can you give us examples of</p> <p>22 payers, both public and private?</p> <p>23 A Probably the biggest payer is</p> <p>24 Medicaid and big insurance companies like Cigna or</p> <p>25 Aetna, health plans like Blue Cross and Blue Shield</p>
<p style="text-align: right;">Page 167</p> <p>1 DAVID B. BROWN</p> <p>2 Beyond the scope of this deposition.</p> <p>3 MR. HEROLD: You can answer.</p> <p>4 THE WITNESS: Yes.</p> <p>5 BY MR. HEROLD:</p> <p>6 Q And what is that difference?</p> <p>7 A Purchasers actually buy either</p> <p>8 directly from GSK or they buy from a wholesaler and</p> <p>9 take possession of our product and then they will</p> <p>10 dispense the product to a patient, a member of a</p> <p>11 third-party payer. Third-party payers don't take</p> <p>12 possession. They basically take or reimburse for</p> <p>13 their members scrips, prescriptions as they are</p> <p>14 filled out at the retail pharmacy or mail order.</p> <p>15 Q And can you give us some examples of</p> <p>16 "drug purchasers," as you used that term?</p> <p>17 MS. CICALA: I am going to</p> <p>18 object entirely and I may, in fact,</p> <p>19 move to strike all of this as beyond</p> <p>20 the scope of our deposition.</p> <p>21 I understand you want this</p> <p>22 testimony, Fred, but this witness is</p> <p>23 designated to talk about rebates,</p> <p>24 not identify your purchasers. This</p> <p>25 is entirely improper.</p>	<p style="text-align: right;">Page 169</p> <p>1 DAVID B. BROWN</p> <p>2 of North Carolina, employers -- big employers like GM</p> <p>3 and small employers.</p> <p>4 Q And where do PBMs fit into this mix?</p> <p>5 A They basically act as a middle man</p> <p>6 between the drug manufacturers and the third-party</p> <p>7 payers. The third-party payers are truly reimbursing</p> <p>8 for the -- the drug and they contract with the PBM to</p> <p>9 provide P & T review, formulary recommendations and</p> <p>10 then negotiations by the PBM with the manufacturers</p> <p>11 to lower the drug cost.</p> <p>12 Q All right.</p> <p>13 A They also contract for other</p> <p>14 services.</p> <p>15 Q All right. Now, I want to show you a</p> <p>16 chart that we prepared to describe all of these</p> <p>17 various relationships.</p> <p>18 MS. CICALA: I am going to</p> <p>19 have a continuing objection. And</p> <p>20 I'm reserving all rights to strike</p> <p>21 this testimony entirely as beyond</p> <p>22 the scope of -- of today's</p> <p>23 deposition.</p> <p>24 BY MR. HEROLD:</p> <p>25 Q Mr. Brown, I would like to -- to have</p>

43 (Pages 166 to 169)

New York
Connecticut

Hudson Reporting & Video
Nationwide 1-800-310-1769

New Jersey
Pennsylvania

Page 170

Page 172

1 DAVID B. BROWN
 2 this chart, first of all, marked, I'm sorry, as
 3 Exhibit 24.
 4 (Whereupon the Exhibit is marked.)
 5 BY MR. HEROLD:
 6 Q Now, Mr. Brown, with respect to this
 7 chart, focusing on the left side, just labeled
 8 "purchaser side," what does that illustrate to you?
 9 A Basically it starts with the
 10 manufacturer, us, who make the medicine. Then we
 11 sell it either to a wholesaler, who then re-sells it
 12 into a secondary purchaser here. It could be PBM
 13 mail-order retail pharmacy or even to hospitals and
 14 government and pursuant to a contract between us and
 15 them. And then also could be direct purchasers other
 16 than wholesalers, like retail pharmacies that have
 17 big warehouses or mass merchandisers like Wal-Mart.
 18 Q All right. These various boxes
 19 represent the main type of purchasers?
 20 A They do.
 21 Q Now, do the entities on the left-hand
 22 side of this chart actually take possession of the
 23 drugs?
 24 A They do.
 25 Q How about the entities on the

Page 171

1 DAVID B. BROWN
 2 right-hand side?
 3 A They do not.
 4 Q Now, there's a notation on this chart
 5 that shows that these purchasing entities received
 6 purchase-based rebates.
 7 Do you see that?
 8 A I do.
 9 Q And can you tell us what a
 10 purchase-based rebate is?
 11 A It is an additional discount offered
 12 to a purchasing entity, like a hospital, that is --
 13 is either performance-based or has not earned at
 14 times of the original sale between the wholesaler and
 15 the entity and is based on performance. And we then
 16 send a rebate that lowers the cost to that holder at
 17 a later date.
 18 Q And do those purchase-based rebates
 19 reduce the net amount paid by the purchasers of the
 20 drugs?
 21 A They do.
 22 Q Now, turning your attention to the
 23 right side of this chart.
 24 Can you describe in your own words
 25 what show -- what is illustrated there?

1 DAVID B. BROWN
 2 A Again, starts on the far right with
 3 the third-party payers and health plans and Medicaid,
 4 they are the ultimate payer for the prescriptions for
 5 the members and they contract with the PBM -- can
 6 contract with the PBM to do the services that I
 7 mentioned before which are drug formulary,
 8 negotiation with manufacturers for rebates to lower
 9 their costs. But they end up paying the PBM, both
 10 the drug cost that they are reimbursing to the
 11 pharmacies and contractual amount based on whatever
 12 services they have.
 13 Q And what are the -- how does a -- how
 14 does a purchaser get paid or reimbursed through this
 15 system?
 16 A They have a contract with either the
 17 third-party payer like Medicaid or the insurance
 18 company or with the PBM that sets a reimbursement
 19 rate -- pharmacy reimbursement rate for the
 20 individual products.
 21 Q And what is your understanding on how
 22 PBMs and third-party payers set reimbursement rates
 23 for the third purchasers of drugs?
 24 A It is basically done at a product
 25 type level and I -- and I am saying that badly but

Page 173

1 DAVID B. BROWN
 2 branded pharmaceuticals would be reimbursed at a
 3 certain rate, generics at a different rate, even
 4 specialty drugs might even have a different
 5 reimbursement rate.
 6 Q And is the reimbursement rate that a
 7 PBM, for example, provides to a purchaser the same or
 8 different based on whether or not there's a
 9 utilization rebate that the PBM receives in
 10 connection with that drug?
 11 A It is the same regardless.
 12 Q Now, there's a notation on this chart
 13 at the top for member utilization rebates, do you see
 14 that, the green line?
 15 A Yes, I do.
 16 Q And can you describe for us what that
 17 illustrates?
 18 A Again, it deals with the contractual
 19 relationship either with the third-party payer -- or
 20 with the PBM on behalf of the third-party payer with
 21 a manufacture to pay rebates based on providing
 22 access to the members or some other performance
 23 requirement.
 24 Q And you said sometimes that rebates
 25 can go to a payer.

44 (Pages 170 to 173)

New York
 Connecticut

Hudson Reporting & Video
 Nationwide 1-800-310-1769

New Jersey
 Pennsylvania

Page 174

Page 176

1 DAVID B. BROWN
2 Can you describe what types of payers
3 get utilization rebates directly?
4 A Big insurance companies like National
5 Insurance, like Cigna, Aetna, government entities
6 like Medicaid.
7 Q And what entity gets the highest
8 level of rebates?
9 What payer entity gets the highest
10 level of utilization rebates?
11 MS. CICALA: Object to form.
12 THE WITNESS: Medicaid.
13 BY MR. HEROLD:
14 Q Now, did the utilization rebates that
15 go to payers go to purchasers of drugs?
16 MS. CICALA: Object to form.
17 THE WITNESS: No, they do
18 not.
19 BY MR. HEROLD:
20 Q And there's an arrow on this chart
21 between the PBMs and the TPP, it says "passed on
22 rebates."
23 Can you explain what that means?
24 A It is our contention that PBM's
25 contract on behalf of the third-party payers, that we

Page 175

1 DAVID B. BROWN
2 provide rebates to lower the costs to the third-party
3 payers and that part of that rebate is passed on to
4 the third-party payer.
5 Q All right. Now, with respect to
6 utilization rebates that go to either PBMs or
7 third-party payers, do any of those rebates get
8 passed on in any way to actual purchasers of the
9 drug?
10 A They do not.
11 Q Do they get passed on to wholesalers?
12 A They do not.
13 Q Do they get passed on to retail
14 pharmacies?
15 A They do not.
16 Q Do they get passed on to any of the
17 purchasing entities illustrated in this graphic?
18 A My opinion, no.
19 Q Do utilization rebates of the kind we
20 have been discussing to PBMs or third-party payers
21 have any effect on the purchase price paid by any
22 purchaser for a drug?
23 A They do not.
24 Q Now, on this chart, there are
25 PBM-owned mail-order pharmacies.

1 DAVID B. BROWN
2 Can you tell us what that is?
3 A It is a pharmacy, much like a retail
4 pharmacy except it's -- they don't do walk-in. They
5 are owned by the PBM and they provide dispensing of
6 product to eligible members through the mail.
7 Q And do PBM mail-order pharmacies, if
8 they are PBM that owns them, receives a rebate?
9 Does that reduce the purchase price
10 of the PBM mail-order pharmacy in your view?
11 A It does not.
12 Q Now, why not?
13 A Two reasons, first off, the PBM
14 actually buys -- the PBM mail order actually buys
15 through a wholesaler. They are paying basically the
16 same price as negotiated between the wholesaler and
17 other pharmacies, which we're assuming as WAC minus
18 2, somewhere north of that because that's what we
19 sell to the wholesaler at.
20 The second piece is, the rebates that
21 we are paying on that mail order utilization, in our
22 opinion, are being passed on for the most part to the
23 third-party plans to reduce their cost.
24 Q Are you familiar with -- I think you
25 testified earlier a few times about AMP, A-M-P.

Page 177

1 DAVID B. BROWN
2 A Yes.
3 Q What is AMP?
4 A It is the average manufacturers
5 price. It is a term in Medicaid to mean the price
6 paid by wholesalers to manufacturers for product
7 that's in the retail class of trade.
8 Q And is AMP designed to be a net price
9 -- the -- the relevant purchaser's pay?
10 A It is, yes.
11 Q Now, are you familiar with --
12 generally with how GSK and its predecessor companies
13 have calculated AMP between 1997 and 2005?
14 MS. CICALA: I have the same
15 objection as earlier. Reserving all
16 rights to strike another subject
17 matter beyond the scope of today's
18 deposition.
19 MR. HEROLD: You can answer.
20 THE WITNESS: I am.
21 BY MR. HEROLD:
22 Q And during that period 1997 through
23 2005 when GSK was calculating its AMP to determine
24 the purchase price and net purchase price for the
25 relevant purchasers, did it include any utilization

45 (Pages 174 to 177)

New York
Connecticut

Hudson Reporting & Video
Nationwide 1-800-310-1769

New Jersey
Pennsylvania

Page 178

Page 180

1 DAVID B. BROWN
2 rebates paid to PBMs or third-party payers?
3 A It did not.
4 Q Why not?
5 A We didn't believe it impacted the
6 price the purchaser paid.
7 Q And when GSK calculated its AMP for
8 that same period, did it include any rebates paid to
9 PBMs that owned mail-order pharmacies to try to
10 reflect the volume of the mail-order pharmacy
11 business?
12 A We did not.
13 Q Why not?
14 A Again, it did not impact the price
15 the purchaser paid to that mail-order pharmacy.
16 Q Okay. Now, if a mail-order pharmacy
17 would purchase directly from GSK -- I don't know if
18 that happened, but if it did and the mail-order
19 pharmacy received a purchase-based rebate, would GSK
20 count that rebate in its AMP calculations?
21 A We would.
22 Q Okay. I would like to show you
23 another document. We will mark as Exhibit 25.
24 (Whereupon the Exhibit is
25 Marked.)

Page 179

1 DAVID B. BROWN
2 BY MR. HEROLD:
3 Q Mr. Brown, have you ever seen
4 Exhibit 25 before?
5 A I have.
6 Q Can you tell us what it is?
7 A It is a -- a chart of customer types
8 with a fairly high level that charge a breakdown,
9 their AMP, what -- how we treat the sales and the
10 discounts within that grouping of customer type for
11 both AMP and best price. And it also includes where
12 we -- where our assumptions are based.
13 Q All right. Now, if you look about
14 two-thirds of the way down, there's an entry that
15 says "pharmacy benefit managers," and then it refers
16 to note 3.
17 Do you see that?
18 A Yes, I do.
19 Q And what does that tell us?
20 A That basically you have to go to note
21 3. It says that for PBM related to drugs -- for
22 rebates paid to PBM traded to drugs dispense either
23 within their mail order or their retail pharmacy
24 network, including those owned by the PBM, the
25 rebates are not counted as reduction of the AMP.

1 DAVID B. BROWN
2 Q All right. And is that consistent
3 with what you just told us?
4 A It is.
5 Q Now, Mr. Brown, the decision by GSK
6 not to count rebates paid to PBMs in its AMP, did
7 that calls the AMP to go up or down as opposed to if
8 GSK made a decision to include those rebates in its
9 AMP?
10 A The AMP would be higher -- it was
11 higher because we did not include the -- the rebates.
12 Q And if the AMP was higher, what, if
13 any, impact did that have on the amount that GSK paid
14 for the Medicaid rebate?
15 A It increased the amount paid to
16 Medicaid.
17 Q So it cost GSK additional money to
18 make that decision not to include PBM rebates in its
19 AMP calculation?
20 A It did.
21 Q And why is it that a -- not including
22 PBM rebates which makes the AMP go up would result in
23 greater manufacturer rebates to -- to Medicaid?
24 A Basically math. Medicaid gets a -- a
25 unit rebate amount of percentage. The higher the

Page 181

1 DAVID B. BROWN
2 number that's applied -- that is applied to, the
3 bigger the rebate.
4 Q All right. Now, we have talked today
5 about terms, such as "net turnover."
6 Do you remember that?
7 A Was it on the -- I think so, yeah.
8 It's on the GSK 20-F.
9 Q All right. Is there a difference
10 between the net turnover or the net amount realized
11 by manufacturer and the net price paid by purchasers
12 for drugs?
13 MS. CICALA: Objection,
14 again. Beyond the scope.
15 THE WITNESS: Yes.
16 BY MR. HEROLD:
17 Q And what is the -- I'm sorry.
18 Okay. And what is the difference?
19 A Basically what a purchaser pays is
20 what we invoice to them, net of any discounts that we
21 give. Net turnover or net sales includes -- starts
22 with "gross sales," which is our sales to purchasers,
23 includes all discounts, allowances, returns, anything
24 that's involving a negative to that sale, including
25 credits from missed shipments, everything, regardless

46 (Pages 178 to 181)

New York
Connecticut

Hudson Reporting & Video
Nationwide 1-800-310-1769

New Jersey
Pennsylvania

Page 182

Page 184

1 DAVID B. BROWN
2 whether it goes to a purchaser or to a third-party
3 payer.

4 Q And would the net prices paid by
5 purchasers, you said, included discount? Does it
6 also include rebate -- purchase-based rebates?

7 A It would, yes.

8 MR. HEROLD: That's all I
9 have. No further questions.

10 MS. CICALA: Nothing.

11 THE VIDEOGRAPHER: This marks
12 the end of today's deposition.

13 The time is 3:58 p.m.

14 And we are going off the
15 record.

16 (Whereupon Transcript is
17 designated confidential.)

18 (Whereupon Witness will read
19 and sign.)

20 (Whereupon Testimony
21 Concluded at 3:58 p.m..)

1 I, S. Arielle Santos, C.S.R., a Certified Shorthand
2 Reporter, Certified LiveNote Reporter do hereby certify:

3 That prior to being examined, the witness named in the
4 forgoing deposition, was by me duly sworn to testify the
5 truth, the whole truth, and nothing but the truth.

6 That said deposition was taken before me at the time and
7 place set forth and was taken down by me in shorthand and
8 thereafter reduced to computerized transcription under my
9 direction and supervision, and I hereby certify the foregoing
10 deposition is a full, true and correct transcript of my
11 shorthand notes so taken.

12 I further certify that I am neither counsel for nor
13 related to any party to said action nor in anywise interested
14 in the outcome thereof.

19 _____
20 S. Arielle Santos
20 Certified Shorthand Reporter
20 Certified LiveNote Reporter

Page 183

Page 185

1 ACKNOWLEDGEMENT

2 STATE OF _____
3 COUNTY OF _____

4
5 I, the undersigned, hereby certify that I have read
6 the transcript of my testimony taken under oath in my
7 deposition; that the transcript is a true and complete and
8 correct record of my testimony, and that the answers on the
9 record as given by me are true and correct.

10
11 _____
12 DAVID B. BROWN

13
14 Signed and subscribed to before me
15 This _____ day of _____,
16 20__.

17
18
19
20
21 _____
22 Notary Public

1 *** ERRATA SHEET ***

2 PAGE LINE FROM TO REASON

2	_____	_____	_____	_____
3	_____	_____	_____	_____
4	_____	_____	_____	_____
5	_____	_____	_____	_____
6	_____	_____	_____	_____
7	_____	_____	_____	_____
8	_____	_____	_____	_____
9	_____	_____	_____	_____
10	_____	_____	_____	_____
11	_____	_____	_____	_____
12	_____	_____	_____	_____
13	_____	_____	_____	_____

14 Subscribed and sworn to before
15 Me this day of 2009

16 NOTARY PUBLIC My Commission Expires

47 (Pages 182 to 185)

New York
Connecticut

Hudson Reporting & Video
Nationwide 1-800-310-1769

New Jersey
Pennsylvania

Attachment C

Refined calculation of percentage of sales “at or about” WAC for 208 GSK NDCs at issue¹

NDC-by-NDC results

¹ I do not agree with the criticisms offered by plaintiffs' counsel and by Mr. Devor concerning my previous calculations. I offer these calculations to demonstrate that these criticisms, with the exception of Mr. Devor's erroneous treatment of utilization-based rebates, do not affect the results and conclusions I previously offered.

Table C.1: Refined calculation of GSK NDCs with more than 50% of units sold “at or about” WAC¹

NDC	Drug detail	Expenditures reported in Plaintiff Exhibit B ²	Percentage of sales units “at or about” WAC ³	Percentage of sales dollars “at or about” WAC
00173067200	AGENERASE 150MG CAPSULE	\$18,225,494	81.5%*†	85.1%
00173068700	AGENERASE 15MG/ML ORAL SOLN	\$1,292,060	89.2%*†	92.2%
00173067900	AGENERASE 50MG CAPSULE	\$42,122	74.7%*†	82.8%
00007550040	ALBENZA 200MG TABLET	\$60,720	79.0%*†	85.9%
00173056100	AMERGE 1MG TABLET	\$340,426	91.1%*†	92.4%
00173056200	AMERGE 2.5MG TABLET	\$3,413,429	85.7%*†	86.9%
00029604412	AMOXIL 200MG TABLET CHEW	\$2,453	95.7%*†	97.6%
00029604420	AMOXIL 200MG TABLET CHEW	\$3,287	50.6%*	80.6%
00029604854	AMOXIL 200MG/5ML SUSPENSION	\$39,534	91.4%*†	95.0%
00029604855	AMOXIL 200MG/5ML SUSPENSION	\$78,316	94.9%*†	97.7%
00029604859	AMOXIL 200MG/5ML SUSPENSION	\$1,125,534	96.0%*†	98.2%
00029604512	AMOXIL 400 MG TABLET CHEW	\$82,274	93.6%*†	95.6%
00029604520	AMOXIL 400MG TABLET CHEW	\$39,200	88.1%*†	91.9%
00029604954	AMOXIL 400MG/5ML SUSPENSION	\$145,711	91.5%*†	95.8%
00029604612	AMOXIL 500MG TABLET	\$29,272	98.2%*†	99.4%
00029604620	AMOXIL 500MG TABLET	\$12,605	88.5%*†	91.8%
00029604712	AMOXIL 875MG TABLET	\$197,938	97.8%*†	98.6%
00029604720	AMOXIL 875MG TABLET	\$248,640	95.5%*†	96.1%
00029604725	AMOXIL 875MG TABLET	\$12,061	96.0%*†	96.4%
00029608522	AUGMENTIN 125-31.25 SUSPEN	\$5,042,231	90.3%*†	92.8%
00029608523	AUGMENTIN 125-31.25 SUSPEN	\$261,545	94.2%*†	95.0%
00029608539	AUGMENTIN 125-31.25 SUSPEN	\$541,708	70.1%*†	71.2%
00029607347	AUGMENTIN 125-31.25 TAB CHEW	\$61,067	88.2%*†	89.4%
00029608729	AUGMENTIN 200-28.5 SUSPEN	\$381,039	91.9%*†	92.6%
00029608739	AUGMENTIN 200-28.5 SUSPEN	\$551,323	92.9%*†	93.7%
00029608751	AUGMENTIN 200-28.5 SUSPEN	\$5,374,365	93.7%*†	94.8%
00029607112	AUGMENTIN 200-28.5 TAB CHEW	\$91,674	92.8%*†	93.8%

¹ This is a NDC-by-NDC summary for the years 1997-2005 for which information is available.

² I obtained the expenditure information directly from Exhibit B of Plaintiffs’ Revised First Amended Consolidated Complaint. Because these expenditures serve illustrative purposes only, I have not independently verified their accuracy.

³ As in my original affidavit, I placed an asterisk next to the units sold “at or about” WAC percentage for each NDC that has an AWP “spread” of less than or equal to 30% for the relevant period. I have not reproduced the results of my “spread” analysis here. I have also added a “†” next to the units sold “at or about” WAC percentage for each NDC that passes the WAC test after inclusion of *all* GSK utilization-based rebates to PBMs and TPPs.

Table C.1 continued

NDC	Drug detail	Expenditures reported in Plaintiff Exhibit B ²	Percentage of sales units "at or about" WAC ³	Percentage of sales dollars "at or about" WAC
00029607527	AUGMENTIN 250-125 TABLET	\$8,190,422	77.3%*†	83.1%
00029609022	AUGMENTIN 250-62.5 SUSPEN	\$12,958,756	84.5%*†	87.8%
00029609023	AUGMENTIN 250-62.5 SUSPEN	\$1,517,244	94.5%*†	95.6%
00029609039	AUGMENTIN 250-62.5 SUSPEN	\$1,086,310	65.3%*†	67.1%
00029607447	AUGMENTIN 250-62.5 TAB CHEW	\$1,118,690	93.6%*†	94.8%
00029609229	AUGMENTIN 400-57 SUSPEN	\$1,214,455	90.0%*†	91.2%
00029609239	AUGMENTIN 400-57 SUSPEN	\$2,323,109	93.8%*†	94.7%
00029609251	AUGMENTIN 400-57 SUSPEN	\$16,542,127	91.5%*†	93.1%
00029607212	AUGMENTIN 400-57 TAB CHEW	\$2,179,443	94.8%*†	95.3%
00029608012	AUGMENTIN 500-125 TABLET	\$21,921,921	87.5%*†	90.8%
00029608612	AUGMENTIN 875-125 TABLET	\$26,493,419	89%*†	91.8%
00029609422	AUGMENTIN ES-600 SUSPENSION	\$808,810	97.9%*†	98.5%
00029609424	AUGMENTIN ES-600 SUSPENSION	\$1,164,532	94.3%*†	96.4%
00029609429	AUGMENTIN ES-600 SUSPENSION	\$265,781	97.8%*†	98.4%
00029609439	AUGMENTIN ES-600 SUSPENSION	\$1,465,455	95.2%*†	96.5%
00029609445	AUGMENTIN ES-600 SUSPENSION	\$3,207,854	95.6%*†	97.0%
00029609451	AUGMENTIN ES-600 SUSPENSION	\$2,830,137	98.3%*†	98.8%
00029609628	AUGMENTIN XR 1000-62.5 TAB	\$689,056	78.8%*†	79.9%
00029609640	AUGMENTIN XR 1000-62.5 TAB	\$1,476,805	97.8%*†	98.1%
00029609648	AUGMENTIN XR 1000-62.5 TAB	\$138,343	94.2%*†	95.7%
00029609660	AUGMENTIN XR 1000-62.5 TAB	\$1,035,534	98.3%*†	98.7%
00029315818	AVANDIA 2MG TABLET	\$5,557,278	72.3%*†	75.9%
00029315913	AVANDIA 4MG TABLET	\$20,997,346	84.9%*†	87.3%
00029315918	AVANDIA 4MG TABLET	\$6,963,246	57.8%*†	61.7%
00029315920	AVANDIA 4MG TABLET	\$27,044,424	68.6%*†	71.2%
00029316013	AVANDIA 8MG TABLET	\$32,995,402	88.6%*†	90.4%
00029152722	BACTROBAN 2% CREAM	\$3,946,032	90.5%*†	91.8%
00029152725	BACTROBAN 2% CREAM	\$10,439,197	94.9%*†	95.6%
00029152522	BACTROBAN 2% OINTMENT	\$5,755,261	71.2%*†	73.8%
00029152525	BACTROBAN 2% OINTMENT	\$7,038,095	93.2%*†	94.1%
00029152544	BACTROBAN 2% OINTMENT	\$6,822,477	73.2%*†	75.8%
00029152611	BACTROBAN NASAL 2% OINTMENT	\$586,740	61.5%*†	60.9%
00173031288	BECLOVENT INHALER	\$7,295,598	61.4%*†	69.1%
00173038879	BECONASE AQ 0.042% SPRAY	\$7,782,163	70%*†	77.9%
00173039501	CEFTIN 125MG TABLET	\$34,621	69.2%*†	79.3%
00173040600	CEFTIN 125MG/5ML ORAL SUSP	\$2,107,728	90.2%*†	92.4%
00173038700	CEFTIN 250MG TABLET	\$3,889,332	86.2%*†	90.7%
00173038742	CEFTIN 250MG TABLET	\$11,978,139	91.7%*†	94.0%

Table C.1 continued

NDC	Drug detail	Expenditures reported in Plaintiff Exhibit B ²	Percentage of sales units "at or about" WAC ³	Percentage of sales dollars "at or about" WAC
00173055400	CEFTIN 250MG/5ML ORAL SUSP	\$410,460	84.4%*†	88.4%
00173055500	CEFTIN 250MG/5ML ORAL SUSP	\$3,228,924	94.1%*†	95.7%
00173039400	CEFTIN 500MG TABLET	\$8,636,779	95.3%*†	96.5%
00173039442	CEFTIN 500MG TABLET	\$10,328,575	79.9%*†	84.7%
58437000218	CIMETIDINE 400MG TABLET	\$252,870	74.3%†	88.0%
58437000225	CIMETIDINE 400MG TABLET	\$10,510	87.3%†	96.7%
00173059500	COMBIVIR TABLET	\$359,621,285	76.6%*†	82.0%
00007336003	COMPAZINE 2.5MG SUPPOSITORY	\$61,273	76.5%*†	80.0%
00007336103	COMPAZINE 5MG SUPPOSITORY	\$144,849	62.7%*†	66.4%
00007336344	COMPAZINE 5MG/5ML SYRUP	\$159,932	70.3%*†	73.9%
00007334615	COMPAZINE SPANSULE 15MG	\$192,882	86.9%*†	88.5%
00007414120	COREG 12.5MG TABLET	\$9,747,684	83.4%*†	86.3%
00007414220	COREG 25MG TABLET	\$10,386,010	81.5%*†	84.6%
00007413920	COREG 3.125MG TABLET	\$9,782,627	84.6%*†	87.5%
00007413955	COREG 3.125MG TABLET	\$72,409	94.7%*†	95.7%
00007414020	COREG 6.25MG TABLET	\$12,182,615	84.8%*†	87.9%
00173020155	DARAPRIM 25MG TABLET	\$587,495	71.0%*†	77.9%
00007351920	DEXEDRINE 5MG TABLET	\$1,370,561	91.4%*†	93.7%
00007351320	DEXEDRINE SPANSULE 10MG	\$742,745	90.2%*†	91.9%
00007351420	DEXEDRINE SPANSULE 15MG	\$479,100	90.4%*†	91.8%
00007351220	DEXEDRINE SPANSULE 5MG	\$172,875	84.7%*†	86.6%
00007365022	DYAZIDE 37.5/25 CAPSULE	\$805,574	98.3%*†	99.2%
00007365030	DYAZIDE 37.5/25 CAPSULE	\$197,401	94.5%*†	98.8%
00173047100	EPIVIR 10MG/ML ORAL SOLN	\$8,098,338	87.9%*†	91.9%
00173047001	EPIVIR 150MG TABLET	\$193,363,884	77.6%*†	82.8%
00173071400	EPIVIR 300 MG TABLET	\$12,965,636	78.3%*†	83.9%
00173066200	EPIVIR HBV 100MG TABLET	\$3,278,549	91.8%*†	93.8%
00173066300	EPIVIR HBV 25MG/5ML SOLN	\$8,323	84.9%*†	91.2%
00007400720	ESKALITH 300MG CAPSULE	\$192,585	96.7%*†	97.9%
00007401020	ESKALITH CR 450MG TABLET SA	\$4,200,584	88.5%*†	89.7%
00173045301	FLONASE 0.05% NASAL SPRAY	\$72,289,825	71.3%*†	77.5%
00173050900	FLOVENT 100MCG ROTADISK	\$112,973	77.4%*†	78.8%
00173049400	FLOVENT 110MCG INHALER	\$42,878,871	71.3%*†	74.1%
00173049500	FLOVENT 220MCG INHALER	\$45,304,636	59.7%*†	63.2%
00173050400	FLOVENT 250MCG ROTADISK	\$73,935	74.6%*†	75.8%
00173049100	FLOVENT 44MCG INHALER	\$13,908,931	77.3%*†	79.8%
00173051100	FLOVENT 50 MCG ROTADISK	\$154,736	80.4%*†	81.9%
00007420105	HYCANTIN 4MG VIAL	\$1,644,638	87.1%*†	86.6%

Table C.1 continued

NDC	Drug detail	Expenditures reported in Plaintiff Exhibit B ²	Percentage of sales units "at or about" WAC ³	Percentage of sales dollars "at or about" WAC
00173045003	IMITREX 100MG TABLET	\$4,169,280	88.4%*†	89.4%
00173073701	IMITREX 100MG TABLET	\$870,056	87.7%*†	88.7%
00173052300	IMITREX 20MG NASAL SPRAY	\$3,757,043	82.6%*†	84.3%
00173073500	IMITREX 25 MG TABLET	\$1,092,935	81.9%*†	84.6%
00173046002	IMITREX 25MG TABLET	\$28,872,486	85.2%*†	86.7%
00173045900	IMITREX 50MG TABLET	\$31,631,041	84.4%*†	86.1%
00173073601	IMITREX 50MG TABLET	\$1,407,670	81.4%*†	84.0%
00173052400	IMITREX 5MG NASAL SPRAY	\$930,319	84.1%*†	86.0%
00173047800	IMITREX 6MG/0.5ML KIT REFL	\$4,716,716	82.0%*†	83.8%
00173047900	IMITREX 6MG/0.5ML SYRNG KIT	\$2,755,280	81.6%*†	83.9%
00173064255	LAMICTAL 100MG TABLET	\$22,960,473	86.0%*†	88.8%
00173064360	LAMICTAL 150MG TABLET	\$4,310,757	86.9%*†	89.6%
00173064460	LAMICTAL 200MG TABLET	\$7,075,265	87.2%*†	90.2%
00173052700	LAMICTAL 25MG DISPER TABLET	\$1,349,810	91.5%*†	92.7%
00173063302	LAMICTAL 25MG TABLET	\$23,058,483	83.5%*†	86.4%
00173052600	LAMICTAL 5MG DISPER TABLET	\$1,220,522	92.0%*†	93.5%
00173024255	LANOXIN 125MCG TABLET	\$1,356,428	59.0%*†	72.1%
00173024275	LANOXIN 125MCG TABLET	\$1,370,508	79.7%*†	86.2%
00173024955	LANOXIN 250MCG TABLET	\$800,296	60.7%*†	73.2%
00173024975	LANOXIN 250MCG TABLET	\$758,917	58.2%*†	70.6%
00173024980	LANOXIN 250MCG TABLET	\$108,508	89.4%*†	94.4%
00173026427	LANOXIN 50MCG/ML ELIXIR	\$433,899	63.6%*†	68.9%
00173063535	LEUKERAN 2MG TABLET	\$198,776	90.7%*†	93.1%
00173069000	LOTRONEX 1MG TABLET	\$354,011	94.8%*†	95.4%
00173069005	LOTRONEX 1MG TABLET	\$109,366	99.5%*†	99.7%
00173066518	MEPRON 750MG/5ML SUSPENSION	\$42,725,300	81.2%*†	85.4%
00007447120	PARNATE 10MG TABLET	\$746,756	93.9%*†	95.5%
00029321013	PAXIL 10MG TABLET	\$28,330,116	87.2%*†	87.6%
00029321548	PAXIL 10MG/5ML SUSPENSION	\$702,225	84.8%*†	85.5%
00029321113	PAXIL 20MG TABLET	\$30,264,498	82.1%*†	85.4%
00029321120	PAXIL 20MG TABLET	\$77,312,392	86.0%*†	87.4%
00029321213	PAXIL 30MG TABLET	\$27,712,259	83.7%*†	85.4%
00029321313	PAXIL 40MG TABLET	\$20,140,666	69.9%*†	72.5%
00029320613	PAXIL CR 12.5MG TABLET	\$7,114,118	83.7%*†	84.5%
00029320713	PAXIL CR 25MG TABLET	\$16,496,204	84.7%*†	85.5%
00029320813	PAXIL CR 37.5MG TABLET	\$5,284,879	85.9%*†	87.1%
00173080725	PURINETHOL 50MG TABLET	\$2,877,463	96.8%*†	97.8%
00173080765	PURINETHOL 50MG TABLET	\$201,081	82.0%*†	85.7%

Table C.1 continued

NDC	Drug detail	Expenditures reported in Plaintiff Exhibit B ²	Percentage of sales units "at or about" WAC ³	Percentage of sales dollars "at or about" WAC
00029485120	RELAFEN 500MG TABLET	\$24,272,494	81.3%*†	88.5%
00029485220	RELAFEN 750MG TABLET	\$10,602,929	95.1%*†	95.6%
00173068101	RELENZA 5 MG DISKHALER	\$118,797	86.8%*†	88.0%
00007489020	REQUIP 0.25MG TABLET	\$1,252,286	87.9%*†	89.7%
00007489120	REQUIP 0.5MG TABLET	\$587,153	88.3%*†	90.3%
00007489220	REQUIP 1MG TABLET	\$927,627	88.4%*†	90.5%
00007489320	REQUIP 2MG TABLET	\$479,790	86.7%*†	89.3%
00007489520	REQUIP 3MG TABLET	\$235,548	94.5%*†	95.7%
00007489620	REQUIP 4MG TABLET	\$206,614	93.3%*†	94.6%
00007489420	REQUIP 5MG TABLET	\$200,800	88.2%*†	90.6%
00173010855	RETROVIR 100MG CAPSULE	\$14,715,610	75.2%*†	79.6%
00173011318	RETROVIR 10MG/ML SYRUP	\$4,210,238	90.0%*†	92.8%
00173050100	RETROVIR 300MG TABLET	\$29,463,427	79.1%*†	83.3%
00173010793	RETROVIR IV INFUSION VIAL	\$7,144	92.3%*†	94.9%
00173046400	SEREVENT 21MCG INHALER	\$42,994,426	72.1%*†	74.5%
00173046500	SEREVENT 21MCG INHLR REFILL	\$631,232	94.2%*†	94.5%
00173052100	SEREVENT DISKUS 50MCG	\$6,681,172	67.0%*†	70.1%
00108490420	STELAZINE 2MG TABLET	\$1,130,971	94.7%*†	96.3%
00108490201	STELAZINE 2MG/ML VIAL	\$1,357	53.4%*†	54.9%
00173045402	TEMOVATE EMOLLIENT 0.05% CRM	\$121,951	76.1%*†	82.0%
00173045403	TEMOVATE EMOLLIENT 0.05% CRM	\$620,918	77.8%*†	83.0%
00173088025	THIOGUANINE TABLOID 40MG TB	\$125,059	73.8%*†	78.5%
00007507103	THORAZINE 100MG SUPPOSITORY	\$15,230	87.0%*†	87.9%
00007507720	THORAZINE 100MG TABLET	\$957,346	95.9%*†	96.9%
00007507244	THORAZINE 10MG/5ML SYRUP	\$91,902	89.1%*†	89.9%
00007507920	THORAZINE 200MG TABLET	\$531,253	95.3%*†	96.5%
00007507930	THORAZINE 200MG TABLET	\$590	80.9%*†	92.1%
00007507420	THORAZINE 25MG TABLET	\$240,126	96.2%*†	96.9%
00007507430	THORAZINE 25MG TABLET	\$1,197	68.4%*†	78.8%
00007506201	THORAZINE 25MG/ML VIAL	\$9,916	84.6%*†	85.8%
00007504744	THORAZINE 30MG/ML LIQ CONC	\$18,892	82.3%*†	86.7%
00007507620	THORAZINE 50MG TABLET	\$523,592	96.9%*†	97.5%
00007507630	THORAZINE 50MG TABLET	\$2,173	80.7%*†	88.6%
00173069100	TRIZIVIR TABLET	\$151,276,862	80.6%*†	84.7%
00173069120	TRIZIVIR TABLET	\$1,493,793	89.2%*†	90.9%
00173056502	VALTREX 1GM CAPLET	\$6,027,190	88.4%*†	90.3%
00173093303	VALTREX 500MG CAPLET	\$10,479,915	87.0%*†	88.7%
00173093308	VALTREX 500MG CAPLET	\$6,386,918	84.7%*†	86.2%

Table C.1 continued

NDC	Drug detail	Expenditures reported in Plaintiff Exhibit B ²	Percentage of sales units "at or about" WAC ³	Percentage of sales dollars "at or about" WAC
00173032198	VENTOLIN 90MCG INH REFILL	\$228,429	95.1%*†	97.4%
00173068200	VENTOLIN HFA 90 MCG INHALER	\$89,584	87.8%*†	88.9%
00173038901	VENTOLIN ROTACAPS 200MCG	\$388,151	94.5%*†	96.4%
00173038902	VENTOLIN ROTACAPS 200MCG	\$59,029	96.6%*†	97.5%
00173038903	VENTOLIN ROTACAPS 200MCG	\$11,476	74.3%*†	85.3%
00173017855	WELLBUTRIN 100MG TABLET	\$2,194,205	75.6%*†	80.4%
00173017755	WELLBUTRIN 75MG TABLET	\$2,121,929	74.8%*†	79.8%
00173094755	WELLBUTRIN SR 100MG TAB SA	\$13,975,288	71.5%*†	74.1%
00173013555	WELLBUTRIN SR 150MG TAB SA	\$47,864,903	72.6%*†	75.5%
00173072200	WELLBUTRIN SR 200MG TAB SA	\$6,091,519	79.0%*†	79.5%
00173073001	WELLBUTRIN XL 150MG TABLET	\$5,281,979	82.8%*†	83.9%
00173073101	WELLBUTRIN XL 300MG TABLET	\$6,708,345	82.1%*†	83.1%
00173034414	ZANTAC 150MG TABLET	\$14,027,260	85.9%*†	89.8%
00173038354	ZANTAC 15MG/ML SYRUP	\$11,275,320	78.4%*†	81.8%
00173066400	ZIAGEN 20 MG/ML SOLUTION	\$2,062,523	90.9%*†	93.4%
00173066101	ZIAGEN 300MG TABLET	\$79,649,369	79.7%*†	83.7%
00173044600	ZOFRAN 4MG TABLET	\$7,562,133	78.0%*†	81.6%
00173044604	ZOFRAN 4MG TABLET	\$156,561	96.4%*†	97.1%
00173048900	ZOFRAN 4MG/5ML ORAL SOLN	\$585,298	70.9%*†	75.2%
00173044700	ZOFRAN 8MG TABLET	\$21,088,905	80.2%*†	85.2%
00173044704	ZOFRAN 8MG TABLET	\$766,926	95.9%*†	96.7%
00173056900	ZOFRAN ODT 4MG TABLET	\$701,567	76.0%*†	80.0%
00173057000	ZOFRAN ODT 8MG TABLET	\$1,717,036	79.1%*†	83.5%
00173095396	ZOVIRAX 200MG/5ML SUSP	\$142,697	78.8%*†	82.2%
00173099394	ZOVIRAX 5% OINTMENT	\$10,934,049	51.8%*†	74.3%
00173055601	ZYBAN 150MG TABLET SA	\$2,227,349	84.6%*†	86.9%
00173055602	ZYBAN 150MG TABLET SA	\$980,406	80.3%*†	83.4%
00173055602	ZYBAN 150MG TABLET SA	\$980,406	80.2%*	83.3%

Table C.2: Refined calculation of GSK NDCs with 50% or less of the units sold “at or about” WAC¹

NDC	Drug detail	Expenditures reported in Plaintiff Exhibit B ²	Percentage of sales units “at or about” WAC ³	Percentage of sales dollars “at or about” WAC
00029316020	AVANDIA 8MG TABLET	\$9,226,664	49.1%*	53.0%
00173042702	ZANTAC 150MG EFFERDOSE TAB	\$262,207	46.7%*	58.6%

¹ This is a NDC-by-NDC summary for the years 1997-2005 for which information is available.

² I obtained the expenditure information directly from Exhibit B of Plaintiffs’ Revised First Amended Consolidated Complaint. Because these expenditures serve illustrative purposes only, I have not independently verified their accuracy.

³ As in my original affidavit, I placed an asterisk next to the units sold “at or about” WAC percentage for each NDC that has an AWP “spread” of less than or equal to 30% for the relevant period. I have not reproduced the results of my “spread” analysis here.

Attachment D

Alternative calculation of percentage of sales “at or about” WAC for 208 GSK NDCs at issue¹

NDC-by-NDC, year-by-year results

¹ I do not agree with the criticisms offered by plaintiffs' counsel and by Mr. Devor concerning my previous calculations. I offer these calculations to demonstrate that these criticisms, with the exception of Mr. Devor's erroneous treatment of utilization-based rebates, do not affect the results and conclusions I previously offered.

Table D.1: Year-by-year breakdown of refined calculation of GSK NDCs with more than 50% of the units sold during the relevant period “at or about” WAC

NDC	Year	Drug detail	Percentage of sales units “at or about” WAC ¹	Percentage of sales dollars “at or about” WAC
00173067200	1999	AGENERASE 150MG CAPSULE	85.7%	88.3%
00173067200	2000	AGENERASE 150MG CAPSULE	83.5%	86.8%
00173067200	2001	AGENERASE 150MG CAPSULE	77.8%	81.7%
00173067200	2002	AGENERASE 150MG CAPSULE	80.4%	84.7%
00173067200	2003	AGENERASE 150MG CAPSULE	81.0%	85.5%
00173067200	2004	AGENERASE 150MG CAPSULE	76.5%	81.4%
00173067200	2005	AGENERASE 150MG CAPSULE	34.4%	41.9%
00173068700	1999	AGENERASE 15MG/ML ORAL SOLN	87.4%	90.6%
00173068700	2000	AGENERASE 15MG/ML ORAL SOLN	89.8%	93.0%
00173068700	2001	AGENERASE 15MG/ML ORAL SOLN	86.7%	90.7%
00173068700	2002	AGENERASE 15MG/ML ORAL SOLN	89.3%	92.5%
00173068700	2003	AGENERASE 15MG/ML ORAL SOLN	90.1%	91.8%
00173068700	2004	AGENERASE 15MG/ML ORAL SOLN	90.1%	92.0%
00173068700	2005	AGENERASE 15MG/ML ORAL SOLN	96.5%	97.4%
00173067900	1999	AGENERASE 50MG CAPSULE	65.0%	74.8%
00173067900	2000	AGENERASE 50MG CAPSULE	79.8%	87.4%
00173067900	2001	AGENERASE 50MG CAPSULE	72.9%	79.6%
00173067900	2002	AGENERASE 50MG CAPSULE	85.4%	89.5%
00173067900	2003	AGENERASE 50MG CAPSULE	67.9%	75.0%
00173067900	2004	AGENERASE 50MG CAPSULE	67.7%	75.4%
00173067900	2005	AGENERASE 50MG CAPSULE	90.6%	92.3%
00007550040	1997	ALBENZA 200MG TABLET	93.1%	94.4%
00007550040	1998	ALBENZA 200MG TABLET	87.3%	90.4%
00007550040	1999	ALBENZA 200MG TABLET	65.5%	68.6%
00007550040	2000	ALBENZA 200MG TABLET	42.8%*	48.9%
00007550040	2001	ALBENZA 200MG TABLET	78.2%	87.6%
00007550040	2002	ALBENZA 200MG TABLET	80.7%	89.5%
00007550040	2003	ALBENZA 200MG TABLET	82.3%	90.6%
00007550040	2004	ALBENZA 200MG TABLET	88.7%	94.4%
00007550040	2005	ALBENZA 200MG TABLET	99.6%	99.8%

¹ As in my original affidavit, for each year on this table in which 50% or less of units sold were “at or about” WAC, I placed an asterisk next to the percentage if, as is almost always true, the NDC for that year had an AWP “spread” of less than or equal to 30%. I have not reproduced the results of my “spread” analysis here.

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00173056100	1998	AMERGE 1MG TABLET	95.0%	96.4%
00173056100	1999	AMERGE 1MG TABLET	87.7%	88.7%
00173056100	2000	AMERGE 1MG TABLET	90.9%	92.4%
00173056100	2001	AMERGE 1MG TABLET	90.3%	91.4%
00173056100	2002	AMERGE 1MG TABLET	92.7%	94.3%
00173056100	2003	AMERGE 1MG TABLET	93.8%	95.1%
00173056100	2004	AMERGE 1MG TABLET	85.7%	87.2%
00173056100	2005	AMERGE 1MG TABLET	91.4%	92.7%
00173056200	1998	AMERGE 2.5MG TABLET	93.8%	94.7%
00173056200	1999	AMERGE 2.5MG TABLET	79.2%	80.0%
00173056200	2000	AMERGE 2.5MG TABLET	91.8%	93.2%
00173056200	2001	AMERGE 2.5MG TABLET	90.1%	91.5%
00173056200	2002	AMERGE 2.5MG TABLET	84.9%	86.7%
00173056200	2003	AMERGE 2.5MG TABLET	82.2%	83.8%
00173056200	2004	AMERGE 2.5MG TABLET	81.4%	82.9%
00173056200	2005	AMERGE 2.5MG TABLET	83.5%	85.2%
00029604412	1999	AMOXIL 200MG TABLET CHEW	99.6%	99.7%
00029604412	2000	AMOXIL 200MG TABLET CHEW	98.4%	99.0%
00029604412	2001	AMOXIL 200MG TABLET CHEW	97.1%	98.6%
00029604412	2002	AMOXIL 200MG TABLET CHEW	86.9%	94.5%
00029604412	2003	AMOXIL 200MG TABLET CHEW	90.1%	94.4%
00029604412	2004	AMOXIL 200MG TABLET CHEW	90.1%	92.6%
00029604412	2005	AMOXIL 200MG TABLET CHEW	89.2%	91.8%
00029604420	1999	AMOXIL 200MG TABLET CHEW	99.9%	100%
00029604420	2000	AMOXIL 200MG TABLET CHEW	98.3%	99.2%
00029604420	2001	AMOXIL 200MG TABLET CHEW	95.5%	98.5%
00029604420	2002	AMOXIL 200MG TABLET CHEW	9.5%*	30.1%
00029604420	2003	AMOXIL 200MG TABLET CHEW	84.8%	92.1%
00029604420	2004	AMOXIL 200MG TABLET CHEW	6.9%*	8.6%
00029604420	2005	AMOXIL 200MG TABLET CHEW	0.0%	0.0%
00029604854	1999	AMOXIL 200MG/5ML SUSPENSION	99.5%	99.6%
00029604854	2000	AMOXIL 200MG/5ML SUSPENSION	99.2%	99.5%
00029604854	2001	AMOXIL 200MG/5ML SUSPENSION	86.2%	93.6%
00029604854	2002	AMOXIL 200MG/5ML SUSPENSION	94.9%	97.9%
00029604854	2003	AMOXIL 200MG/5ML SUSPENSION	71.3%	76.8%
00029604854	2004	AMOXIL 200MG/5ML SUSPENSION	78.0%	83.4%
00029604854	2005	AMOXIL 200MG/5ML SUSPENSION	89.3%	93.3%
00029604855	1999	AMOXIL 200MG/5ML SUSPENSION	99.7%	99.8%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00029604855	2000	AMOXIL 200MG/5ML SUSPENSION	99.7%	99.8%
00029604855	2001	AMOXIL 200MG/5ML SUSPENSION	91.9%	96.8%
00029604855	2002	AMOXIL 200MG/5ML SUSPENSION	95.7%	98.8%
00029604855	2003	AMOXIL 200MG/5ML SUSPENSION	90.2%	95.0%
00029604855	2004	AMOXIL 200MG/5ML SUSPENSION	80.3%	85.2%
00029604855	2005	AMOXIL 200MG/5ML SUSPENSION	88.0%	92.4%
00029604859	1999	AMOXIL 200MG/5ML SUSPENSION	99.7%	99.8%
00029604859	2000	AMOXIL 200MG/5ML SUSPENSION	99.6%	99.8%
00029604859	2001	AMOXIL 200MG/5ML SUSPENSION	94.0%	97.4%
00029604859	2002	AMOXIL 200MG/5ML SUSPENSION	96.8%	99.0%
00029604859	2003	AMOXIL 200MG/5ML SUSPENSION	91.4%	95.6%
00029604859	2004	AMOXIL 200MG/5ML SUSPENSION	76.6%	81.2%
00029604859	2005	AMOXIL 200MG/5ML SUSPENSION	84.7%	90.0%
00029604512	1999	AMOXIL 400 MG TABLET CHEW	99.9%	99.9%
00029604512	2000	AMOXIL 400 MG TABLET CHEW	99.4%	99.6%
00029604512	2001	AMOXIL 400 MG TABLET CHEW	97.0%	98.6%
00029604512	2002	AMOXIL 400 MG TABLET CHEW	62.6%	69.4%
00029604512	2003	AMOXIL 400 MG TABLET CHEW	56.0%	68.2%
00029604512	2004	AMOXIL 400 MG TABLET CHEW	67.2%	72.7%
00029604512	2005	AMOXIL 400 MG TABLET CHEW	81.6%	86.6%
00029604520	1999	AMOXIL 400MG TABLET CHEW	99.8%	99.8%
00029604520	2000	AMOXIL 400MG TABLET CHEW	99.1%	99.5%
00029604520	2001	AMOXIL 400MG TABLET CHEW	94.5%	98.2%
00029604520	2002	AMOXIL 400MG TABLET CHEW	42.7%*	49.2%
00029604520	2003	AMOXIL 400MG TABLET CHEW	54.4%	72.8%
00029604520	2004	AMOXIL 400MG TABLET CHEW	48.1%*	54.5%
00029604954	1999	AMOXIL 400MG/5ML SUSPENSION	99.6%	99.6%
00029604954	2000	AMOXIL 400MG/5ML SUSPENSION	99.1%	99.5%
00029604954	2001	AMOXIL 400MG/5ML SUSPENSION	92.7%	97.4%
00029604954	2002	AMOXIL 400MG/5ML SUSPENSION	93.1%	97.9%
00029604954	2003	AMOXIL 400MG/5ML SUSPENSION	84.3%	92.0%
00029604954	2004	AMOXIL 400MG/5ML SUSPENSION	49.5%*	55.1%
00029604954	2005	AMOXIL 400MG/5ML SUSPENSION	73.3%	79.2%
00029604612	1998	AMOXIL 500MG TABLET	100.0%	100.0%
00029604612	1999	AMOXIL 500MG TABLET	99.5%	99.7%
00029604612	2000	AMOXIL 500MG TABLET	100.0%	100.0%
00029604612	2001	AMOXIL 500MG TABLET	92.8%	98.3%
00029604612	2002	AMOXIL 500MG TABLET	99.5%	99.7%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00029604612	2003	AMOXIL 500MG TABLET	92.7%	95.9%
00029604612	2004	AMOXIL 500MG TABLET	82.4%	89.6%
00029604620	1998	AMOXIL 500MG TABLET	100.0%	100.0%
00029604620	1999	AMOXIL 500MG TABLET	97.5%	98.0%
00029604620	2000	AMOXIL 500MG TABLET	99.6%	99.7%
00029604620	2001	AMOXIL 500MG TABLET	85.4%	86.9%
00029604620	2002	AMOXIL 500MG TABLET	81.4%	83.9%
00029604620	2003	AMOXIL 500MG TABLET	82.5%	89.1%
00029604620	2004	AMOXIL 500MG TABLET	80.0%	86.8%
00029604620	2005	AMOXIL 500MG TABLET	64.5%	77.6%
00029604712	1998	AMOXIL 875MG TABLET	100.0%	100.0%
00029604712	1999	AMOXIL 875MG TABLET	99.4%	99.5%
00029604712	2000	AMOXIL 875MG TABLET	99.4%	99.6%
00029604712	2001	AMOXIL 875MG TABLET	97.0%	98.2%
00029604712	2002	AMOXIL 875MG TABLET	90.0%	92.5%
00029604712	2003	AMOXIL 875MG TABLET	78.4%	85.8%
00029604712	2004	AMOXIL 875MG TABLET	50.8%	62.8%
00029604720	1998	AMOXIL 875MG TABLET	100.0%	100.0%
00029604720	1999	AMOXIL 875MG TABLET	99.6%	99.7%
00029604720	2000	AMOXIL 875MG TABLET	99.2%	99.2%
00029604720	2001	AMOXIL 875MG TABLET	71.5%	73.0%
00029604720	2002	AMOXIL 875MG TABLET	72.8%	75.8%
00029604720	2003	AMOXIL 875MG TABLET	78.2%	84.8%
00029604720	2004	AMOXIL 875MG TABLET	66.6%	76.1%
00029604720	2005	AMOXIL 875MG TABLET	70.3%	81.4%
00029604725	1998	AMOXIL 875MG TABLET	100.0%	100.0%
00029604725	1999	AMOXIL 875MG TABLET	99.9%	99.9%
00029604725	2000	AMOXIL 875MG TABLET	95.0%	95.1%
00029604725	2001	AMOXIL 875MG TABLET	97.6%	98.2%
00029604725	2002	AMOXIL 875MG TABLET	87.9%	90.6%
00029604725	2003	AMOXIL 875MG TABLET	73.4%	80.0%
00029604725	2004	AMOXIL 875MG TABLET	51.9%	61.1%
00029608522	1997	AUGMENTIN 125-31.25 SUSPEN	88.5%	90.9%
00029608522	1998	AUGMENTIN 125-31.25 SUSPEN	89.7%	92.0%
00029608522	1999	AUGMENTIN 125-31.25 SUSPEN	90.7%	93.0%
00029608522	2000	AUGMENTIN 125-31.25 SUSPEN	91.5%	93.4%
00029608522	2001	AUGMENTIN 125-31.25 SUSPEN	92.1%	94.1%
00029608522	2002	AUGMENTIN 125-31.25 SUSPEN	91.3%	93.7%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00029608522	2003	AUGMENTIN 125-31.25 SUSPEN	92.6%	95.1%
00029608522	2004	AUGMENTIN 125-31.25 SUSPEN	88.4%	91.7%
00029608522	2005	AUGMENTIN 125-31.25 SUSPEN	90.2%	92.8%
00029608523	1997	AUGMENTIN 125-31.25 SUSPEN	96.3%	96.7%
00029608523	1998	AUGMENTIN 125-31.25 SUSPEN	95.6%	96.1%
00029608523	1999	AUGMENTIN 125-31.25 SUSPEN	96.0%	96.5%
00029608523	2000	AUGMENTIN 125-31.25 SUSPEN	94.9%	95.2%
00029608523	2001	AUGMENTIN 125-31.25 SUSPEN	94.5%	95.3%
00029608523	2002	AUGMENTIN 125-31.25 SUSPEN	94.2%	95.1%
00029608523	2003	AUGMENTIN 125-31.25 SUSPEN	93.8%	95.6%
00029608523	2004	AUGMENTIN 125-31.25 SUSPEN	87.2%	90.7%
00029608523	2005	AUGMENTIN 125-31.25 SUSPEN	89.9%	92.1%
00029608539	1997	AUGMENTIN 125-31.25 SUSPEN	73.3%	74.6%
00029608539	1998	AUGMENTIN 125-31.25 SUSPEN	71.0%	72.6%
00029608539	1999	AUGMENTIN 125-31.25 SUSPEN	75.3%	77.0%
00029608539	2000	AUGMENTIN 125-31.25 SUSPEN	74.8%	75.8%
00029608539	2001	AUGMENTIN 125-31.25 SUSPEN	66.6%	68.4%
00029608539	2002	AUGMENTIN 125-31.25 SUSPEN	64.4%	66.2%
00029608539	2003	AUGMENTIN 125-31.25 SUSPEN	74.5%	76.1%
00029608539	2004	AUGMENTIN 125-31.25 SUSPEN	52.0%	54.1%
00029608539	2005	AUGMENTIN 125-31.25 SUSPEN	56.2%	58.5%
00029607347	1997	AUGMENTIN 125-31.25 TAB CHEW	91.4%	92.4%
00029607347	1998	AUGMENTIN 125-31.25 TAB CHEW	89.7%	90.9%
00029607347	1999	AUGMENTIN 125-31.25 TAB CHEW	86.2%	87.8%
00029607347	2000	AUGMENTIN 125-31.25 TAB CHEW	82.9%	84.1%
00029607347	2001	AUGMENTIN 125-31.25 TAB CHEW	82.1%	84.4%
00029607347	2002	AUGMENTIN 125-31.25 TAB CHEW	84.1%	87.2%
00029607347	2003	AUGMENTIN 125-31.25 TAB CHEW	89.8%	91.7%
00029607347	2004	AUGMENTIN 125-31.25 TAB CHEW	83.4%	85.6%
00029607347	2005	AUGMENTIN 125-31.25 TAB CHEW	89.0%	90.7%
00029608729	1997	AUGMENTIN 200-28.5 SUSPEN	95.2%	95.7%
00029608729	1998	AUGMENTIN 200-28.5 SUSPEN	92.6%	93.4%
00029608729	1999	AUGMENTIN 200-28.5 SUSPEN	93.2%	94.0%
00029608729	2000	AUGMENTIN 200-28.5 SUSPEN	91.8%	92.6%
00029608729	2001	AUGMENTIN 200-28.5 SUSPEN	92.0%	92.8%
00029608729	2002	AUGMENTIN 200-28.5 SUSPEN	89.3%	90.6%
00029608729	2003	AUGMENTIN 200-28.5 SUSPEN	87.0%	89.0%
00029608729	2004	AUGMENTIN 200-28.5 SUSPEN	4.9%*	5.5%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00029608729	2005	AUGMENTIN 200-28.5 SUSPEN	71.1%	73.5%
00029608739	1997	AUGMENTIN 200-28.5 SUSPEN	94.3%	95.0%
00029608739	1998	AUGMENTIN 200-28.5 SUSPEN	93.5%	94.3%
00029608739	1999	AUGMENTIN 200-28.5 SUSPEN	93.1%	94.0%
00029608739	2000	AUGMENTIN 200-28.5 SUSPEN	94.3%	95.1%
00029608739	2001	AUGMENTIN 200-28.5 SUSPEN	93.6%	94.4%
00029608739	2002	AUGMENTIN 200-28.5 SUSPEN	91.3%	92.4%
00029608739	2003	AUGMENTIN 200-28.5 SUSPEN	87.2%	89.5%
00029608739	2004	AUGMENTIN 200-28.5 SUSPEN	5.9%*	6.5%
00029608739	2005	AUGMENTIN 200-28.5 SUSPEN	70.3%	73.2%
00029608751	1997	AUGMENTIN 200-28.5 SUSPEN	95.8%	96.5%
00029608751	1998	AUGMENTIN 200-28.5 SUSPEN	94.8%	95.8%
00029608751	1999	AUGMENTIN 200-28.5 SUSPEN	94.7%	95.9%
00029608751	2000	AUGMENTIN 200-28.5 SUSPEN	93.8%	95.0%
00029608751	2001	AUGMENTIN 200-28.5 SUSPEN	94.6%	95.7%
00029608751	2002	AUGMENTIN 200-28.5 SUSPEN	92.4%	94.2%
00029608751	2003	AUGMENTIN 200-28.5 SUSPEN	52.0%	56.7%
00029608751	2004	AUGMENTIN 200-28.5 SUSPEN	5.7%*	6.9%
00029608751	2005	AUGMENTIN 200-28.5 SUSPEN	60.0%	69.4%
00029607112	1997	AUGMENTIN 200-28.5 TAB CHEW	95.2%	95.9%
00029607112	1998	AUGMENTIN 200-28.5 TAB CHEW	94.0%	94.8%
00029607112	1999	AUGMENTIN 200-28.5 TAB CHEW	93.7%	94.7%
00029607112	2000	AUGMENTIN 200-28.5 TAB CHEW	92.5%	93.7%
00029607112	2001	AUGMENTIN 200-28.5 TAB CHEW	93.6%	94.6%
00029607112	2002	AUGMENTIN 200-28.5 TAB CHEW	89.4%	91.3%
00029607112	2003	AUGMENTIN 200-28.5 TAB CHEW	75.5%	80.9%
00029607112	2004	AUGMENTIN 200-28.5 TAB CHEW	71.1%	76.6%
00029607112	2005	AUGMENTIN 200-28.5 TAB CHEW	57.8%	64.9%
00029607527	1997	AUGMENTIN 250-125 TABLET	81.9%	86.5%
00029607527	1998	AUGMENTIN 250-125 TABLET	77.5%	83.5%
00029607527	1999	AUGMENTIN 250-125 TABLET	79.3%	85.7%
00029607527	2000	AUGMENTIN 250-125 TABLET	62.4%	68.2%
00029607527	2001	AUGMENTIN 250-125 TABLET	78.3%	85.7%
00029607527	2002	AUGMENTIN 250-125 TABLET	76.8%	85.0%
00029607527	2003	AUGMENTIN 250-125 TABLET	78.9%	87.1%
00029607527	2004	AUGMENTIN 250-125 TABLET	71.7%	77.1%
00029607527	2005	AUGMENTIN 250-125 TABLET	81.1%	86.1%
00029609022	1997	AUGMENTIN 250-62.5 SUSPEN	81.2%	85.3%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00029609022	1998	AUGMENTIN 250-62.5 SUSPEN	85.0%	88.1%
00029609022	1999	AUGMENTIN 250-62.5 SUSPEN	88.3%	91.0%
00029609022	2000	AUGMENTIN 250-62.5 SUSPEN	71.2%	73.7%
00029609022	2001	AUGMENTIN 250-62.5 SUSPEN	89.7%	92.2%
00029609022	2002	AUGMENTIN 250-62.5 SUSPEN	90.0%	92.6%
00029609022	2003	AUGMENTIN 250-62.5 SUSPEN	88.8%	92.8%
00029609022	2004	AUGMENTIN 250-62.5 SUSPEN	83.2%	85.6%
00029609022	2005	AUGMENTIN 250-62.5 SUSPEN	88.6%	91.5%
00029609023	1997	AUGMENTIN 250-62.5 SUSPEN	94.3%	94.9%
00029609023	1998	AUGMENTIN 250-62.5 SUSPEN	94.5%	95.2%
00029609023	1999	AUGMENTIN 250-62.5 SUSPEN	95.3%	95.9%
00029609023	2000	AUGMENTIN 250-62.5 SUSPEN	95.6%	96.1%
00029609023	2001	AUGMENTIN 250-62.5 SUSPEN	96.3%	96.8%
00029609023	2002	AUGMENTIN 250-62.5 SUSPEN	96.5%	97.1%
00029609023	2003	AUGMENTIN 250-62.5 SUSPEN	92.5%	95.7%
00029609023	2004	AUGMENTIN 250-62.5 SUSPEN	91.2%	92.6%
00029609023	2005	AUGMENTIN 250-62.5 SUSPEN	93.5%	95.2%
00029609039	1997	AUGMENTIN 250-62.5 SUSPEN	61.9%	63.4%
00029609039	1998	AUGMENTIN 250-62.5 SUSPEN	58.6%	60.8%
00029609039	1999	AUGMENTIN 250-62.5 SUSPEN	70.0%	72.2%
00029609039	2000	AUGMENTIN 250-62.5 SUSPEN	71.0%	72.3%
00029609039	2001	AUGMENTIN 250-62.5 SUSPEN	67.1%	68.6%
00029609039	2002	AUGMENTIN 250-62.5 SUSPEN	69.3%	71.1%
00029609039	2003	AUGMENTIN 250-62.5 SUSPEN	79.2%	81.4%
00029609039	2004	AUGMENTIN 250-62.5 SUSPEN	43.1%*	44.9%
00029609039	2005	AUGMENTIN 250-62.5 SUSPEN	62.9%	64.9%
00029607447	1997	AUGMENTIN 250-62.5 TAB CHEW	93.4%	94.6%
00029607447	1998	AUGMENTIN 250-62.5 TAB CHEW	94.3%	95.2%
00029607447	1999	AUGMENTIN 250-62.5 TAB CHEW	92.2%	93.3%
00029607447	2000	AUGMENTIN 250-62.5 TAB CHEW	92.9%	94.2%
00029607447	2001	AUGMENTIN 250-62.5 TAB CHEW	95.3%	96.2%
00029607447	2002	AUGMENTIN 250-62.5 TAB CHEW	94.9%	96.0%
00029607447	2003	AUGMENTIN 250-62.5 TAB CHEW	94.7%	96.4%
00029607447	2004	AUGMENTIN 250-62.5 TAB CHEW	90.2%	92.0%
00029607447	2005	AUGMENTIN 250-62.5 TAB CHEW	93.5%	95.0%
00029609229	1997	AUGMENTIN 400-57 SUSPEN	93.5%	94.3%
00029609229	1998	AUGMENTIN 400-57 SUSPEN	90.9%	92.2%
00029609229	1999	AUGMENTIN 400-57 SUSPEN	92.2%	93.5%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00029609229	2000	AUGMENTIN 400-57 SUSPEN	92.0%	93.2%
00029609229	2001	AUGMENTIN 400-57 SUSPEN	90.3%	91.6%
00029609229	2002	AUGMENTIN 400-57 SUSPEN	88.5%	90.1%
00029609229	2003	AUGMENTIN 400-57 SUSPEN	72.7%	77.7%
00029609229	2004	AUGMENTIN 400-57 SUSPEN	4.0%*	4.7%
00029609229	2005	AUGMENTIN 400-57 SUSPEN	25.0%*	27.7%
00029609239	1997	AUGMENTIN 400-57 SUSPEN	94.2%	95.1%
00029609239	1998	AUGMENTIN 400-57 SUSPEN	93.1%	94.1%
00029609239	1999	AUGMENTIN 400-57 SUSPEN	94.3%	95.2%
00029609239	2000	AUGMENTIN 400-57 SUSPEN	94.7%	95.4%
00029609239	2001	AUGMENTIN 400-57 SUSPEN	95.6%	96.3%
00029609239	2002	AUGMENTIN 400-57 SUSPEN	93.9%	94.9%
00029609239	2003	AUGMENTIN 400-57 SUSPEN	79.7%	84.5%
00029609239	2004	AUGMENTIN 400-57 SUSPEN	4.6%*	5.4%
00029609239	2005	AUGMENTIN 400-57 SUSPEN	46.1%*	51.8%
00029609251	1997	AUGMENTIN 400-57 SUSPEN	94.9%	95.9%
00029609251	1998	AUGMENTIN 400-57 SUSPEN	93.4%	94.8%
00029609251	1999	AUGMENTIN 400-57 SUSPEN	93.4%	94.9%
00029609251	2000	AUGMENTIN 400-57 SUSPEN	91.6%	93.1%
00029609251	2001	AUGMENTIN 400-57 SUSPEN	93.2%	94.8%
00029609251	2002	AUGMENTIN 400-57 SUSPEN	90.7%	93.0%
00029609251	2003	AUGMENTIN 400-57 SUSPEN	52.0%	60.0%
00029609251	2004	AUGMENTIN 400-57 SUSPEN	4.3%*	5.5%
00029609251	2005	AUGMENTIN 400-57 SUSPEN	51.2%	60.9%
00029607212	1997	AUGMENTIN 400-57 TAB CHEW	95.9%	96.4%
00029607212	1998	AUGMENTIN 400-57 TAB CHEW	95.6%	96.2%
00029607212	1999	AUGMENTIN 400-57 TAB CHEW	95.6%	96.2%
00029607212	2000	AUGMENTIN 400-57 TAB CHEW	94.3%	94.8%
00029607212	2001	AUGMENTIN 400-57 TAB CHEW	96.4%	97.0%
00029607212	2002	AUGMENTIN 400-57 TAB CHEW	95.9%	96.7%
00029607212	2003	AUGMENTIN 400-57 TAB CHEW	93.4%	94.9%
00029607212	2004	AUGMENTIN 400-57 TAB CHEW	10.9%*	11.7%
00029607212	2005	AUGMENTIN 400-57 TAB CHEW	82.0%	85.7%
00029608012	1997	AUGMENTIN 500-125 TABLET	90.1%	92.0%
00029608012	1998	AUGMENTIN 500-125 TABLET	87.4%	90.6%
00029608012	1999	AUGMENTIN 500-125 TABLET	91.2%	94.0%
00029608012	2000	AUGMENTIN 500-125 TABLET	85.8%	89.1%
00029608012	2001	AUGMENTIN 500-125 TABLET	89.8%	93.1%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00029608012	2002	AUGMENTIN 500-125 TABLET	88.5%	92.5%
00029608012	2003	AUGMENTIN 500-125 TABLET	7.8%	12.9%
00029608012	2004	AUGMENTIN 500-125 TABLET	6.3%*	8.4%
00029608012	2005	AUGMENTIN 500-125 TABLET	67.4%	76.8%
00029608612	1997	AUGMENTIN 875-125 TABLET	93.4%	94.7%
00029608612	1998	AUGMENTIN 875-125 TABLET	88.7%	91.5%
00029608612	1999	AUGMENTIN 875-125 TABLET	91.2%	93.6%
00029608612	2000	AUGMENTIN 875-125 TABLET	89.6%	92.1%
00029608612	2001	AUGMENTIN 875-125 TABLET	91.7%	94.1%
00029608612	2002	AUGMENTIN 875-125 TABLET	91.1%	93.7%
00029608612	2003	AUGMENTIN 875-125 TABLET	9.8%*	14.9%
00029608612	2004	AUGMENTIN 875-125 TABLET	10.1%*	12.9%
00029608612	2005	AUGMENTIN 875-125 TABLET	59.3%	69.3%
00029609422	2001	AUGMENTIN ES-600 SUSPENSION	99.6%	99.7%
00029609422	2002	AUGMENTIN ES-600 SUSPENSION	98.0%	98.6%
00029609422	2003	AUGMENTIN ES-600 SUSPENSION	96.9%	97.9%
00029609424	2003	AUGMENTIN ES-600 SUSPENSION	96.0%	97.7%
00029609424	2004	AUGMENTIN ES-600 SUSPENSION	93.3%	95.7%
00029609424	2005	AUGMENTIN ES-600 SUSPENSION	13.9%*	17.7%
00029609429	2001	AUGMENTIN ES-600 SUSPENSION	99.6%	99.7%
00029609429	2002	AUGMENTIN ES-600 SUSPENSION	97.8%	98.3%
00029609429	2003	AUGMENTIN ES-600 SUSPENSION	96.5%	97.9%
00029609439	2001	AUGMENTIN ES-600 SUSPENSION	99.7%	99.8%
00029609439	2002	AUGMENTIN ES-600 SUSPENSION	98.9%	99.1%
00029609439	2003	AUGMENTIN ES-600 SUSPENSION	95.6%	97.1%
00029609439	2004	AUGMENTIN ES-600 SUSPENSION	92.6%	94.7%
00029609439	2005	AUGMENTIN ES-600 SUSPENSION	7.9%*	9.5%
00029609445	2003	AUGMENTIN ES-600 SUSPENSION	97.3%	98.4%
00029609445	2004	AUGMENTIN ES-600 SUSPENSION	95.0%	96.5%
00029609445	2005	AUGMENTIN ES-600 SUSPENSION	4.9%*	6.4%
00029609451	2001	AUGMENTIN ES-600 SUSPENSION	99.7%	99.8%
00029609451	2002	AUGMENTIN ES-600 SUSPENSION	98.6%	99.0%
00029609451	2003	AUGMENTIN ES-600 SUSPENSION	97.2%	98.1%
00029609628	2002	AUGMENTIN XR 1000-62.5 TAB	45.1%*	46.0%
00029609628	2003	AUGMENTIN XR 1000-62.5 TAB	94.4%	95.4%
00029609640	2002	AUGMENTIN XR 1000-62.5 TAB	91.2%	91.7%
00029609640	2003	AUGMENTIN XR 1000-62.5 TAB	99.3%	99.5%
00029609640	2004	AUGMENTIN XR 1000-62.5 TAB	100.0%	100.0%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00029609648	2003	AUGMENTIN XR 1000-62.5 TAB	96.8%	98.3%
00029609648	2004	AUGMENTIN XR 1000-62.5 TAB	93.9%	95.4%
00029609648	2005	AUGMENTIN XR 1000-62.5 TAB	92.5%	94.3%
00029609660	2003	AUGMENTIN XR 1000-62.5 TAB	99.5%	99.7%
00029609660	2004	AUGMENTIN XR 1000-62.5 TAB	98.1%	98.6%
00029609660	2005	AUGMENTIN XR 1000-62.5 TAB	98.0%	98.5%
00029315818	1999	AVANDIA 2MG TABLET	91.1%	92.0%
00029315818	2000	AVANDIA 2MG TABLET	83.1%	85.4%
00029315818	2001	AVANDIA 2MG TABLET	72.9%	76.1%
00029315818	2002	AVANDIA 2MG TABLET	70.0%	73.7%
00029315818	2003	AVANDIA 2MG TABLET	67.8%	71.2%
00029315818	2004	AVANDIA 2MG TABLET	63.3%	67.8%
00029315818	2005	AVANDIA 2MG TABLET	75.5%	79.0%
00029315913	1999	AVANDIA 4MG TABLET	86.3%	87.5%
00029315913	2000	AVANDIA 4MG TABLET	90.6%	91.7%
00029315913	2001	AVANDIA 4MG TABLET	84.9%	87.2%
00029315913	2002	AVANDIA 4MG TABLET	85.3%	87.5%
00029315913	2003	AVANDIA 4MG TABLET	84.7%	87.0%
00029315913	2004	AVANDIA 4MG TABLET	82.3%	85.6%
00029315913	2005	AVANDIA 4MG TABLET	83.9%	86.8%
00029315918	1999	AVANDIA 4MG TABLET	94.3%	95.5%
00029315918	2000	AVANDIA 4MG TABLET	69.7%	71.2%
00029315918	2001	AVANDIA 4MG TABLET	66.6%	69.6%
00029315918	2002	AVANDIA 4MG TABLET	53.0%	58.2%
00029315918	2003	AVANDIA 4MG TABLET	48.1%*	53.1%
00029315918	2004	AVANDIA 4MG TABLET	47.5%*	53.6%
00029315918	2005	AVANDIA 4MG TABLET	44.8%*	50.4%
00029315920	1999	AVANDIA 4MG TABLET	80.6%	82.4%
00029315920	2000	AVANDIA 4MG TABLET	85.8%	86.9%
00029315920	2001	AVANDIA 4MG TABLET	72.9%	74.7%
00029315920	2002	AVANDIA 4MG TABLET	71.5%	73.5%
00029315920	2003	AVANDIA 4MG TABLET	61.7%	64.5%
00029315920	2004	AVANDIA 4MG TABLET	56.8%	60.7%
00029315920	2005	AVANDIA 4MG TABLET	67.5%	71.9%
00029316013	1999	AVANDIA 8MG TABLET	78.3%	79.8%
00029316013	2000	AVANDIA 8MG TABLET	94.6%	94.9%
00029316013	2001	AVANDIA 8MG TABLET	93.1%	93.7%
00029316013	2002	AVANDIA 8MG TABLET	91.2%	92.3%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00029316013	2003	AVANDIA 8MG TABLET	87.8%	89.9%
00029316013	2004	AVANDIA 8MG TABLET	85.9%	88.6%
00029316013	2005	AVANDIA 8MG TABLET	83.7%	87.8%
00029152722	1998	BACTROBAN 2% CREAM	99.4%	99.5%
00029152722	1999	BACTROBAN 2% CREAM	96.6%	96.9%
00029152722	2000	BACTROBAN 2% CREAM	95.5%	95.9%
00029152722	2001	BACTROBAN 2% CREAM	97.8%	98.2%
00029152722	2002	BACTROBAN 2% CREAM	92.1%	93.0%
00029152722	2003	BACTROBAN 2% CREAM	81.0%	84.8%
00029152722	2004	BACTROBAN 2% CREAM	81.4%	84.6%
00029152722	2005	BACTROBAN 2% CREAM	89.0%	91.0%
00029152725	1998	BACTROBAN 2% CREAM	99.3%	99.3%
00029152725	1999	BACTROBAN 2% CREAM	98.6%	98.7%
00029152725	2000	BACTROBAN 2% CREAM	97.9%	98.1%
00029152725	2001	BACTROBAN 2% CREAM	98.1%	98.3%
00029152725	2002	BACTROBAN 2% CREAM	95.7%	96.4%
00029152725	2003	BACTROBAN 2% CREAM	93.7%	94.8%
00029152725	2004	BACTROBAN 2% CREAM	88.5%	90.3%
00029152725	2005	BACTROBAN 2% CREAM	94.5%	95.9%
00029152522	1997	BACTROBAN 2% OINTMENT	80.5%	82.7%
00029152522	1998	BACTROBAN 2% OINTMENT	73.6%	76.5%
00029152522	1999	BACTROBAN 2% OINTMENT	57.6%	61.7%
00029152522	2000	BACTROBAN 2% OINTMENT	75.8%	80.9%
00029152525	1997	BACTROBAN 2% OINTMENT	95.7%	96.3%
00029152525	1998	BACTROBAN 2% OINTMENT	92.5%	93.4%
00029152525	1999	BACTROBAN 2% OINTMENT	92.3%	93.5%
00029152525	2000	BACTROBAN 2% OINTMENT	89.9%	91.9%
00029152544	2000	BACTROBAN 2% OINTMENT	88.6%	90.3%
00029152544	2001	BACTROBAN 2% OINTMENT	75.9%	78.3%
00029152544	2002	BACTROBAN 2% OINTMENT	79.1%	81.9%
00029152544	2003	BACTROBAN 2% OINTMENT	67.5%	71.6%
00029152544	2004	BACTROBAN 2% OINTMENT	6.7%*	8.2%
00029152544	2005	BACTROBAN 2% OINTMENT	42.0%*	52.0%
00029152611	1997	BACTROBAN NASAL 2% OINTMENT	98.5%	98.8%
00029152611	1998	BACTROBAN NASAL 2% OINTMENT	93.7%	94.2%
00029152611	1999	BACTROBAN NASAL 2% OINTMENT	95.8%	96.3%
00029152611	2000	BACTROBAN NASAL 2% OINTMENT	96.6%	97.0%
00029152611	2001	BACTROBAN NASAL 2% OINTMENT	70.9%	71.5%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00029152611	2002	BACTROBAN NASAL 2% OINTMENT	55.1%	57.0%
00029152611	2003	BACTROBAN NASAL 2% OINTMENT	55.2%	56.8%
00029152611	2004	BACTROBAN NASAL 2% OINTMENT	46.4%*	47.9%
00029152611	2005	BACTROBAN NASAL 2% OINTMENT	10.9%*	11.4%
00173031288	1997	BECLOVENT INHALER	64.6%	71.3%
00173031288	1998	BECLOVENT INHALER	65.1%	72.1%
00173031288	1999	BECLOVENT INHALER	58.8%	68.5%
00173031288	2000	BECLOVENT INHALER	33.2%*	43.1%
00173031288	2001	BECLOVENT INHALER	4.3%*	5.6%
00173031288	2002	BECLOVENT INHALER	0.0%	0.0%
00173038879	1997	BECONASE AQ 0.042% SPRAY	26.5%*	28.7%
00173038879	1998	BECONASE AQ 0.042% SPRAY	78.6%	82.3%
00173038879	1999	BECONASE AQ 0.042% SPRAY	77.1%	81.7%
00173038879	2000	BECONASE AQ 0.042% SPRAY	78.8%	83.1%
00173038879	2001	BECONASE AQ 0.042% SPRAY	78.8%	82.7%
00173038879	2002	BECONASE AQ 0.042% SPRAY	86.3%	91.6%
00173038879	2003	BECONASE AQ 0.042% SPRAY	88.5%	93.8%
00173038879	2004	BECONASE AQ 0.042% SPRAY	90.4%	94.5%
00173038879	2005	BECONASE AQ 0.042% SPRAY	89.7%	94.1%
00173039501	1997	CEFTIN 125MG TABLET	85.5%	90.4%
00173039501	1998	CEFTIN 125MG TABLET	81.6%	87.1%
00173039501	1999	CEFTIN 125MG TABLET	63.2%	75.3%
00173039501	2000	CEFTIN 125MG TABLET	53.1%	69.4%
00173039501	2002	CEFTIN 125MG TABLET	61.6%	64.8%
00173039501	2003	CEFTIN 125MG TABLET	56.4%	60.9%
00173040600	1997	CEFTIN 125MG/5ML ORAL SUSP	93.4%	94.9%
00173040600	1998	CEFTIN 125MG/5ML ORAL SUSP	92.9%	94.3%
00173040600	1999	CEFTIN 125MG/5ML ORAL SUSP	89.5%	92.3%
00173040600	2000	CEFTIN 125MG/5ML ORAL SUSP	84.0%	89.5%
00173040600	2002	CEFTIN 125MG/5ML ORAL SUSP	92.2%	93.2%
00173040600	2003	CEFTIN 125MG/5ML ORAL SUSP	90.0%	91.5%
00173040600	2004	CEFTIN 125MG/5ML ORAL SUSP	84.4%	86.1%
00173040600	2005	CEFTIN 125MG/5ML ORAL SUSP	80.0%	80.8%
00173038700	1997	CEFTIN 250MG TABLET	85.5%	89.7%
00173038700	1998	CEFTIN 250MG TABLET	93.3%	95.9%
00173038700	1999	CEFTIN 250MG TABLET	82.3%	88.6%
00173038700	2000	CEFTIN 250MG TABLET	85.7%	91.1%
00173038700	2002	CEFTIN 250MG TABLET	87.6%	89.9%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00173038700	2003	CEFTIN 250MG TABLET	42.9%	58.2%
00173038700	2004	CEFTIN 250MG TABLET	68.1%	78.0%
00173038700	2005	CEFTIN 250MG TABLET	79.6%	87.7%
00173038742	1997	CEFTIN 250MG TABLET	92.6%	94.6%
00173038742	1998	CEFTIN 250MG TABLET	93.3%	95.2%
00173038742	1999	CEFTIN 250MG TABLET	92.0%	94.5%
00173038742	2000	CEFTIN 250MG TABLET	90.9%	93.8%
00173038742	2002	CEFTIN 250MG TABLET	70.5%	74.2%
00173038742	2003	CEFTIN 250MG TABLET	5.7%*	17.5%
00173038742	2004	CEFTIN 250MG TABLET	41.9%*	52.3%
00173038742	2005	CEFTIN 250MG TABLET	66.7%	67.8%
00173055400	1997	CEFTIN 250MG/5ML ORAL SUSP	84.2%	90.8%
00173055400	1998	CEFTIN 250MG/5ML ORAL SUSP	90.1%	92.1%
00173055400	1999	CEFTIN 250MG/5ML ORAL SUSP	86.8%	91.0%
00173055400	2000	CEFTIN 250MG/5ML ORAL SUSP	77.9%	85.2%
00173055400	2002	CEFTIN 250MG/5ML ORAL SUSP	71.5%	74.4%
00173055400	2003	CEFTIN 250MG/5ML ORAL SUSP	90.3%	92.2%
00173055400	2004	CEFTIN 250MG/5ML ORAL SUSP	80.1%	83.7%
00173055400	2005	CEFTIN 250MG/5ML ORAL SUSP	0.0%	0.0%
00173055500	1997	CEFTIN 250MG/5ML ORAL SUSP	93.9%	96.2%
00173055500	1998	CEFTIN 250MG/5ML ORAL SUSP	95.7%	96.9%
00173055500	1999	CEFTIN 250MG/5ML ORAL SUSP	95.4%	96.8%
00173055500	2000	CEFTIN 250MG/5ML ORAL SUSP	91.5%	94.5%
00173055500	2002	CEFTIN 250MG/5ML ORAL SUSP	94.6%	95.6%
00173055500	2003	CEFTIN 250MG/5ML ORAL SUSP	94.4%	95.9%
00173055500	2004	CEFTIN 250MG/5ML ORAL SUSP	91.6%	93.3%
00173055500	2005	CEFTIN 250MG/5ML ORAL SUSP	60.0%	60.9%
00173039400	1997	CEFTIN 500MG TABLET	97.8%	98.4%
00173039400	1998	CEFTIN 500MG TABLET	97.5%	98.4%
00173039400	1999	CEFTIN 500MG TABLET	95.8%	97.5%
00173039400	2000	CEFTIN 500MG TABLET	92.9%	96.0%
00173039400	2002	CEFTIN 500MG TABLET	90.3%	91.5%
00173039400	2003	CEFTIN 500MG TABLET	52.0%	65.6%
00173039400	2004	CEFTIN 500MG TABLET	41.8%	46.5%
00173039400	2005	CEFTIN 500MG TABLET	23.4%	26.7%
00173039442	1997	CEFTIN 500MG TABLET	83.5%	86.9%
00173039442	1998	CEFTIN 500MG TABLET	82.7%	86.8%
00173039442	1999	CEFTIN 500MG TABLET	77.1%	83.5%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00173039442	2000	CEFTIN 500MG TABLET	79.1%	85.8%
00173039442	2002	CEFTIN 500MG TABLET	80.0%	82.6%
00173039442	2003	CEFTIN 500MG TABLET	3.6%	5.4%
00173039442	2004	CEFTIN 500MG TABLET	40.3%	49.7%
00173039442	2005	CEFTIN 500MG TABLET	21.2%	25.0%
58437000218	1997	CIMETIDINE 400MG TABLET	92.4%	97.9%
58437000218	1998	CIMETIDINE 400MG TABLET	15.4%	24.5%
58437000218	1999	CIMETIDINE 400MG TABLET	34.4%	38.8%
58437000218	2000	CIMETIDINE 400MG TABLET	100.0%	100.0%
58437000218	2001	CIMETIDINE 400MG TABLET	100.0%	100.0%
58437000218	2002	CIMETIDINE 400MG TABLET	98.8%	99.5%
58437000218	2003	CIMETIDINE 400MG TABLET	94.2%	98.2%
58437000218	2004	CIMETIDINE 400MG TABLET	68.5%	84.9%
58437000218	2005	CIMETIDINE 400MG TABLET	100.0%	100.0%
58437000225	1997	CIMETIDINE 400MG TABLET	87.2%	96.7%
58437000225	1998	CIMETIDINE 400MG TABLET	100.0%	100.0%
00173059500	1997	COMBIVIR TABLET	83.7%	88.5%
00173059500	1998	COMBIVIR TABLET	82.2%	86.1%
00173059500	1999	COMBIVIR TABLET	75.8%	80.7%
00173059500	2000	COMBIVIR TABLET	76.5%	81.5%
00173059500	2001	COMBIVIR TABLET	74.6%	79.8%
00173059500	2002	COMBIVIR TABLET	77.2%	82.9%
00173059500	2003	COMBIVIR TABLET	76.0%	81.9%
00173059500	2004	COMBIVIR TABLET	75.9%	82.0%
00173059500	2005	COMBIVIR TABLET	75.7%	82.3%
00007336003	1997	COMPAZINE 2.5MG SUPPOSITORY	85.4%	87.5%
00007336003	1998	COMPAZINE 2.5MG SUPPOSITORY	72.2%	76.2%
00007336003	1999	COMPAZINE 2.5MG SUPPOSITORY	88.1%	89.9%
00007336003	2000	COMPAZINE 2.5MG SUPPOSITORY	71.8%	75.5%
00007336003	2001	COMPAZINE 2.5MG SUPPOSITORY	75.8%	80.6%
00007336003	2002	COMPAZINE 2.5MG SUPPOSITORY	61.5%	66.1%
00007336003	2003	COMPAZINE 2.5MG SUPPOSITORY	70.7%	75.5%
00007336003	2004	COMPAZINE 2.5MG SUPPOSITORY	75.9%	81.9%
00007336103	1997	COMPAZINE 5MG SUPPOSITORY	81.4%	84.0%
00007336103	1998	COMPAZINE 5MG SUPPOSITORY	74.4%	77.5%
00007336103	1999	COMPAZINE 5MG SUPPOSITORY	81.6%	83.5%
00007336103	2000	COMPAZINE 5MG SUPPOSITORY	53.9%	57.9%
00007336103	2001	COMPAZINE 5MG SUPPOSITORY	50.9%	56.8%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00007336103	2002	COMPAZINE 5MG SUPPOSITORY	73.6%	79.3%
00007336103	2003	COMPAZINE 5MG SUPPOSITORY	6.0%*	6.7%
00007336103	2004	COMPAZINE 5MG SUPPOSITORY	43.9%*	52.3%
00007336344	1997	COMPAZINE 5MG/5ML SYRUP	80.5%	84.0%
00007336344	1998	COMPAZINE 5MG/5ML SYRUP	82.0%	85.3%
00007336344	1999	COMPAZINE 5MG/5ML SYRUP	83.1%	86.0%
00007336344	2000	COMPAZINE 5MG/5ML SYRUP	51.1%	55.5%
00007336344	2001	COMPAZINE 5MG/5ML SYRUP	30.6%*	34.2%
00007336344	2002	COMPAZINE 5MG/5ML SYRUP	0.0%*	0.0%
00007334615	1997	COMPAZINE SPANSULE 15MG	91.3%	93.0%
00007334615	1998	COMPAZINE SPANSULE 15MG	93.0%	94.8%
00007334615	1999	COMPAZINE SPANSULE 15MG	92.0%	93.5%
00007334615	2000	COMPAZINE SPANSULE 15MG	79.1%	81.9%
00007334615	2001	COMPAZINE SPANSULE 15MG	60.6%	63.1%
00007334615	2002	COMPAZINE SPANSULE 15MG	3.1%*	27.2%
00007414120	1997	COREG 12.5MG TABLET	97.1%	97.8%
00007414120	1998	COREG 12.5MG TABLET	85.9%	89.1%
00007414120	1999	COREG 12.5MG TABLET	94.0%	95.5%
00007414120	2000	COREG 12.5MG TABLET	90.0%	92.3%
00007414120	2001	COREG 12.5MG TABLET	89.2%	91.7%
00007414120	2002	COREG 12.5MG TABLET	88.4%	91.3%
00007414120	2003	COREG 12.5MG TABLET	84.9%	90.8%
00007414120	2004	COREG 12.5MG TABLET	83.1%	86.6%
00007414120	2005	COREG 12.5MG TABLET	75.1%	77.5%
00007414220	1997	COREG 25MG TABLET	96.6%	97.4%
00007414220	1998	COREG 25MG TABLET	85.8%	87.1%
00007414220	1999	COREG 25MG TABLET	92.7%	94.6%
00007414220	2000	COREG 25MG TABLET	88.2%	90.7%
00007414220	2001	COREG 25MG TABLET	87.7%	90.5%
00007414220	2002	COREG 25MG TABLET	85.8%	89.2%
00007414220	2003	COREG 25MG TABLET	84.2%	89.3%
00007414220	2004	COREG 25MG TABLET	82.6%	86.8%
00007414220	2005	COREG 25MG TABLET	70.6%	73.7%
00007413920	1997	COREG 3.125MG TABLET	97.3%	98.0%
00007413920	1998	COREG 3.125MG TABLET	86.3%	87.7%
00007413920	1999	COREG 3.125MG TABLET	94.6%	95.9%
00007413920	2000	COREG 3.125MG TABLET	89.9%	92.1%
00007413920	2001	COREG 3.125MG TABLET	89.8%	92.1%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00007413920	2002	COREG 3.125MG TABLET	86.7%	89.4%
00007413920	2003	COREG 3.125MG TABLET	84.1%	91.7%
00007413920	2004	COREG 3.125MG TABLET	78.2%	81.1%
00007413920	2005	COREG 3.125MG TABLET	81.9%	84.1%
00007413955	2002	COREG 3.125MG TABLET	94.8%	95.8%
00007413955	2003	COREG 3.125MG TABLET	0.0%*	0.0%
00007414020	1997	COREG 6.25MG TABLET	96.8%	97.6%
00007414020	1998	COREG 6.25MG TABLET	85.7%	88.5%
00007414020	1999	COREG 6.25MG TABLET	94.0%	95.6%
00007414020	2000	COREG 6.25MG TABLET	89.7%	92.0%
00007414020	2001	COREG 6.25MG TABLET	89.3%	91.9%
00007414020	2002	COREG 6.25MG TABLET	88.6%	91.5%
00007414020	2003	COREG 6.25MG TABLET	84.5%	91.1%
00007414020	2004	COREG 6.25MG TABLET	81.5%	84.8%
00007414020	2005	COREG 6.25MG TABLET	81.1%	83.5%
00173020155	1997	DARAPRIM 25MG TABLET	78.5%	83.8%
00173020155	1998	DARAPRIM 25MG TABLET	75.9%	81.8%
00173020155	1999	DARAPRIM 25MG TABLET	72.1%	79.0%
00173020155	2000	DARAPRIM 25MG TABLET	75.0%	81.5%
00173020155	2001	DARAPRIM 25MG TABLET	69.2%	76.2%
00173020155	2002	DARAPRIM 25MG TABLET	61.5%	70.0%
00173020155	2003	DARAPRIM 25MG TABLET	61.1%	69.0%
00173020155	2004	DARAPRIM 25MG TABLET	60.0%	68.5%
00173020155	2005	DARAPRIM 25MG TABLET	76.4%	87.4%
00007351920	1997	DEXEDRINE 5MG TABLET	94.1%	95.8%
00007351920	1998	DEXEDRINE 5MG TABLET	93.3%	95.2%
00007351920	1999	DEXEDRINE 5MG TABLET	93.2%	95.7%
00007351920	2000	DEXEDRINE 5MG TABLET	93.5%	96.2%
00007351920	2001	DEXEDRINE 5MG TABLET	92.3%	95.8%
00007351920	2002	DEXEDRINE 5MG TABLET	88.0%	93.8%
00007351920	2003	DEXEDRINE 5MG TABLET	67.5%	73.0%
00007351920	2004	DEXEDRINE 5MG TABLET	88.3%	92.2%
00007351920	2005	DEXEDRINE 5MG TABLET	91.4%	95.0%
00007351320	1999	DEXEDRINE SPANSULE 10MG	94.6%	95.9%
00007351320	2000	DEXEDRINE SPANSULE 10MG	93.5%	95.3%
00007351320	2001	DEXEDRINE SPANSULE 10MG	93.2%	95.1%
00007351320	2002	DEXEDRINE SPANSULE 10MG	84.7%	88.6%
00007351320	2003	DEXEDRINE SPANSULE 10MG	59.5%	63.5%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00007351320	2004	DEXEDRINE SPANSULE 10MG	89.0%	93.1%
00007351320	2005	DEXEDRINE SPANSULE 10MG	90.0%	94.5%
00007351420	1999	DEXEDRINE SPANSULE 15MG	95.6%	96.7%
00007351420	2000	DEXEDRINE SPANSULE 15MG	94.6%	96.1%
00007351420	2001	DEXEDRINE SPANSULE 15MG	94.5%	96.2%
00007351420	2002	DEXEDRINE SPANSULE 15MG	66.1%	68.7%
00007351420	2003	DEXEDRINE SPANSULE 15MG	87.0%	91.3%
00007351420	2004	DEXEDRINE SPANSULE 15MG	91.4%	94.5%
00007351420	2005	DEXEDRINE SPANSULE 15MG	92.2%	95.6%
00007351220	1999	DEXEDRINE SPANSULE 5MG	93.8%	95.6%
00007351220	2000	DEXEDRINE SPANSULE 5MG	88.1%	90.6%
00007351220	2001	DEXEDRINE SPANSULE 5MG	86.9%	90.0%
00007351220	2002	DEXEDRINE SPANSULE 5MG	70.5%	75.4%
00007351220	2003	DEXEDRINE SPANSULE 5MG	48.9%*	55.5%
00007351220	2004	DEXEDRINE SPANSULE 5MG	87.6%	91.8%
00007351220	2005	DEXEDRINE SPANSULE 5MG	62.7%	67.0%
00007365022	1997	DYAZIDE 37.5/25 CAPSULE	97.2%	98.7%
00007365022	1998	DYAZIDE 37.5/25 CAPSULE	98.4%	99.3%
00007365022	1999	DYAZIDE 37.5/25 CAPSULE	99.3%	99.8%
00007365022	2000	DYAZIDE 37.5/25 CAPSULE	98.7%	99.6%
00007365022	2001	DYAZIDE 37.5/25 CAPSULE	98.6%	99.4%
00007365022	2002	DYAZIDE 37.5/25 CAPSULE	98.2%	99.1%
00007365022	2003	DYAZIDE 37.5/25 CAPSULE	97.2%	98.4%
00007365022	2004	DYAZIDE 37.5/25 CAPSULE	97.0%	98.2%
00007365022	2005	DYAZIDE 37.5/25 CAPSULE	99.5%	99.8%
00007365030	1997	DYAZIDE 37.5/25 CAPSULE	96.3%	98.3%
00007365030	1998	DYAZIDE 37.5/25 CAPSULE	97.0%	98.6%
00007365030	1999	DYAZIDE 37.5/25 CAPSULE	95.4%	99.3%
00007365030	2000	DYAZIDE 37.5/25 CAPSULE	90.3%	98.8%
00007365030	2001	DYAZIDE 37.5/25 CAPSULE	91.7%	99.0%
00007365030	2002	DYAZIDE 37.5/25 CAPSULE	92.7%	98.9%
00007365030	2003	DYAZIDE 37.5/25 CAPSULE	88.7%	98.3%
00007365030	2004	DYAZIDE 37.5/25 CAPSULE	98.7%	99.2%
00007365030	2005	DYAZIDE 37.5/25 CAPSULE	99.4%	99.4%
00173047100	1997	EPIVIR 10MG/ML ORAL SOLN	84.4%	90.8%
00173047100	1998	EPIVIR 10MG/ML ORAL SOLN	89.6%	92.8%
00173047100	1999	EPIVIR 10MG/ML ORAL SOLN	88.6%	92.0%
00173047100	2000	EPIVIR 10MG/ML ORAL SOLN	89.1%	92.2%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00173047100	2001	EPIVIR 10MG/ML ORAL SOLN	89.3%	92.4%
00173047100	2002	EPIVIR 10MG/ML ORAL SOLN	87.8%	91.7%
00173047100	2003	EPIVIR 10MG/ML ORAL SOLN	86.7%	91.4%
00173047100	2004	EPIVIR 10MG/ML ORAL SOLN	88.7%	92.2%
00173047100	2005	EPIVIR 10MG/ML ORAL SOLN	86.8%	91.2%
00173047001	1997	EPIVIR 150MG TABLET	79.9%	85.0%
00173047001	1998	EPIVIR 150MG TABLET	78.8%	83.0%
00173047001	1999	EPIVIR 150MG TABLET	76.9%	81.7%
00173047001	2000	EPIVIR 150MG TABLET	77.7%	82.8%
00173047001	2001	EPIVIR 150MG TABLET	76.0%	81.0%
00173047001	2002	EPIVIR 150MG TABLET	77.9%	83.7%
00173047001	2003	EPIVIR 150MG TABLET	76.6%	82.7%
00173047001	2004	EPIVIR 150MG TABLET	75.8%	82.0%
00173047001	2005	EPIVIR 150MG TABLET	74.7%	81.2%
00173071400	2002	EPIVIR 300 MG TABLET	97.8%	98.2%
00173071400	2003	EPIVIR 300 MG TABLET	82.3%	86.5%
00173071400	2004	EPIVIR 300 MG TABLET	77.6%	83.5%
00173071400	2005	EPIVIR 300 MG TABLET	76.1%	82.5%
00173066200	1998	EPIVIR HBV 100MG TABLET	100.0%	100.0%
00173066200	1999	EPIVIR HBV 100MG TABLET	61.7%	64.0%
00173066200	2000	EPIVIR HBV 100MG TABLET	96.6%	97.6%
00173066200	2001	EPIVIR HBV 100MG TABLET	95.3%	96.7%
00173066200	2002	EPIVIR HBV 100MG TABLET	94.8%	96.1%
00173066200	2003	EPIVIR HBV 100MG TABLET	91.5%	93.8%
00173066200	2004	EPIVIR HBV 100MG TABLET	92.1%	95.1%
00173066200	2005	EPIVIR HBV 100MG TABLET	86.3%	90.1%
00173066300	1999	EPIVIR HBV 25MG/5ML SOLN	68.7%	77.7%
00173066300	2000	EPIVIR HBV 25MG/5ML SOLN	83.6%	89.4%
00173066300	2001	EPIVIR HBV 25MG/5ML SOLN	86.7%	91.3%
00173066300	2002	EPIVIR HBV 25MG/5ML SOLN	92.0%	95.1%
00173066300	2003	EPIVIR HBV 25MG/5ML SOLN	90.8%	94.5%
00173066300	2004	EPIVIR HBV 25MG/5ML SOLN	89.9%	94.9%
00173066300	2005	EPIVIR HBV 25MG/5ML SOLN	89.4%	93.9%
00007400720	1997	ESKALITH 300MG CAPSULE	99.2%	99.4%
00007400720	1998	ESKALITH 300MG CAPSULE	98.5%	98.9%
00007400720	1999	ESKALITH 300MG CAPSULE	98.1%	98.6%
00007400720	2000	ESKALITH 300MG CAPSULE	99.0%	99.3%
00007400720	2001	ESKALITH 300MG CAPSULE	97.4%	98.3%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00007400720	2002	ESKALITH 300MG CAPSULE	95.4%	96.1%
00007400720	2003	ESKALITH 300MG CAPSULE	85.9%	94.1%
00007400720	2004	ESKALITH 300MG CAPSULE	91.0%	93.9%
00007400720	2005	ESKALITH 300MG CAPSULE	93.6%	95.3%
00007401020	1997	ESKALITH CR 450MG TABLET SA	91.7%	93.2%
00007401020	1998	ESKALITH CR 450MG TABLET SA	90.2%	91.9%
00007401020	1999	ESKALITH CR 450MG TABLET SA	92.5%	94.0%
00007401020	2000	ESKALITH CR 450MG TABLET SA	92.1%	93.8%
00007401020	2001	ESKALITH CR 450MG TABLET SA	91.4%	93.1%
00007401020	2002	ESKALITH CR 450MG TABLET SA	90.0%	92.2%
00007401020	2003	ESKALITH CR 450MG TABLET SA	87.7%	90.7%
00007401020	2004	ESKALITH CR 450MG TABLET SA	55.1%	59.0%
00007401020	2005	ESKALITH CR 450MG TABLET SA	25.2%*	27.7%
00173045301	1997	FLONASE 0.05% NASAL SPRAY	94.3%	95.2%
00173045301	1998	FLONASE 0.05% NASAL SPRAY	81.0%	82.8%
00173045301	1999	FLONASE 0.05% NASAL SPRAY	49.4%*	51.1%
00173045301	2000	FLONASE 0.05% NASAL SPRAY	77.1%	82.2%
00173045301	2001	FLONASE 0.05% NASAL SPRAY	72.1%	82.4%
00173045301	2002	FLONASE 0.05% NASAL SPRAY	67.2%	76.8%
00173045301	2003	FLONASE 0.05% NASAL SPRAY	71.7%	78.2%
00173045301	2004	FLONASE 0.05% NASAL SPRAY	67.3%	73.7%
00173045301	2005	FLONASE 0.05% NASAL SPRAY	74.5%	80.6%
00173050900	1998	FLOVENT 100MCG ROTADISK	79.6%	81.2%
00173050900	1999	FLOVENT 100MCG ROTADISK	51.4%	52.2%
00173050900	2000	FLOVENT 100MCG ROTADISK	88.3%	89.8%
00173050900	2001	FLOVENT 100MCG ROTADISK	87.8%	88.5%
00173050900	2002	FLOVENT 100MCG ROTADISK	85.3%	86.0%
00173050900	2003	FLOVENT 100MCG ROTADISK	68.2%	69.5%
00173050900	2004	FLOVENT 100MCG ROTADISK	77.7%	78.8%
00173050900	2005	FLOVENT 100MCG ROTADISK	75.0%	88.9%
00173049400	1997	FLOVENT 110MCG INHALER	90.2%	91.1%
00173049400	1998	FLOVENT 110MCG INHALER	75.4%	77.0%
00173049400	1999	FLOVENT 110MCG INHALER	49.3%*	51.0%
00173049400	2000	FLOVENT 110MCG INHALER	78.4%	81.3%
00173049400	2001	FLOVENT 110MCG INHALER	76.0%	79.2%
00173049400	2002	FLOVENT 110MCG INHALER	71.0%	74.1%
00173049400	2003	FLOVENT 110MCG INHALER	71.5%	74.8%
00173049400	2004	FLOVENT 110MCG INHALER	70.3%	73.9%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00173049400	2005	FLOVENT 110MCG INHALER	44.7%*	47.7%
00173049500	1997	FLOVENT 220MCG INHALER	85.0%	86.7%
00173049500	1998	FLOVENT 220MCG INHALER	67.1%	69.8%
00173049500	1999	FLOVENT 220MCG INHALER	43.5%*	45.9%
00173049500	2000	FLOVENT 220MCG INHALER	65.0%	68.9%
00173049500	2001	FLOVENT 220MCG INHALER	63.7%	68.5%
00173049500	2002	FLOVENT 220MCG INHALER	56.2%	61.1%
00173049500	2003	FLOVENT 220MCG INHALER	56.8%	62.2%
00173049500	2004	FLOVENT 220MCG INHALER	55.3%	61.3%
00173049500	2005	FLOVENT 220MCG INHALER	15.0%*	17.6%
00173050400	1998	FLOVENT 250MCG ROTADISK	67.3%	68.1%
00173050400	1999	FLOVENT 250MCG ROTADISK	77.3%	78.6%
00173050400	2000	FLOVENT 250MCG ROTADISK	85.7%	86.6%
00173050400	2001	FLOVENT 250MCG ROTADISK	82.2%	84.3%
00173050400	2002	FLOVENT 250MCG ROTADISK	77.5%	79.5%
00173050400	2003	FLOVENT 250MCG ROTADISK	57.3%	59.5%
00173050400	2004	FLOVENT 250MCG ROTADISK	69.2%	71.3%
00173050400	2005	FLOVENT 250MCG ROTADISK	100.0%	100.0%
00173049100	1997	FLOVENT 44MCG INHALER	93.0%	93.7%
00173049100	1998	FLOVENT 44MCG INHALER	84.4%	85.6%
00173049100	1999	FLOVENT 44MCG INHALER	52.4%	53.6%
00173049100	2000	FLOVENT 44MCG INHALER	84.5%	86.7%
00173049100	2001	FLOVENT 44MCG INHALER	82.3%	85.2%
00173049100	2002	FLOVENT 44MCG INHALER	76.7%	80.0%
00173049100	2003	FLOVENT 44MCG INHALER	77.1%	79.7%
00173049100	2004	FLOVENT 44MCG INHALER	77.0%	80.3%
00173049100	2005	FLOVENT 44MCG INHALER	58.7%	61.6%
00173051100	1998	FLOVENT 50 MCG ROTADISK	65.9%	67.4%
00173051100	1999	FLOVENT 50 MCG ROTADISK	65.1%	65.8%
00173051100	2000	FLOVENT 50 MCG ROTADISK	88.2%	89.3%
00173051100	2001	FLOVENT 50 MCG ROTADISK	92.5%	93.4%
00173051100	2002	FLOVENT 50 MCG ROTADISK	91.4%	92.1%
00173051100	2003	FLOVENT 50 MCG ROTADISK	75.5%	76.9%
00173051100	2004	FLOVENT 50 MCG ROTADISK	85.8%	86.8%
00173051100	2005	FLOVENT 50 MCG ROTADISK	100.0%	100.0%
00007420105	1997	HYCANTIN 4MG VIAL	100.0%	100.0%
00007420105	1998	HYCANTIN 4MG VIAL	100.0%	100.0%
00007420105	1999	HYCANTIN 4MG VIAL	99.8%	99.8%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00007420105	2000	HYCAMPIN 4MG VIAL	96.3%	98.7%
00007420105	2001	HYCAMPIN 4MG VIAL	95.1%	97.3%
00007420105	2002	HYCAMPIN 4MG VIAL	88.5%	91.1%
00007420105	2003	HYCAMPIN 4MG VIAL	79.6%	83.1%
00007420105	2004	HYCAMPIN 4MG VIAL	51.3%	56.1%
00007420105	2005	HYCAMPIN 4MG VIAL	48.7%*	54.1%
00173045003	2000	IMITREX 100MG TABLET	94.0%	94.3%
00173045003	2001	IMITREX 100MG TABLET	92.2%	92.8%
00173045003	2002	IMITREX 100MG TABLET	86.8%	87.8%
00173045003	2003	IMITREX 100MG TABLET	88.1%	89.2%
00173045003	2004	IMITREX 100MG TABLET	13.0%*	17.5%
00173045003	2005	IMITREX 100MG TABLET	0.0%*	0.0%
00173073701	2004	IMITREX 100MG TABLET	86.6%	87.5%
00173073701	2005	IMITREX 100MG TABLET	88.6%	89.6%
00173052300	1997	IMITREX 20MG NASAL SPRAY	95.9%	96.1%
00173052300	1998	IMITREX 20MG NASAL SPRAY	89.0%	90.0%
00173052300	1999	IMITREX 20MG NASAL SPRAY	61.6%	62.5%
00173052300	2000	IMITREX 20MG NASAL SPRAY	88.7%	90.4%
00173052300	2001	IMITREX 20MG NASAL SPRAY	88.4%	90.2%
00173052300	2002	IMITREX 20MG NASAL SPRAY	84.6%	86.4%
00173052300	2003	IMITREX 20MG NASAL SPRAY	82.2%	83.9%
00173052300	2004	IMITREX 20MG NASAL SPRAY	81.2%	83.0%
00173052300	2005	IMITREX 20MG NASAL SPRAY	84.5%	86.2%
00173073500	2004	IMITREX 25 MG TABLET	79.0%	81.7%
00173073500	2005	IMITREX 25 MG TABLET	85.1%	88.0%
00173046002	1997	IMITREX 25MG TABLET	94.6%	95.5%
00173046002	1998	IMITREX 25MG TABLET	86.1%	87.9%
00173046002	1999	IMITREX 25MG TABLET	79.5%	81.7%
00173046002	2000	IMITREX 25MG TABLET	83.7%	86.4%
00173046002	2001	IMITREX 25MG TABLET	82.5%	85.7%
00173046002	2002	IMITREX 25MG TABLET	77.0%	80.6%
00173046002	2003	IMITREX 25MG TABLET	74.7%	78.8%
00173046002	2004	IMITREX 25MG TABLET	38.6%*	56.6%
00173046002	2005	IMITREX 25MG TABLET	94.1%	95.8%
00173045900	1997	IMITREX 50MG TABLET	93.5%	94.3%
00173045900	1998	IMITREX 50MG TABLET	85.3%	86.8%
00173045900	1999	IMITREX 50MG TABLET	83.7%	84.8%
00173045900	2000	IMITREX 50MG TABLET	88.6%	90.2%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00173045900	2001	IMITREX 50MG TABLET	85.7%	87.7%
00173045900	2002	IMITREX 50MG TABLET	78.6%	80.9%
00173045900	2003	IMITREX 50MG TABLET	77.8%	81.0%
00173045900	2004	IMITREX 50MG TABLET	20.7%*	30.4%
00173045900	2005	IMITREX 50MG TABLET	25.0%*	27.2%
00173073601	2004	IMITREX 50MG TABLET	80.8%	83.1%
00173073601	2005	IMITREX 50MG TABLET	82.2%	84.9%
00173052400	1997	IMITREX 5MG NASAL SPRAY	99.5%	99.7%
00173052400	1998	IMITREX 5MG NASAL SPRAY	84.3%	86.1%
00173052400	1999	IMITREX 5MG NASAL SPRAY	75.0%	76.6%
00173052400	2000	IMITREX 5MG NASAL SPRAY	89.1%	90.9%
00173052400	2001	IMITREX 5MG NASAL SPRAY	85.8%	88.1%
00173052400	2002	IMITREX 5MG NASAL SPRAY	83.1%	85.2%
00173052400	2003	IMITREX 5MG NASAL SPRAY	81.9%	84.2%
00173052400	2004	IMITREX 5MG NASAL SPRAY	83.2%	85.3%
00173052400	2005	IMITREX 5MG NASAL SPRAY	85.3%	87.6%
00173047800	1997	IMITREX 6MG/0.5ML KIT REFL	89.9%	91.2%
00173047800	1998	IMITREX 6MG/0.5ML KIT REFL	82.0%	84.2%
00173047800	1999	IMITREX 6MG/0.5ML KIT REFL	84.5%	87.0%
00173047800	2000	IMITREX 6MG/0.5ML KIT REFL	86.4%	88.7%
00173047800	2001	IMITREX 6MG/0.5ML KIT REFL	81.9%	84.7%
00173047800	2002	IMITREX 6MG/0.5ML KIT REFL	78.0%	80.5%
00173047800	2003	IMITREX 6MG/0.5ML KIT REFL	74.5%	77.0%
00173047800	2004	IMITREX 6MG/0.5ML KIT REFL	75.9%	78.4%
00173047800	2005	IMITREX 6MG/0.5ML KIT REFL	80.3%	82.9%
00173047900	1997	IMITREX 6MG/0.5ML SYRNG KIT	86.7%	88.0%
00173047900	1998	IMITREX 6MG/0.5ML SYRNG KIT	80.3%	83.2%
00173047900	1999	IMITREX 6MG/0.5ML SYRNG KIT	77.7%	80.6%
00173047900	2000	IMITREX 6MG/0.5ML SYRNG KIT	84.1%	87.3%
00173047900	2001	IMITREX 6MG/0.5ML SYRNG KIT	82.8%	86.0%
00173047900	2002	IMITREX 6MG/0.5ML SYRNG KIT	81.3%	84.3%
00173047900	2003	IMITREX 6MG/0.5ML SYRNG KIT	78.8%	81.9%
00173047900	2004	IMITREX 6MG/0.5ML SYRNG KIT	77.8%	80.5%
00173047900	2005	IMITREX 6MG/0.5ML SYRNG KIT	79.4%	82.2%
00173064255	1997	LAMICTAL 100MG TABLET	93.8%	94.9%
00173064255	1998	LAMICTAL 100MG TABLET	92.7%	94.0%
00173064255	1999	LAMICTAL 100MG TABLET	52.8%	53.9%
00173064255	2000	LAMICTAL 100MG TABLET	89.0%	91.1%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00173064255	2001	LAMICTAL 100MG TABLET	87.2%	89.4%
00173064255	2002	LAMICTAL 100MG TABLET	90.5%	92.8%
00173064255	2003	LAMICTAL 100MG TABLET	84.2%	86.7%
00173064255	2004	LAMICTAL 100MG TABLET	85.3%	88.0%
00173064255	2005	LAMICTAL 100MG TABLET	90.1%	92.4%
00173064360	1997	LAMICTAL 150MG TABLET	93.9%	95.0%
00173064360	1998	LAMICTAL 150MG TABLET	92.5%	94.0%
00173064360	1999	LAMICTAL 150MG TABLET	52.6%	53.6%
00173064360	2000	LAMICTAL 150MG TABLET	89.7%	92.0%
00173064360	2001	LAMICTAL 150MG TABLET	88.8%	90.6%
00173064360	2002	LAMICTAL 150MG TABLET	89.8%	92.1%
00173064360	2003	LAMICTAL 150MG TABLET	83.5%	86.1%
00173064360	2004	LAMICTAL 150MG TABLET	85.3%	87.7%
00173064360	2005	LAMICTAL 150MG TABLET	91.6%	93.7%
00173064460	1997	LAMICTAL 200MG TABLET	94.1%	95.2%
00173064460	1998	LAMICTAL 200MG TABLET	92.5%	93.8%
00173064460	1999	LAMICTAL 200MG TABLET	36.3%*	37.0%
00173064460	2000	LAMICTAL 200MG TABLET	90.9%	92.8%
00173064460	2001	LAMICTAL 200MG TABLET	90.1%	91.9%
00173064460	2002	LAMICTAL 200MG TABLET	90.5%	92.5%
00173064460	2003	LAMICTAL 200MG TABLET	85.4%	87.8%
00173064460	2004	LAMICTAL 200MG TABLET	87.2%	89.5%
00173064460	2005	LAMICTAL 200MG TABLET	92.0%	94.2%
00173052700	1998	LAMICTAL 25MG DISPER TABLET	99.9%	99.9%
00173052700	1999	LAMICTAL 25MG DISPER TABLET	90.8%	92.2%
00173052700	2000	LAMICTAL 25MG DISPER TABLET	94.3%	95.0%
00173052700	2001	LAMICTAL 25MG DISPER TABLET	92.5%	93.5%
00173052700	2002	LAMICTAL 25MG DISPER TABLET	93.9%	95.0%
00173052700	2003	LAMICTAL 25MG DISPER TABLET	90.1%	91.8%
00173052700	2004	LAMICTAL 25MG DISPER TABLET	90.0%	91.5%
00173052700	2005	LAMICTAL 25MG DISPER TABLET	91.3%	92.8%
00173063302	1997	LAMICTAL 25MG TABLET	93.7%	94.8%
00173063302	1998	LAMICTAL 25MG TABLET	92.6%	93.9%
00173063302	1999	LAMICTAL 25MG TABLET	49.5%*	50.6%
00173063302	2000	LAMICTAL 25MG TABLET	88.3%	90.6%
00173063302	2001	LAMICTAL 25MG TABLET	87.3%	89.5%
00173063302	2002	LAMICTAL 25MG TABLET	89.0%	91.5%
00173063302	2003	LAMICTAL 25MG TABLET	82.0%	84.8%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00173063302	2004	LAMICTAL 25MG TABLET	80.5%	83.8%
00173063302	2005	LAMICTAL 25MG TABLET	87.5%	90.4%
00173052600	1998	LAMICTAL 5MG DISPER TABLET	99.8%	99.8%
00173052600	1999	LAMICTAL 5MG DISPER TABLET	88.1%	89.5%
00173052600	2000	LAMICTAL 5MG DISPER TABLET	94.1%	95.1%
00173052600	2001	LAMICTAL 5MG DISPER TABLET	91.4%	93.2%
00173052600	2002	LAMICTAL 5MG DISPER TABLET	93.9%	95.4%
00173052600	2003	LAMICTAL 5MG DISPER TABLET	91.2%	92.9%
00173052600	2004	LAMICTAL 5MG DISPER TABLET	90.8%	92.7%
00173052600	2005	LAMICTAL 5MG DISPER TABLET	91.5%	93.6%
00173024255	1997	LANOXIN 125MCG TABLET	38.6%*	52.2%
00173024255	1998	LANOXIN 125MCG TABLET	64.9%	78.0%
00173024255	1999	LANOXIN 125MCG TABLET	77.1%	85.2%
00173024255	2000	LANOXIN 125MCG TABLET	66.5%	76.5%
00173024255	2001	LANOXIN 125MCG TABLET	51.3%	64.7%
00173024255	2002	LANOXIN 125MCG TABLET	62.4%	71.0%
00173024255	2003	LANOXIN 125MCG TABLET	58.4%	67.0%
00173024255	2004	LANOXIN 125MCG TABLET	55.2%	75.3%
00173024255	2005	LANOXIN 125MCG TABLET	60.0%	69.6%
00173024275	1997	LANOXIN 125MCG TABLET	84.3%	88.5%
00173024275	1998	LANOXIN 125MCG TABLET	86.1%	90.8%
00173024275	1999	LANOXIN 125MCG TABLET	76.6%	80.0%
00173024275	2000	LANOXIN 125MCG TABLET	84.7%	89.6%
00173024275	2001	LANOXIN 125MCG TABLET	84.5%	90.4%
00173024275	2002	LANOXIN 125MCG TABLET	68.6%	76.5%
00173024275	2003	LANOXIN 125MCG TABLET	70.9%	85.7%
00173024275	2004	LANOXIN 125MCG TABLET	64.9%	83.4%
00173024275	2005	LANOXIN 125MCG TABLET	60.7%	82.3%
00173024955	1997	LANOXIN 250MCG TABLET	39.2%	52.5%
00173024955	1998	LANOXIN 250MCG TABLET	78.6%	88.4%
00173024955	1999	LANOXIN 250MCG TABLET	68.2%	78.2%
00173024955	2000	LANOXIN 250MCG TABLET	48.8%	59.1%
00173024955	2001	LANOXIN 250MCG TABLET	37.8%	51.6%
00173024955	2002	LANOXIN 250MCG TABLET	62.9%	73.0%
00173024955	2003	LANOXIN 250MCG TABLET	58.0%	70.6%
00173024955	2004	LANOXIN 250MCG TABLET	67.7%	79.9%
00173024955	2005	LANOXIN 250MCG TABLET	66.1%	76.3%
00173024975	1997	LANOXIN 250MCG TABLET	59.9%	69.3%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00173024975	1998	LANOXIN 250MCG TABLET	70.3%	81.5%
00173024975	1999	LANOXIN 250MCG TABLET	62.0%	70.9%
00173024975	2000	LANOXIN 250MCG TABLET	53.5%	64.6%
00173024975	2001	LANOXIN 250MCG TABLET	58.1%	70.0%
00173024975	2002	LANOXIN 250MCG TABLET	49.4%*	62.3%
00173024975	2003	LANOXIN 250MCG TABLET	48.1%*	69.7%
00173024975	2004	LANOXIN 250MCG TABLET	47.6%*	69.8%
00173024975	2005	LANOXIN 250MCG TABLET	42.3%*	67.4%
00173024980	1997	LANOXIN 250MCG TABLET	85.6%	88.0%
00173024980	1998	LANOXIN 250MCG TABLET	93.6%	96.8%
00173024980	1999	LANOXIN 250MCG TABLET	92.5%	94.9%
00173024980	2000	LANOXIN 250MCG TABLET	96.2%	97.5%
00173024980	2001	LANOXIN 250MCG TABLET	89.8%	93.7%
00173024980	2002	LANOXIN 250MCG TABLET	83.5%	91.9%
00173024980	2003	LANOXIN 250MCG TABLET	85.5%	97.5%
00173024980	2004	LANOXIN 250MCG TABLET	76.0%	95.0%
00173024980	2005	LANOXIN 250MCG TABLET	73.7%	95.5%
00173026427	1997	LANOXIN 50MCG/ML ELIXIR	35.8%	37.6%
00173026427	1998	LANOXIN 50MCG/ML ELIXIR	62.9%	67.3%
00173026427	1999	LANOXIN 50MCG/ML ELIXIR	56.3%	60.0%
00173026427	2000	LANOXIN 50MCG/ML ELIXIR	77.8%	80.3%
00173026427	2001	LANOXIN 50MCG/ML ELIXIR	83.5%	86.0%
00173026427	2002	LANOXIN 50MCG/ML ELIXIR	76.5%	78.8%
00173026427	2003	LANOXIN 50MCG/ML ELIXIR	82.0%	84.6%
00173026427	2004	LANOXIN 50MCG/ML ELIXIR	81.7%	84.2%
00173026427	2005	LANOXIN 50MCG/ML ELIXIR	53.7%	55.3%
00173063535	1997	LEUKERAN 2MG TABLET	91.7%	93.6%
00173063535	1998	LEUKERAN 2MG TABLET	91.2%	93.5%
00173063535	1999	LEUKERAN 2MG TABLET	91.2%	93.7%
00173063535	2000	LEUKERAN 2MG TABLET	91.9%	94.2%
00173063535	2001	LEUKERAN 2MG TABLET	89.6%	92.1%
00173063535	2002	LEUKERAN 2MG TABLET	88.3%	91.4%
00173063535	2003	LEUKERAN 2MG TABLET	88.7%	91.6%
00173063535	2004	LEUKERAN 2MG TABLET	90.8%	93.6%
00173063535	2005	LEUKERAN 2MG TABLET	90.9%	93.3%
00173069000	2000	LOTRONEX 1MG TABLET	95.2%	95.9%
00173069000	2001	LOTRONEX 1MG TABLET	13.0%	13.8%
00173069000	2002	LOTRONEX 1MG TABLET	100.0%	100.0%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00173069005	2002	LOTRONEX 1MG TABLET	100.0%	100.0%
00173069005	2003	LOTRONEX 1MG TABLET	99.3%	99.6%
00173069005	2004	LOTRONEX 1MG TABLET	99.1%	99.5%
00173069005	2005	LOTRONEX 1MG TABLET	100.0%	100.0%
00173066518	1997	MEPRON 750MG/5ML SUSPENSION	84.1%	86.5%
00173066518	1998	MEPRON 750MG/5ML SUSPENSION	80.6%	83.3%
00173066518	1999	MEPRON 750MG/5ML SUSPENSION	80.1%	83.6%
00173066518	2000	MEPRON 750MG/5ML SUSPENSION	81.6%	85.3%
00173066518	2001	MEPRON 750MG/5ML SUSPENSION	76.5%	80.5%
00173066518	2002	MEPRON 750MG/5ML SUSPENSION	79.3%	83.7%
00173066518	2003	MEPRON 750MG/5ML SUSPENSION	81.8%	86.7%
00173066518	2004	MEPRON 750MG/5ML SUSPENSION	82.5%	87.0%
00173066518	2005	MEPRON 750MG/5ML SUSPENSION	83.7%	88.3%
00007447120	1997	PARNATE 10MG TABLET	96.2%	97.1%
00007447120	1998	PARNATE 10MG TABLET	77.1%	78.6%
00007447120	1999	PARNATE 10MG TABLET	96.2%	97.2%
00007447120	2000	PARNATE 10MG TABLET	95.0%	96.1%
00007447120	2001	PARNATE 10MG TABLET	94.7%	96.0%
00007447120	2002	PARNATE 10MG TABLET	94.6%	96.1%
00007447120	2003	PARNATE 10MG TABLET	95.0%	96.6%
00007447120	2004	PARNATE 10MG TABLET	96.7%	98.0%
00007447120	2005	PARNATE 10MG TABLET	99.8%	99.8%
00029321013	1997	PAXIL 10MG TABLET	97.6%	97.8%
00029321013	1998	PAXIL 10MG TABLET	93.4%	93.9%
00029321013	1999	PAXIL 10MG TABLET	91.3%	92.1%
00029321013	2000	PAXIL 10MG TABLET	89.9%	90.8%
00029321013	2001	PAXIL 10MG TABLET	85.8%	86.9%
00029321013	2002	PAXIL 10MG TABLET	84.3%	85.4%
00029321013	2003	PAXIL 10MG TABLET	74.1%	76.1%
00029321013	2004	PAXIL 10MG TABLET	28.2%*	29.8%
00029321013	2005	PAXIL 10MG TABLET	50.8%	52.5%
00029321548	1998	PAXIL 10MG/5ML SUSPENSION	96.1%	96.3%
00029321548	1999	PAXIL 10MG/5ML SUSPENSION	89.5%	90.1%
00029321548	2000	PAXIL 10MG/5ML SUSPENSION	89.6%	90.1%
00029321548	2001	PAXIL 10MG/5ML SUSPENSION	87.9%	88.5%
00029321548	2002	PAXIL 10MG/5ML SUSPENSION	92.2%	92.9%
00029321548	2003	PAXIL 10MG/5ML SUSPENSION	72.2%	73.8%
00029321548	2004	PAXIL 10MG/5ML SUSPENSION	68.6%	71.5%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00029321548	2005	PAXIL 10MG/5ML SUSPENSION	93.0%	93.7%
00029321113	1997	PAXIL 20MG TABLET	87.6%	91.1%
00029321113	1998	PAXIL 20MG TABLET	80.5%	83.4%
00029321113	1999	PAXIL 20MG TABLET	79.3%	82.6%
00029321113	2000	PAXIL 20MG TABLET	82.5%	86.1%
00029321113	2001	PAXIL 20MG TABLET	82.6%	85.8%
00029321113	2002	PAXIL 20MG TABLET	82.9%	86.0%
00029321113	2003	PAXIL 20MG TABLET	78.7%	82.6%
00029321113	2004	PAXIL 20MG TABLET	84.4%	86.7%
00029321113	2005	PAXIL 20MG TABLET	95.4%	97.0%
00029321120	1997	PAXIL 20MG TABLET	94.1%	95.3%
00029321120	1998	PAXIL 20MG TABLET	91.4%	92.9%
00029321120	1999	PAXIL 20MG TABLET	92.1%	94.0%
00029321120	2000	PAXIL 20MG TABLET	86.5%	88.5%
00029321120	2001	PAXIL 20MG TABLET	84.7%	86.7%
00029321120	2002	PAXIL 20MG TABLET	81.6%	83.8%
00029321120	2003	PAXIL 20MG TABLET	73.4%	76.9%
00029321120	2004	PAXIL 20MG TABLET	14.2%*	16.1%
00029321120	2005	PAXIL 20MG TABLET	82.6%	87.8%
00029321213	1997	PAXIL 30MG TABLET	92.3%	93.6%
00029321213	1998	PAXIL 30MG TABLET	88.3%	89.9%
00029321213	1999	PAXIL 30MG TABLET	88.7%	90.5%
00029321213	2000	PAXIL 30MG TABLET	86.6%	88.6%
00029321213	2001	PAXIL 30MG TABLET	84.4%	86.4%
00029321213	2002	PAXIL 30MG TABLET	82.6%	85.0%
00029321213	2003	PAXIL 30MG TABLET	71.6%	75.5%
00029321213	2004	PAXIL 30MG TABLET	14.6%*	16.0%
00029321213	2005	PAXIL 30MG TABLET	92.5%	94.9%
00029321313	1997	PAXIL 40MG TABLET	90.8%	92.2%
00029321313	1998	PAXIL 40MG TABLET	84.4%	86.3%
00029321313	1999	PAXIL 40MG TABLET	82.1%	84.5%
00029321313	2000	PAXIL 40MG TABLET	80.4%	83.2%
00029321313	2001	PAXIL 40MG TABLET	37.5%*	39.3%
00029321313	2002	PAXIL 40MG TABLET	78.7%	82.2%
00029321313	2003	PAXIL 40MG TABLET	70.8%	75.8%
00029321313	2004	PAXIL 40MG TABLET	15.2%*	17.0%
00029321313	2005	PAXIL 40MG TABLET	92.2%	94.5%
00029320613	2002	PAXIL CR 12.5MG TABLET	89.2%	89.5%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00029320613	2003	PAXIL CR 12.5MG TABLET	84.0%	84.8%
00029320613	2004	PAXIL CR 12.5MG TABLET	80.6%	81.5%
00029320613	2005	PAXIL CR 12.5MG TABLET	86.0%	87.2%
00029320713	2002	PAXIL CR 25MG TABLET	89.1%	89.4%
00029320713	2003	PAXIL CR 25MG TABLET	85.5%	86.2%
00029320713	2004	PAXIL CR 25MG TABLET	82.6%	83.5%
00029320713	2005	PAXIL CR 25MG TABLET	86.0%	87.4%
00029320813	2002	PAXIL CR 37.5MG TABLET	91.9%	92.1%
00029320813	2003	PAXIL CR 37.5MG TABLET	86.5%	87.5%
00029320813	2004	PAXIL CR 37.5MG TABLET	83.9%	85.2%
00029320813	2005	PAXIL CR 37.5MG TABLET	86.5%	88.8%
00173080725	1997	PURINETHOL 50MG TABLET	96.8%	97.6%
00173080725	1998	PURINETHOL 50MG TABLET	97.1%	98.0%
00173080725	1999	PURINETHOL 50MG TABLET	96.9%	98.0%
00173080725	2000	PURINETHOL 50MG TABLET	97.1%	98.1%
00173080725	2001	PURINETHOL 50MG TABLET	97.1%	98.0%
00173080725	2002	PURINETHOL 50MG TABLET	96.6%	97.6%
00173080725	2003	PURINETHOL 50MG TABLET	96.1%	97.1%
00173080765	1997	PURINETHOL 50MG TABLET	86.2%	90.1%
00173080765	1998	PURINETHOL 50MG TABLET	87.8%	92.0%
00173080765	1999	PURINETHOL 50MG TABLET	86.6%	91.5%
00173080765	2000	PURINETHOL 50MG TABLET	88.2%	92.4%
00173080765	2001	PURINETHOL 50MG TABLET	84.4%	89.0%
00173080765	2002	PURINETHOL 50MG TABLET	66.0%	69.9%
00173080765	2003	PURINETHOL 50MG TABLET	86.3%	90.0%
00029485120	1997	RELAFEN 500MG TABLET	95.3%	96.2%
00029485120	1998	RELAFEN 500MG TABLET	89.2%	90.1%
00029485120	1999	RELAFEN 500MG TABLET	88.9%	89.9%
00029485120	2000	RELAFEN 500MG TABLET	84.7%	87.8%
00029485120	2001	RELAFEN 500MG TABLET	38.1%*	58.4%
00029485120	2002	RELAFEN 500MG TABLET	4.9%*	29.4%
00029485120	2003	RELAFEN 500MG TABLET	17.9%*	65.0%
00029485120	2004	RELAFEN 500MG TABLET	79.7%	87.4%
00029485120	2005	RELAFEN 500MG TABLET	84.3%	92.1%
00029485220	1997	RELAFEN 750MG TABLET	97.5%	97.8%
00029485220	1998	RELAFEN 750MG TABLET	92.2%	92.5%
00029485220	1999	RELAFEN 750MG TABLET	97.8%	98.2%
00029485220	2000	RELAFEN 750MG TABLET	96.4%	97.0%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00029485220	2001	RELAFEN 750MG TABLET	96.6%	97.5%
00029485220	2002	RELAFEN 750MG TABLET	71.6%	79.0%
00029485220	2003	RELAFEN 750MG TABLET	35.8%*	39.7%
00029485220	2004	RELAFEN 750MG TABLET	61.4%	71.8%
00029485220	2005	RELAFEN 750MG TABLET	89.1%	94.8%
00173068101	1999	RELENZA 5 MG DISKHALER	88.8%	89.6%
00173068101	2000	RELENZA 5 MG DISKHALER	99.5%	99.7%
00173068101	2001	RELENZA 5 MG DISKHALER	32.8%*	36.9%
00173068101	2002	RELENZA 5 MG DISKHALER	71.0%	88.5%
00173068101	2003	RELENZA 5 MG DISKHALER	66.3%	67.6%
00173068101	2004	RELENZA 5 MG DISKHALER	84.1%	85.3%
00173068101	2005	RELENZA 5 MG DISKHALER	2.2%*	3.4%
00007489020	1997	REQUIP 0.25MG TABLET	99.6%	99.7%
00007489020	1998	REQUIP 0.25MG TABLET	96.4%	97.0%
00007489020	1999	REQUIP 0.25MG TABLET	94.2%	95.3%
00007489020	2000	REQUIP 0.25MG TABLET	92.7%	94.3%
00007489020	2001	REQUIP 0.25MG TABLET	92.1%	94.1%
00007489020	2002	REQUIP 0.25MG TABLET	89.5%	92.4%
00007489020	2003	REQUIP 0.25MG TABLET	73.5%	77.1%
00007489020	2004	REQUIP 0.25MG TABLET	76.8%	79.5%
00007489020	2005	REQUIP 0.25MG TABLET	89.9%	92.7%
00007489120	1997	REQUIP 0.5MG TABLET	99.4%	99.6%
00007489120	1998	REQUIP 0.5MG TABLET	96.0%	96.7%
00007489120	1999	REQUIP 0.5MG TABLET	94.1%	95.1%
00007489120	2000	REQUIP 0.5MG TABLET	94.1%	95.4%
00007489120	2001	REQUIP 0.5MG TABLET	95.0%	96.4%
00007489120	2002	REQUIP 0.5MG TABLET	91.8%	94.0%
00007489120	2003	REQUIP 0.5MG TABLET	77.9%	81.2%
00007489120	2004	REQUIP 0.5MG TABLET	79.0%	81.6%
00007489120	2005	REQUIP 0.5MG TABLET	90.6%	93.4%
00007489220	1997	REQUIP 1MG TABLET	99.9%	99.9%
00007489220	1998	REQUIP 1MG TABLET	97.7%	98.1%
00007489220	1999	REQUIP 1MG TABLET	95.4%	96.3%
00007489220	2000	REQUIP 1MG TABLET	93.9%	95.3%
00007489220	2001	REQUIP 1MG TABLET	92.8%	94.7%
00007489220	2002	REQUIP 1MG TABLET	90.8%	94.0%
00007489220	2003	REQUIP 1MG TABLET	76.3%	80.7%
00007489220	2004	REQUIP 1MG TABLET	76.2%	80.1%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00007489220	2005	REQUIP 1MG TABLET	87.9%	91.7%
00007489320	1997	REQUIP 2MG TABLET	99.9%	99.9%
00007489320	1998	REQUIP 2MG TABLET	96.3%	97.1%
00007489320	1999	REQUIP 2MG TABLET	95.7%	96.6%
00007489320	2000	REQUIP 2MG TABLET	93.1%	94.5%
00007489320	2001	REQUIP 2MG TABLET	93.4%	95.1%
00007489320	2002	REQUIP 2MG TABLET	89.2%	92.4%
00007489320	2003	REQUIP 2MG TABLET	77.0%	82.1%
00007489320	2004	REQUIP 2MG TABLET	76.2%	80.4%
00007489320	2005	REQUIP 2MG TABLET	84.9%	89.9%
00007489520	2001	REQUIP 3MG TABLET	98.9%	99.2%
00007489520	2002	REQUIP 3MG TABLET	96.2%	96.8%
00007489520	2003	REQUIP 3MG TABLET	94.9%	95.8%
00007489520	2004	REQUIP 3MG TABLET	93.8%	95.0%
00007489520	2005	REQUIP 3MG TABLET	94.4%	95.9%
00007489620	1999	REQUIP 4MG TABLET	99.8%	99.9%
00007489620	2000	REQUIP 4MG TABLET	91.2%	93.5%
00007489620	2001	REQUIP 4MG TABLET	97.8%	98.3%
00007489620	2002	REQUIP 4MG TABLET	94.3%	95.3%
00007489620	2003	REQUIP 4MG TABLET	90.9%	92.7%
00007489620	2004	REQUIP 4MG TABLET	92.1%	93.4%
00007489620	2005	REQUIP 4MG TABLET	93.6%	95.3%
00007489420	1997	REQUIP 5MG TABLET	99.8%	99.8%
00007489420	1998	REQUIP 5MG TABLET	95.6%	96.4%
00007489420	1999	REQUIP 5MG TABLET	95.7%	96.7%
00007489420	2000	REQUIP 5MG TABLET	93.2%	94.6%
00007489420	2001	REQUIP 5MG TABLET	81.3%	84.5%
00007489420	2002	REQUIP 5MG TABLET	90.0%	92.2%
00007489420	2003	REQUIP 5MG TABLET	84.5%	87.6%
00007489420	2004	REQUIP 5MG TABLET	86.4%	89.1%
00007489420	2005	REQUIP 5MG TABLET	90.6%	93.1%
00173010855	1997	RETROVIR 100MG CAPSULE	72.1%	76.7%
00173010855	1998	RETROVIR 100MG CAPSULE	76.8%	80.1%
00173010855	1999	RETROVIR 100MG CAPSULE	78.6%	82.0%
00173010855	2000	RETROVIR 100MG CAPSULE	81.4%	85.0%
00173010855	2001	RETROVIR 100MG CAPSULE	82.6%	86.4%
00173010855	2002	RETROVIR 100MG CAPSULE	81.5%	85.7%
00173010855	2003	RETROVIR 100MG CAPSULE	82.7%	86.6%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00173010855	2004	RETROVIR 100MG CAPSULE	82.4%	86.3%
00173010855	2005	RETROVIR 100MG CAPSULE	81.9%	86.2%
00173011318	1997	RETROVIR 10MG/ML SYRUP	87.5%	91.7%
00173011318	1998	RETROVIR 10MG/ML SYRUP	88.9%	92.2%
00173011318	1999	RETROVIR 10MG/ML SYRUP	89.4%	92.0%
00173011318	2000	RETROVIR 10MG/ML SYRUP	91.3%	93.3%
00173011318	2001	RETROVIR 10MG/ML SYRUP	92.4%	94.4%
00173011318	2002	RETROVIR 10MG/ML SYRUP	91.1%	93.5%
00173011318	2003	RETROVIR 10MG/ML SYRUP	91.1%	93.5%
00173011318	2004	RETROVIR 10MG/ML SYRUP	90.6%	93.1%
00173011318	2005	RETROVIR 10MG/ML SYRUP	89.7%	92.5%
00173050100	1997	RETROVIR 300MG TABLET	82.4%	86.1%
00173050100	1998	RETROVIR 300MG TABLET	78.4%	82.8%
00173050100	1999	RETROVIR 300MG TABLET	80.1%	83.6%
00173050100	2000	RETROVIR 300MG TABLET	81.0%	85.0%
00173050100	2001	RETROVIR 300MG TABLET	81.0%	85.1%
00173050100	2002	RETROVIR 300MG TABLET	74.0%	79.5%
00173050100	2003	RETROVIR 300MG TABLET	74.6%	80.2%
00173050100	2004	RETROVIR 300MG TABLET	73.2%	79.1%
00173050100	2005	RETROVIR 300MG TABLET	71.6%	78.3%
00173010793	1997	RETROVIR IV INFUSION VIAL	80.7%	88.6%
00173010793	1998	RETROVIR IV INFUSION VIAL	95.7%	96.5%
00173010793	1999	RETROVIR IV INFUSION VIAL	86.9%	90.1%
00173010793	2000	RETROVIR IV INFUSION VIAL	94.6%	95.4%
00173010793	2001	RETROVIR IV INFUSION VIAL	95.7%	97.1%
00173010793	2002	RETROVIR IV INFUSION VIAL	91.2%	93.8%
00173010793	2003	RETROVIR IV INFUSION VIAL	96.8%	97.6%
00173010793	2004	RETROVIR IV INFUSION VIAL	95.9%	97.0%
00173010793	2005	RETROVIR IV INFUSION VIAL	94.7%	96.5%
00173046400	1997	SEREVENT 21MCG INHALER	90.0%	91.4%
00173046400	1998	SEREVENT 21MCG INHALER	76.9%	78.9%
00173046400	1999	SEREVENT 21MCG INHALER	71.6%	74.2%
00173046400	2000	SEREVENT 21MCG INHALER	76.9%	80.3%
00173046400	2001	SEREVENT 21MCG INHALER	69.8%	74.1%
00173046400	2002	SEREVENT 21MCG INHALER	61.3%	65.9%
00173046400	2003	SEREVENT 21MCG INHALER	43.4%*	47.7%
00173046400	2004	SEREVENT 21MCG INHALER	20.9%	23.2%
00173046400	2005	SEREVENT 21MCG INHALER	100.0%	100.0%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00173046500	1997	SEREVENT 21MCG INHLR REFILL	98.3%	98.8%
00173046500	1998	SEREVENT 21MCG INHLR REFILL	97.5%	98.2%
00173046500	1999	SEREVENT 21MCG INHLR REFILL	88.9%	89.3%
00173046500	2000	SEREVENT 21MCG INHLR REFILL	95.5%	96.1%
00173046500	2001	SEREVENT 21MCG INHLR REFILL	95.1%	96.0%
00173046500	2002	SEREVENT 21MCG INHLR REFILL	93.2%	94.8%
00173046500	2003	SEREVENT 21MCG INHLR REFILL	12.9%*	13.7%
00173046500	2004	SEREVENT 21MCG INHLR REFILL	50.0%	55.3%
00173052100	1997	SEREVENT DISKUS 50MCG	100.0%	100.0%
00173052100	1998	SEREVENT DISKUS 50MCG	81.3%	81.9%
00173052100	1999	SEREVENT DISKUS 50MCG	83.0%	83.3%
00173052100	2000	SEREVENT DISKUS 50MCG	88.0%	88.4%
00173052100	2001	SEREVENT DISKUS 50MCG	83.6%	84.3%
00173052100	2002	SEREVENT DISKUS 50MCG	75.2%	76.4%
00173052100	2003	SEREVENT DISKUS 50MCG	62.5%	67.1%
00173052100	2004	SEREVENT DISKUS 50MCG	56.3%	62.0%
00173052100	2005	SEREVENT DISKUS 50MCG	62.1%	67.4%
00108490420	1997	STELAZINE 2MG TABLET	92.4%	94.9%
00108490420	1998	STELAZINE 2MG TABLET	94.2%	95.9%
00108490420	1999	STELAZINE 2MG TABLET	96.4%	97.5%
00108490420	2000	STELAZINE 2MG TABLET	97.3%	98.1%
00108490420	2001	STELAZINE 2MG TABLET	97.7%	98.4%
00108490420	2002	STELAZINE 2MG TABLET	92.1%	93.8%
00108490420	2003	STELAZINE 2MG TABLET	96.6%	97.8%
00108490201	1997	STELAZINE 2MG/ML VIAL	56.9%	59.1%
00108490201	1998	STELAZINE 2MG/ML VIAL	84.1%	86.5%
00108490201	1999	STELAZINE 2MG/ML VIAL	50.2%	52.3%
00108490201	2000	STELAZINE 2MG/ML VIAL	88.2%	90.8%
00108490201	2001	STELAZINE 2MG/ML VIAL	30.4%*	31.9%
00108490201	2002	STELAZINE 2MG/ML VIAL	31.3%*	33.5%
00108490201	2003	STELAZINE 2MG/ML VIAL	27.6%	28.9%
00173045402	1997	TEMOVATE EMOLLIENT 0.05% CRM	89.0%	92.5%
00173045402	1998	TEMOVATE EMOLLIENT 0.05% CRM	89.7%	93.7%
00173045402	1999	TEMOVATE EMOLLIENT 0.05% CRM	83.7%	89.8%
00173045402	2000	TEMOVATE EMOLLIENT 0.05% CRM	51.4%	72.0%
00173045402	2001	TEMOVATE EMOLLIENT 0.05% CRM	0.0%	0.0%
00173045402	2002	TEMOVATE EMOLLIENT 0.05% CRM	100.0%	100.0%
00173045403	1997	TEMOVATE EMOLLIENT 0.05% CRM	95.3%	96.6%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00173045403	1998	TEMOVATE EMOLLIENT 0.05% CRM	94.9%	96.7%
00173045403	1999	TEMOVATE EMOLLIENT 0.05% CRM	92.1%	94.8%
00173045403	2000	TEMOVATE EMOLLIENT 0.05% CRM	55.4%	80.9%
00173045403	2001	TEMOVATE EMOLLIENT 0.05% CRM	0.0%*	0.0%
00173045403	2002	TEMOVATE EMOLLIENT 0.05% CRM	0.0%*	0.0%
00173088025	1997	THIOGUANINE TABLOID 40MG TB	70.2%	73.6%
00173088025	1998	THIOGUANINE TABLOID 40MG TB	69.7%	74.4%
00173088025	1999	THIOGUANINE TABLOID 40MG TB	68.7%	75.0%
00173088025	2000	THIOGUANINE TABLOID 40MG TB	75.0%	79.7%
00173088025	2001	THIOGUANINE TABLOID 40MG TB	75.2%	79.0%
00173088025	2002	THIOGUANINE TABLOID 40MG TB	75.4%	78.3%
00173088025	2003	THIOGUANINE TABLOID 40MG TB	80.1%	83.1%
00173088025	2004	THIOGUANINE TABLOID 40MG TB	78.3%	81.5%
00173088025	2005	THIOGUANINE TABLOID 40MG TB	78.6%	82.7%
00007507103	1997	THORAZINE 100MG SUPPOSITORY	97.2%	97.7%
00007507103	1998	THORAZINE 100MG SUPPOSITORY	94.0%	95.1%
00007507103	1999	THORAZINE 100MG SUPPOSITORY	87.9%	89.0%
00007507103	2000	THORAZINE 100MG SUPPOSITORY	94.7%	95.5%
00007507103	2001	THORAZINE 100MG SUPPOSITORY	76.7%	78.3%
00007507103	2002	THORAZINE 100MG SUPPOSITORY	75.6%	78.0%
00007507103	2003	THORAZINE 100MG SUPPOSITORY	69.6%	72.8%
00007507720	1997	THORAZINE 100MG TABLET	97.1%	97.9%
00007507720	1998	THORAZINE 100MG TABLET	96.7%	97.8%
00007507720	1999	THORAZINE 100MG TABLET	97.2%	98.1%
00007507720	2000	THORAZINE 100MG TABLET	90.2%	91.4%
00007507720	2001	THORAZINE 100MG TABLET	97.4%	98.2%
00007507720	2002	THORAZINE 100MG TABLET	96.4%	97.4%
00007507720	2003	THORAZINE 100MG TABLET	73.6%	81.7%
00007507244	1997	THORAZINE 10MG/5ML SYRUP	88.3%	89.1%
00007507244	1998	THORAZINE 10MG/5ML SYRUP	97.4%	98.1%
00007507244	1999	THORAZINE 10MG/5ML SYRUP	85.7%	86.9%
00007507244	2000	THORAZINE 10MG/5ML SYRUP	95.8%	96.5%
00007507244	2001	THORAZINE 10MG/5ML SYRUP	81.9%	83.2%
00007507244	2002	THORAZINE 10MG/5ML SYRUP	89.2%	90.1%
00007507244	2003	THORAZINE 10MG/5ML SYRUP	70.8%	72.4%
00007507920	1997	THORAZINE 200MG TABLET	95.1%	96.6%
00007507920	1998	THORAZINE 200MG TABLET	97.6%	98.3%
00007507920	1999	THORAZINE 200MG TABLET	97.3%	98.1%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00007507920	2000	THORAZINE 200MG TABLET	87.9%	89.6%
00007507920	2001	THORAZINE 200MG TABLET	96.8%	97.8%
00007507920	2002	THORAZINE 200MG TABLET	98.4%	99.0%
00007507930	1997	THORAZINE 200MG TABLET	60.1%	82.0%
00007507930	1998	THORAZINE 200MG TABLET	90.8%	93.2%
00007507930	1999	THORAZINE 200MG TABLET	100.0%	100.0%
00007507930	2000	THORAZINE 200MG TABLET	100.0%	100.0%
00007507420	1997	THORAZINE 25MG TABLET	97.8%	98.5%
00007507420	1998	THORAZINE 25MG TABLET	98.1%	98.7%
00007507420	1999	THORAZINE 25MG TABLET	98.5%	98.9%
00007507420	2000	THORAZINE 25MG TABLET	88.7%	89.5%
00007507420	2001	THORAZINE 25MG TABLET	96.5%	97.5%
00007507420	2002	THORAZINE 25MG TABLET	96.7%	97.7%
00007507430	1997	THORAZINE 25MG TABLET	72.7%	88.4%
00007507430	1998	THORAZINE 25MG TABLET	62.4%	69.1%
00007507430	1999	THORAZINE 25MG TABLET	72.0%	79.4%
00007507430	2000	THORAZINE 25MG TABLET	33.3%*	41.6%
00007506201	1997	THORAZINE 25MG/ML VIAL	82.3%	84.1%
00007506201	1998	THORAZINE 25MG/ML VIAL	94.1%	95.8%
00007506201	1999	THORAZINE 25MG/ML VIAL	85.7%	87.6%
00007506201	2000	THORAZINE 25MG/ML VIAL	97.5%	98.2%
00007506201	2001	THORAZINE 25MG/ML VIAL	73.3%	74.9%
00007506201	2002	THORAZINE 25MG/ML VIAL	78.7%	80.1%
00007506201	2003	THORAZINE 25MG/ML VIAL	81.7%	83.3%
00007506201	2004	THORAZINE 25MG/ML VIAL	100.0%	100.0%
00007504744	1997	THORAZINE 30MG/ML LIQ CONC	83.2%	87.4%
00007504744	1998	THORAZINE 30MG/ML LIQ CONC	0.0%	0.0%
00007507620	1997	THORAZINE 50MG TABLET	97.2%	98.1%
00007507620	1998	THORAZINE 50MG TABLET	98.2%	98.8%
00007507620	1999	THORAZINE 50MG TABLET	98.4%	98.9%
00007507620	2000	THORAZINE 50MG TABLET	98.5%	98.9%
00007507620	2001	THORAZINE 50MG TABLET	98.1%	98.7%
00007507620	2002	THORAZINE 50MG TABLET	94.2%	95.3%
00007507620	2003	THORAZINE 50MG TABLET	72.7%	74.6%
00007507630	1997	THORAZINE 50MG TABLET	80.5%	90.6%
00007507630	1998	THORAZINE 50MG TABLET	81.4%	86.3%
00007507630	1999	THORAZINE 50MG TABLET	74.3%	82.0%
00007507630	2000	THORAZINE 50MG TABLET	100.0%	100.0%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00173069100	2000	TRIZIVIR TABLET	93.1%	95.2%
00173069100	2001	TRIZIVIR TABLET	83.0%	86.3%
00173069100	2002	TRIZIVIR TABLET	79.4%	83.7%
00173069100	2003	TRIZIVIR TABLET	80.7%	84.5%
00173069100	2004	TRIZIVIR TABLET	80.0%	84.3%
00173069100	2005	TRIZIVIR TABLET	80.6%	84.9%
00173069120	2004	TRIZIVIR TABLET	95.8%	96.9%
00173069120	2005	TRIZIVIR TABLET	58.2%	61.9%
00173056502	2001	VALTREX 1GM CAPLET	99.9%	99.9%
00173056502	2002	VALTREX 1GM CAPLET	89.6%	91.4%
00173056502	2003	VALTREX 1GM CAPLET	87.8%	89.6%
00173056502	2004	VALTREX 1GM CAPLET	86.6%	88.7%
00173056502	2005	VALTREX 1GM CAPLET	89.2%	91.1%
00173093303	1997	VALTREX 500MG CAPLET	95.9%	96.7%
00173093303	1998	VALTREX 500MG CAPLET	90.3%	91.4%
00173093303	1999	VALTREX 500MG CAPLET	58.3%	59.2%
00173093303	2000	VALTREX 500MG CAPLET	92.2%	93.5%
00173093303	2001	VALTREX 500MG CAPLET	92.5%	93.8%
00173093303	2002	VALTREX 500MG CAPLET	91.9%	93.3%
00173093303	2003	VALTREX 500MG CAPLET	89.5%	91.7%
00173093308	2003	VALTREX 500MG CAPLET	85.1%	85.9%
00173093308	2004	VALTREX 500MG CAPLET	83.2%	84.6%
00173093308	2005	VALTREX 500MG CAPLET	85.7%	87.6%
00173032198	1997	VENTOLIN 90MCG INH REFILL	97.8%	99.0%
00173032198	1998	VENTOLIN 90MCG INH REFILL	94.6%	97.7%
00173032198	1999	VENTOLIN 90MCG INH REFILL	89.3%	94.5%
00173032198	2000	VENTOLIN 90MCG INH REFILL	91.2%	95.2%
00173032198	2001	VENTOLIN 90MCG INH REFILL	94.6%	96.1%
00173032198	2002	VENTOLIN 90MCG INH REFILL	94.9%	96.3%
00173032198	2003	VENTOLIN 90MCG INH REFILL	99.1%	99.4%
00173068200	2002	VENTOLIN HFA 90 MCG INHALER	64.6%	65.9%
00173068200	2003	VENTOLIN HFA 90 MCG INHALER	98.5%	98.9%
00173068200	2004	VENTOLIN HFA 90 MCG INHALER	98.1%	99.0%
00173068200	2005	VENTOLIN HFA 90 MCG INHALER	98.3%	98.7%
00173038901	1997	VENTOLIN ROTACAPS 200MCG	93.0%	94.3%
00173038901	1998	VENTOLIN ROTACAPS 200MCG	97.4%	98.4%
00173038901	1999	VENTOLIN ROTACAPS 200MCG	95.7%	97.3%
00173038901	2000	VENTOLIN ROTACAPS 200MCG	93.6%	96.4%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00173038901	2001	VENTOLIN ROTACAPS 200MCG	88.7%	93.6%
00173038901	2002	VENTOLIN ROTACAPS 200MCG	66.7%	75.6%
00173038902	1997	VENTOLIN ROTACAPS 200MCG	94.4%	95.5%
00173038902	1998	VENTOLIN ROTACAPS 200MCG	97.9%	98.6%
00173038902	1999	VENTOLIN ROTACAPS 200MCG	97.3%	98.0%
00173038902	2000	VENTOLIN ROTACAPS 200MCG	97.8%	98.3%
00173038902	2001	VENTOLIN ROTACAPS 200MCG	96.5%	97.4%
00173038902	2002	VENTOLIN ROTACAPS 200MCG	0.0%	0.0%
00173038903	1997	VENTOLIN ROTACAPS 200MCG	70.2%	82.0%
00173038903	1998	VENTOLIN ROTACAPS 200MCG	81.4%	90.2%
00173038903	1999	VENTOLIN ROTACAPS 200MCG	0.0%	0.0%
00173038903	2000	VENTOLIN ROTACAPS 200MCG	0.0%	0.0%
00173017855	1997	WELLBUTRIN 100MG TABLET	81.0%	84.2%
00173017855	1998	WELLBUTRIN 100MG TABLET	75.1%	79.5%
00173017855	1999	WELLBUTRIN 100MG TABLET	73.4%	78.9%
00173017855	2000	WELLBUTRIN 100MG TABLET	65.5%	73.9%
00173017855	2001	WELLBUTRIN 100MG TABLET	59.1%	67.7%
00173017855	2002	WELLBUTRIN 100MG TABLET	84.7%	89.7%
00173017855	2003	WELLBUTRIN 100MG TABLET	85.8%	91.3%
00173017855	2004	WELLBUTRIN 100MG TABLET	83.7%	88.2%
00173017855	2005	WELLBUTRIN 100MG TABLET	91.7%	94.7%
00173017755	1997	WELLBUTRIN 75MG TABLET	79.1%	82.8%
00173017755	1998	WELLBUTRIN 75MG TABLET	75.0%	79.5%
00173017755	1999	WELLBUTRIN 75MG TABLET	73.1%	78.7%
00173017755	2000	WELLBUTRIN 75MG TABLET	61.7%	69.8%
00173017755	2001	WELLBUTRIN 75MG TABLET	58.9%	67.5%
00173017755	2002	WELLBUTRIN 75MG TABLET	87.4%	91.4%
00173017755	2003	WELLBUTRIN 75MG TABLET	89.3%	93.4%
00173017755	2004	WELLBUTRIN 75MG TABLET	89.2%	91.6%
00173017755	2005	WELLBUTRIN 75MG TABLET	95.8%	97.3%
00173094755	1997	WELLBUTRIN SR 100MG TAB SA	93.9%	94.6%
00173094755	1998	WELLBUTRIN SR 100MG TAB SA	78.3%	79.7%
00173094755	1999	WELLBUTRIN SR 100MG TAB SA	46.7%*	47.9%
00173094755	2000	WELLBUTRIN SR 100MG TAB SA	83.0%	85.5%
00173094755	2001	WELLBUTRIN SR 100MG TAB SA	78.9%	81.6%
00173094755	2002	WELLBUTRIN SR 100MG TAB SA	77.5%	80.3%
00173094755	2003	WELLBUTRIN SR 100MG TAB SA	70.1%	74.0%
00173094755	2004	WELLBUTRIN SR 100MG TAB SA	8.4%*	10.3%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00173094755	2005	WELLBUTRIN SR 100MG TAB SA	12.0%*	14.4%
00173013555	1997	WELLBUTRIN SR 150MG TAB SA	95.4%	96.0%
00173013555	1998	WELLBUTRIN SR 150MG TAB SA	81.0%	82.3%
00173013555	1999	WELLBUTRIN SR 150MG TAB SA	19.2%*	19.7%
00173013555	2000	WELLBUTRIN SR 150MG TAB SA	85.5%	87.9%
00173013555	2001	WELLBUTRIN SR 150MG TAB SA	81.3%	83.7%
00173013555	2002	WELLBUTRIN SR 150MG TAB SA	79.9%	82.4%
00173013555	2003	WELLBUTRIN SR 150MG TAB SA	76.7%	79.3%
00173013555	2004	WELLBUTRIN SR 150MG TAB SA	62.4%	69.2%
00173013555	2005	WELLBUTRIN SR 150MG TAB SA	11.2%*	13.3%
00173072200	2002	WELLBUTRIN SR 200MG TAB SA	76.7%	76.9%
00173072200	2003	WELLBUTRIN SR 200MG TAB SA	83.8%	84.4%
00173072200	2004	WELLBUTRIN SR 200MG TAB SA	79.3%	80.0%
00173072200	2005	WELLBUTRIN SR 200MG TAB SA	22.7%*	24.3%
00173073001	2003	WELLBUTRIN XL 150MG TABLET	83.1%	83.4%
00173073001	2004	WELLBUTRIN XL 150MG TABLET	81.8%	82.5%
00173073001	2005	WELLBUTRIN XL 150MG TABLET	83.5%	84.8%
00173073101	2003	WELLBUTRIN XL 300MG TABLET	80.7%	81.2%
00173073101	2004	WELLBUTRIN XL 300MG TABLET	81.3%	82.0%
00173073101	2005	WELLBUTRIN XL 300MG TABLET	82.9%	84.2%
00173034414	1997	ZANTAC 150MG TABLET	85.1%	87.3%
00173034414	1998	ZANTAC 150MG TABLET	88.8%	95.4%
00173034414	1999	ZANTAC 150MG TABLET	85.7%	93.9%
00173034414	2000	ZANTAC 150MG TABLET	94.4%	98.1%
00173034414	2001	ZANTAC 150MG TABLET	89.0%	95.5%
00173034414	2002	ZANTAC 150MG TABLET	90.2%	97.7%
00173034414	2003	ZANTAC 150MG TABLET	71.4%	95.3%
00173034414	2004	ZANTAC 150MG TABLET	83.3%	86.2%
00173034414	2005	ZANTAC 150MG TABLET	74.5%	80.0%
00173038354	1997	ZANTAC 15MG/ML SYRUP	63.1%	66.0%
00173038354	1998	ZANTAC 15MG/ML SYRUP	67.9%	70.5%
00173038354	1999	ZANTAC 15MG/ML SYRUP	68.0%	71.1%
00173038354	2000	ZANTAC 15MG/ML SYRUP	86.1%	88.8%
00173038354	2001	ZANTAC 15MG/ML SYRUP	85.1%	87.4%
00173038354	2002	ZANTAC 15MG/ML SYRUP	84.6%	87.1%
00173038354	2003	ZANTAC 15MG/ML SYRUP	78.3%	80.6%
00173038354	2004	ZANTAC 15MG/ML SYRUP	79.6%	82.4%
00173038354	2005	ZANTAC 15MG/ML SYRUP	90.0%	92.7%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00173066400	1999	ZIAGEN 20 MG/ML SOLUTION	88.0%	90.9%
00173066400	2000	ZIAGEN 20 MG/ML SOLUTION	90.8%	93.2%
00173066400	2001	ZIAGEN 20 MG/ML SOLUTION	90.3%	93.0%
00173066400	2002	ZIAGEN 20 MG/ML SOLUTION	91.8%	94.1%
00173066400	2003	ZIAGEN 20 MG/ML SOLUTION	93.0%	94.7%
00173066400	2004	ZIAGEN 20 MG/ML SOLUTION	91.8%	94.0%
00173066400	2005	ZIAGEN 20 MG/ML SOLUTION	89.8%	92.8%
00173066101	1999	ZIAGEN 300MG TABLET	84.4%	87.0%
00173066101	2000	ZIAGEN 300MG TABLET	82.1%	85.6%
00173066101	2001	ZIAGEN 300MG TABLET	77.8%	81.7%
00173066101	2002	ZIAGEN 300MG TABLET	78.3%	82.8%
00173066101	2003	ZIAGEN 300MG TABLET	78.9%	83.5%
00173066101	2004	ZIAGEN 300MG TABLET	79.4%	84.1%
00173066101	2005	ZIAGEN 300MG TABLET	76.3%	81.8%
00173044600	1997	ZOFRAN 4MG TABLET	73.8%	77.2%
00173044600	1998	ZOFRAN 4MG TABLET	73.4%	77.5%
00173044600	1999	ZOFRAN 4MG TABLET	70.1%	74.8%
00173044600	2000	ZOFRAN 4MG TABLET	79.6%	83.1%
00173044600	2001	ZOFRAN 4MG TABLET	80.6%	83.7%
00173044600	2002	ZOFRAN 4MG TABLET	83.1%	86.2%
00173044600	2003	ZOFRAN 4MG TABLET	73.4%	76.1%
00173044600	2004	ZOFRAN 4MG TABLET	78.4%	81.8%
00173044600	2005	ZOFRAN 4MG TABLET	80.7%	84.2%
00173044604	1997	ZOFRAN 4MG TABLET	92.8%	93.9%
00173044604	1998	ZOFRAN 4MG TABLET	90.6%	91.9%
00173044604	1999	ZOFRAN 4MG TABLET	89.5%	91.2%
00173044604	2000	ZOFRAN 4MG TABLET	96.3%	96.9%
00173044604	2001	ZOFRAN 4MG TABLET	96.9%	97.4%
00173044604	2002	ZOFRAN 4MG TABLET	97.1%	97.5%
00173044604	2003	ZOFRAN 4MG TABLET	97.2%	97.6%
00173044604	2004	ZOFRAN 4MG TABLET	97.3%	97.7%
00173044604	2005	ZOFRAN 4MG TABLET	97.3%	97.6%
00173048900	1997	ZOFRAN 4MG/5ML ORAL SOLN	87.5%	88.8%
00173048900	1998	ZOFRAN 4MG/5ML ORAL SOLN	68.3%	71.8%
00173048900	1999	ZOFRAN 4MG/5ML ORAL SOLN	63.4%	68.9%
00173048900	2000	ZOFRAN 4MG/5ML ORAL SOLN	73.0%	77.8%
00173048900	2001	ZOFRAN 4MG/5ML ORAL SOLN	70.5%	75.2%
00173048900	2002	ZOFRAN 4MG/5ML ORAL SOLN	72.7%	77.0%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00173048900	2003	ZOFRAN 4MG/5ML ORAL SOLN	70.3%	74.2%
00173048900	2004	ZOFRAN 4MG/5ML ORAL SOLN	68.1%	72.7%
00173048900	2005	ZOFRAN 4MG/5ML ORAL SOLN	72.2%	76.5%
00173044700	1997	ZOFRAN 8MG TABLET	78.3%	81.8%
00173044700	1998	ZOFRAN 8MG TABLET	78.9%	83.2%
00173044700	1999	ZOFRAN 8MG TABLET	76.3%	81.3%
00173044700	2000	ZOFRAN 8MG TABLET	81.5%	85.8%
00173044700	2001	ZOFRAN 8MG TABLET	82.3%	87.0%
00173044700	2002	ZOFRAN 8MG TABLET	82.3%	86.9%
00173044700	2003	ZOFRAN 8MG TABLET	80.6%	85.4%
00173044700	2004	ZOFRAN 8MG TABLET	80.7%	86.4%
00173044700	2005	ZOFRAN 8MG TABLET	78.5%	84.3%
00173044704	1997	ZOFRAN 8MG TABLET	96.4%	96.9%
00173044704	1998	ZOFRAN 8MG TABLET	94.7%	95.4%
00173044704	1999	ZOFRAN 8MG TABLET	93.3%	94.4%
00173044704	2000	ZOFRAN 8MG TABLET	96.0%	96.8%
00173044704	2001	ZOFRAN 8MG TABLET	95.8%	96.7%
00173044704	2002	ZOFRAN 8MG TABLET	96.1%	96.8%
00173044704	2003	ZOFRAN 8MG TABLET	95.8%	96.6%
00173044704	2004	ZOFRAN 8MG TABLET	96.4%	97.2%
00173044704	2005	ZOFRAN 8MG TABLET	96.7%	97.4%
00173056900	1999	ZOFRAN ODT 4MG TABLET	77.0%	80.9%
00173056900	2000	ZOFRAN ODT 4MG TABLET	62.9%	67.5%
00173056900	2001	ZOFRAN ODT 4MG TABLET	72.6%	76.3%
00173056900	2002	ZOFRAN ODT 4MG TABLET	75.4%	78.8%
00173056900	2003	ZOFRAN ODT 4MG TABLET	77.9%	81.0%
00173056900	2004	ZOFRAN ODT 4MG TABLET	74.7%	78.7%
00173056900	2005	ZOFRAN ODT 4MG TABLET	77.4%	81.5%
00173057000	1999	ZOFRAN ODT 8MG TABLET	74.6%	76.6%
00173057000	2000	ZOFRAN ODT 8MG TABLET	74.7%	78.7%
00173057000	2001	ZOFRAN ODT 8MG TABLET	76.8%	81.0%
00173057000	2002	ZOFRAN ODT 8MG TABLET	76.2%	80.9%
00173057000	2003	ZOFRAN ODT 8MG TABLET	83.2%	87.1%
00173057000	2004	ZOFRAN ODT 8MG TABLET	77.6%	82.0%
00173057000	2005	ZOFRAN ODT 8MG TABLET	80.4%	85.1%
00173095396	1997	ZOVIRAX 200MG/5ML SUSP	87.5%	90.4%
00173095396	1998	ZOVIRAX 200MG/5ML SUSP	82.1%	87.0%
00173095396	1999	ZOVIRAX 200MG/5ML SUSP	66.6%	73.8%

Table D.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC ¹	Percentage of sales dollars "at or about" WAC
00173095396	2000	ZOVIRAX 200MG/5ML SUSP	68.3%	75.8%
00173095396	2001	ZOVIRAX 200MG/5ML SUSP	62.5%	69.5%
00173095396	2002	ZOVIRAX 200MG/5ML SUSP	60.7%	68.2%
00173095396	2003	ZOVIRAX 200MG/5ML SUSP	69.1%	74.2%
00173095396	2004	ZOVIRAX 200MG/5ML SUSP	3.2%*	3.8%
00173095396	2005	ZOVIRAX 200MG/5ML SUSP	26.5%*	30.1%
00173099394	1997	ZOVIRAX 5% OINTMENT	85.9%	88.7%
00173099394	1998	ZOVIRAX 5% OINTMENT	87.9%	90.9%
00173099394	1999	ZOVIRAX 5% OINTMENT	82.3%	86.4%
00173099394	2000	ZOVIRAX 5% OINTMENT	87.6%	91.2%
00173099394	2001	ZOVIRAX 5% OINTMENT	84.5%	87.6%
00173099394	2002	ZOVIRAX 5% OINTMENT	0.0%*	0.0%
00173099394	2003	ZOVIRAX 5% OINTMENT	0.0%	0.0%
00173099394	2004	ZOVIRAX 5% OINTMENT	0.0%	0.0%
00173099394	2005	ZOVIRAX 5% OINTMENT	0.0%	0.0%
00173055601	1997	ZYBAN 150MG TABLET SA	96.6%	96.9%
00173055601	1998	ZYBAN 150MG TABLET SA	95.7%	96.8%
00173055601	1999	ZYBAN 150MG TABLET SA	58.5%	60.3%
00173055601	2000	ZYBAN 150MG TABLET SA	90.9%	93.6%
00173055601	2001	ZYBAN 150MG TABLET SA	89.1%	92.5%
00173055601	2002	ZYBAN 150MG TABLET SA	87.2%	91.5%
00173055601	2003	ZYBAN 150MG TABLET SA	81.0%	87.1%
00173055601	2004	ZYBAN 150MG TABLET SA	68.4%	77.0%
00173055601	2005	ZYBAN 150MG TABLET SA	0.8%*	1.0%
00173055602	1997	ZYBAN 150MG TABLET SA	90.9%	91.7%
00173055602	1998	ZYBAN 150MG TABLET SA	95.1%	96.3%
00173055602	1999	ZYBAN 150MG TABLET SA	50.2%	51.8%
00173055602	2000	ZYBAN 150MG TABLET SA	87.3%	90.3%
00173055602	2001	ZYBAN 150MG TABLET SA	86.4%	90.5%
00173055602	2002	ZYBAN 150MG TABLET SA	83.2%	88.8%
00173055602	2003	ZYBAN 150MG TABLET SA	78.5%	84.7%
00173055602	2004	ZYBAN 150MG TABLET SA	69.6%	77.7%
00173055602	2005	ZYBAN 150MG TABLET SA	2.9%*	3.7%

Table D.2: Year-by-year breakdown of refined calculation of GSK NDCs with 50% or less of the units sold during the relevant period “at or about” WAC

NDC	Year	Drug detail	Percentage of sales units “at or about” WAC	Percentage of sales dollars “at or about” WAC
00029316020	1999	AVANDIA 8MG TABLET	84.6%	85.5%
00029316020	2000	AVANDIA 8MG TABLET	65.8%	67.2%
00029316020	2001	AVANDIA 8MG TABLET	53.5%	55.5%
00029316020	2002	AVANDIA 8MG TABLET	55.4%	58.0%
00029316020	2003	AVANDIA 8MG TABLET	45.7%	48.6%
00029316020	2004	AVANDIA 8MG TABLET	37.2%	42.2%
00029316020	2005	AVANDIA 8MG TABLET	48.4%	55.8%
00173042702	1997	ZANTAC 150MG EFFERDOSE TAB	50.6%	57.9%
00173042702	1998	ZANTAC 150MG EFFERDOSE TAB	58.6%	69.6%
00173042702	1999	ZANTAC 150MG EFFERDOSE TAB	49.1%	64.7%
00173042702	2000	ZANTAC 150MG EFFERDOSE TAB	59.0%	78.4%
00173042702	2001	ZANTAC 150MG EFFERDOSE TAB	36.5%	50.9%
00173042702	2002	ZANTAC 150MG EFFERDOSE TAB	48.5%	64.4%
00173042702	2003	ZANTAC 150MG EFFERDOSE TAB	46.8%	78.4%
00173042702	2004	ZANTAC 150MG EFFERDOSE TAB	2.7%	3.0%
00173042702	2005	ZANTAC 150MG EFFERDOSE TAB	60.3%	65.0%

Attachment E

**Adjustments to Mr. Devor's calculation of percentage of
sales "at or about" WAC for 208 GSK NDCs at issue**

NDC-by-NDC results

Table E.1: Refined Devor methodology calculation of GSK NDCs with more than 50% of units sold “at or about” WAC¹

NDC	Drug detail	Expenditures reported in Plaintiff Exhibit B ²	Percentage of sales units “at or about” WAC
00173067200	AGENERASE 150MG CAPSULE	\$18,225,494	75.2%
00173068700	AGENERASE 15MG/ML ORAL SOLN	\$1,292,060	82.7%
00173067900	AGENERASE 50MG CAPSULE	\$42,122	67.6%
00007550040	ALBENZA 200MG TABLET	\$60,720	80.4%
00173056100	AMERGE 1MG TABLET	\$340,426	88.3%
00173056200	AMERGE 2.5MG TABLET	\$3,413,429	83.4%
00029604412	AMOXIL 200MG TABLET CHEW	\$2,453	91.3%
00029604854	AMOXIL 200MG/5ML SUSPENSION	\$39,534	91.2%
00029604855	AMOXIL 200MG/5ML SUSPENSION	\$78,316	92.0%
00029604859	AMOXIL 200MG/5ML SUSPENSION	\$1,125,534	92.9%
00029604512	AMOXIL 400 MG TABLET CHEW	\$82,274	91.3%
00029604520	AMOXIL 400MG TABLET CHEW	\$39,200	88.2%
00029604954	AMOXIL 400MG/5ML SUSPENSION	\$145,711	88.8%
00029604612	AMOXIL 500MG TABLET	\$29,272	94.1%
00029604620	AMOXIL 500MG TABLET	\$12,605	89.2%
00029604712	AMOXIL 875MG TABLET	\$197,938	94.4%
00029604720	AMOXIL 875MG TABLET	\$248,640	94.4%
00029604725	AMOXIL 875MG TABLET	\$12,061	93.3%
00029608522	AUGMENTIN 125-31.25 SUSPEN	\$5,042,231	83.2%
00029608523	AUGMENTIN 125-31.25 SUSPEN	\$261,545	89.6%
00029608539	AUGMENTIN 125-31.25 SUSPEN	\$541,708	65.4%
00029607347	AUGMENTIN 125-31.25 TAB CHEW	\$61,067	84.0%
00029608729	AUGMENTIN 200-28.5 SUSPEN	\$381,039	88.6%
00029608739	AUGMENTIN 200-28.5 SUSPEN	\$551,323	89.9%
00029608751	AUGMENTIN 200-28.5 SUSPEN	\$5,374,365	89.5%
00029607112	AUGMENTIN 200-28.5 TAB CHEW	\$91,674	87.9%
00029607527	AUGMENTIN 250-125 TABLET	\$8,190,422	70.3%
00029609022	AUGMENTIN 250-62.5 SUSPEN	\$12,958,756	79.0%
00029609023	AUGMENTIN 250-62.5 SUSPEN	\$1,517,244	91.4%
00029609039	AUGMENTIN 250-62.5 SUSPEN	\$1,086,310	62.8%
00029607447	AUGMENTIN 250-62.5 TAB CHEW	\$1,118,690	86.8%

¹ This is a NDC-by-NDC summary for the years 1997-2005 for which information is available.

² I obtained the expenditure information directly from Exhibit B of Plaintiffs’ Revised First Amended Consolidated Complaint. Because these expenditures serve illustrative purposes only, I have not independently verified their accuracy.

Table E.1 continued

NDC	Drug detail	Expenditures reported in Plaintiff Exhibit B ²	Percentage of sales units "at or about" WAC
00029609229	AUGMENTIN 400-57 SUSPEN	\$1,214,455	86.0%
00029609239	AUGMENTIN 400-57 SUSPEN	\$2,323,109	89.7%
00029609251	AUGMENTIN 400-57 SUSPEN	\$16,542,127	74.1%
00029607212	AUGMENTIN 400-57 TAB CHEW	\$2,179,443	90.0%
00029608012	AUGMENTIN 500-125 TABLET	\$21,921,921	81.7%
00029608612	AUGMENTIN 875-125 TABLET	\$26,493,419	84.6%
00029609422	AUGMENTIN ES-600 SUSPENSION	\$808,810	97.6%
00029609424	AUGMENTIN ES-600 SUSPENSION	\$1,164,532	94.6%
00029609429	AUGMENTIN ES-600 SUSPENSION	\$265,781	97.6%
00029609439	AUGMENTIN ES-600 SUSPENSION	\$1,465,455	94.9%
00029609445	AUGMENTIN ES-600 SUSPENSION	\$3,207,854	95.7%
00029609451	AUGMENTIN ES-600 SUSPENSION	\$2,830,137	97.7%
00029609628	AUGMENTIN XR 1000-62.5 TAB	\$689,056	97.7%
00029609640	AUGMENTIN XR 1000-62.5 TAB	\$1,476,805	99.3%
00029609648	AUGMENTIN XR 1000-62.5 TAB	\$138,343	93.7%
00029609660	AUGMENTIN XR 1000-62.5 TAB	\$1,035,534	98.0%
00029315818	AVANDIA 2MG TABLET	\$5,557,278	72.9%
00029315913	AVANDIA 4MG TABLET	\$20,997,346	81.0%
00029315920	AVANDIA 4MG TABLET	\$27,044,424	75.6%
00029316013	AVANDIA 8MG TABLET	\$32,995,402	84.6%
00029316020	AVANDIA 8MG TABLET	\$9,226,664	60.8%
00029152722	BACTROBAN 2% CREAM	\$3,946,032	89.3%
00029152725	BACTROBAN 2% CREAM	\$10,439,197	92.2%
00029152522	BACTROBAN 2% OINTMENT	\$5,755,261	70.0%
00029152525	BACTROBAN 2% OINTMENT	\$7,038,095	87.2%
00029152544	BACTROBAN 2% OINTMENT	\$6,822,477	70.8%
00029152611	BACTROBAN NASAL 2% OINTMENT	\$586,740	62.8%
00173031288	BECLOVENT INHALER	\$7,295,598	57.9%
00173038879	BECONASE AQ 0.042% SPRAY	\$7,782,163	80.9%
00173039501	CEFTIN 125MG TABLET	\$34,621	68.3%
00173040600	CEFTIN 125MG/5ML ORAL SUSP	\$2,107,728	89.9%
00173038700	CEFTIN 250MG TABLET	\$3,889,332	85.9%
00173038742	CEFTIN 250MG TABLET	\$11,978,139	89.4%
00173055400	CEFTIN 250MG/5ML ORAL SUSP	\$410,460	85.8%
00173055500	CEFTIN 250MG/5ML ORAL SUSP	\$3,228,924	93.5%
00173039400	CEFTIN 500MG TABLET	\$8,636,779	92.0%
00173039442	CEFTIN 500MG TABLET	\$10,328,575	79.6%
58437000218	CIMETIDINE 400MG TABLET	\$252,870	95.3%
58437000225	CIMETIDINE 400MG TABLET	\$10,510	88.6%

Table E.1 continued

NDC	Drug detail	Expenditures reported in Plaintiff Exhibit B ²	Percentage of sales units "at or about" WAC
00173059500	COMBIVIR TABLET	\$359,621,285	72.8%
00007336003	COMPAZINE 2.5MG SUPPOSITORY	\$61,273	78.0%
00007336103	COMPAZINE 5MG SUPPOSITORY	\$144,849	61.8%
00007336344	COMPAZINE 5MG/5ML SYRUP	\$159,932	64.8%
00007334615	COMPAZINE SPANSULE 15MG	\$192,882	84.4%
00007414120	COREG 12.5MG TABLET	\$9,747,684	80.6%
00007414220	COREG 25MG TABLET	\$10,386,010	79.4%
00007413920	COREG 3.125MG TABLET	\$9,782,627	81.7%
00007413955	COREG 3.125MG TABLET	\$72,409	94.6%
00007414020	COREG 6.25MG TABLET	\$12,182,615	80.6%
00173020155	DARAPRIM 25MG TABLET	\$587,495	70.8%
00007351920	DEXEDRINE 5MG TABLET	\$1,370,561	90.8%
00007351320	DEXEDRINE SPANSULE 10MG	\$742,745	90.3%
00007351420	DEXEDRINE SPANSULE 15MG	\$479,100	88.6%
00007351220	DEXEDRINE SPANSULE 5MG	\$172,875	84.8%
00007365022	DYAZIDE 37.5/25 CAPSULE	\$805,574	94.4%
00007365030	DYAZIDE 37.5/25 CAPSULE	\$197,401	91.8%
00173047100	EPIVIR 10MG/ML ORAL SOLN	\$8,098,338	84.8%
00173047001	EPIVIR 150MG TABLET	\$193,363,884	74.6%
00173071400	EPIVIR 300 MG TABLET	\$12,965,636	77.4%
00173066200	EPIVIR HBV 100MG TABLET	\$3,278,549	90.7%
00173066300	EPIVIR HBV 25MG/5ML SOLN	\$8,323	85.7%
00007400720	ESKALITH 300MG CAPSULE	\$192,585	95.2%
00007401020	ESKALITH CR 450MG TABLET SA	\$4,200,584	86.9%
00173045301	FLONASE 0.05% NASAL SPRAY	\$72,289,825	69.2%
00173050900	FLOVENT 100MCG ROTADISK	\$112,973	83.7%
00173049400	FLOVENT 110MCG INHALER	\$42,878,871	68.0%
00173049500	FLOVENT 220MCG INHALER	\$45,304,636	54.9%
00173050400	FLOVENT 250MCG ROTADISK	\$73,935	76.5%
00173049100	FLOVENT 44MCG INHALER	\$13,908,931	76.0%
00173051100	FLOVENT 50 MCG ROTADISK	\$154,736	84.6%
00007420105	HYCAMTIN 4MG VIAL	\$1,644,638	85.3%
00173045003	IMITREX 100MG TABLET	\$4,169,280	87.4%
00173073701	IMITREX 100MG TABLET	\$870,056	86.6%
00173052300	IMITREX 20MG NASAL SPRAY	\$3,757,043	79.5%
00173073500	IMITREX 25 MG TABLET	\$1,092,935	81.6%
00173046002	IMITREX 25MG TABLET	\$28,872,486	77.9%
00173045900	IMITREX 50MG TABLET	\$31,631,041	77.6%
00173073601	IMITREX 50MG TABLET	\$1,407,670	79.9%

Table E.1 continued

NDC	Drug detail	Expenditures reported in Plaintiff Exhibit B ²	Percentage of sales units "at or about" WAC
00173052400	IMITREX 5MG NASAL SPRAY	\$930,319	77.9%
00173047800	IMITREX 6MG/0.5ML KIT REFL	\$4,716,716	76.4%
00173047900	IMITREX 6MG/0.5ML SYRNG KIT	\$2,755,280	74.3%
00173064255	LAMICTAL 100MG TABLET	\$22,960,473	85.1%
00173064360	LAMICTAL 150MG TABLET	\$4,310,757	86.3%
00173064460	LAMICTAL 200MG TABLET	\$7,075,265	86.9%
00173052700	LAMICTAL 25MG DISPER TABLET	\$1,349,810	89.8%
00173063302	LAMICTAL 25MG TABLET	\$23,058,483	83.4%
00173052600	LAMICTAL 5MG DISPER TABLET	\$1,220,522	89.6%
00173024255	LANOXIN 125MCG TABLET	\$1,356,428	58.5%
00173024275	LANOXIN 125MCG TABLET	\$1,370,508	79.0%
00173024955	LANOXIN 250MCG TABLET	\$800,296	62.3%
00173024975	LANOXIN 250MCG TABLET	\$758,917	57.4%
00173024980	LANOXIN 250MCG TABLET	\$108,508	89.3%
00173026427	LANOXIN 50MCG/ML ELIXIR	\$433,899	68.0%
00173063535	LEUKERAN 2MG TABLET	\$198,776	86.7%
00173069000	LOTRONEX 1MG TABLET	\$354,011	97.1%
00173069005	LOTRONEX 1MG TABLET	\$109,366	97.8%
00173066518	MEPRON 750MG/5ML SUSPENSION	\$42,725,300	78.4%
00007447120	PARNATE 10MG TABLET	\$746,756	92.2%
00029321013	PAXIL 10MG TABLET	\$28,330,116	83.1%
00029321548	PAXIL 10MG/5ML SUSPENSION	\$702,225	82.7%
00029321113	PAXIL 20MG TABLET	\$30,264,498	76.9%
00029321120	PAXIL 20MG TABLET	\$77,312,392	82.0%
00029321213	PAXIL 30MG TABLET	\$27,712,259	79.2%
00029321313	PAXIL 40MG TABLET	\$20,140,666	73.4%
00029320613	PAXIL CR 12.5MG TABLET	\$7,114,118	86.1%
00029320713	PAXIL CR 25MG TABLET	\$16,496,204	87.6%
00029320813	PAXIL CR 37.5MG TABLET	\$5,284,879	84.4%
00173080725	PURINETHOL 50MG TABLET	\$2,877,463	92.3%
00173080765	PURINETHOL 50MG TABLET	\$201,081	80.3%
00029485120	RELAFEN 500MG TABLET	\$24,272,494	76.5%
00029485220	RELAFEN 750MG TABLET	\$10,602,929	84.9%
00173068101	RELENZA 5 MG DISKHALER	\$118,797	88.5%
00007489020	REQUIP 0.25MG TABLET	\$1,252,286	86.3%
00007489120	REQUIP 0.5MG TABLET	\$587,153	86.8%
00007489220	REQUIP 1MG TABLET	\$927,627	85.4%
00007489320	REQUIP 2MG TABLET	\$479,790	84.4%
00007489520	REQUIP 3MG TABLET	\$235,548	93.0%

Table E.1 continued

NDC	Drug detail	Expenditures reported in Plaintiff Exhibit B ²	Percentage of sales units "at or about" WAC
00007489620	REQUIP 4MG TABLET	\$206,614	90.7%
00007489420	REQUIP 5MG TABLET	\$200,800	87.3%
00173010855	RETROVIR 100MG CAPSULE	\$14,715,610	73.1%
00173011318	RETROVIR 10MG/ML SYRUP	\$4,210,238	87.0%
00173050100	RETROVIR 300MG TABLET	\$29,463,427	76.8%
00173010793	RETROVIR IV INFUSION VIAL	\$7,144	96.2%
00173046400	SEREVENT 21MCG INHALER	\$42,994,426	64.8%
00173046500	SEREVENT 21MCG INHLR REFILL	\$631,232	89.5%
00173052100	SEREVENT DISKUS 50MCG	\$6,681,172	64.0%
00108490420	STELAZINE 2MG TABLET	\$1,130,971	92.5%
00108490201	STELAZINE 2MG/ML VIAL	\$1,357	51.5%
00173045402	TEMOVATE EMOLLIENT 0.05% CRM	\$121,951	77.5%
00173045403	TEMOVATE EMOLLIENT 0.05% CRM	\$620,918	84.4%
00173088025	THIOGUANINE TABLOID 40MG TB	\$125,059	70.5%
00007507103	THORAZINE 100MG SUPPOSITORY	\$15,230	86.5%
00007507720	THORAZINE 100MG TABLET	\$957,346	95.7%
00007507244	THORAZINE 10MG/5ML SYRUP	\$91,902	87.7%
00007507920	THORAZINE 200MG TABLET	\$531,253	95.4%
00007507930	THORAZINE 200MG TABLET	\$590	79.1%
00007507420	THORAZINE 25MG TABLET	\$240,126	96.2%
00007507430	THORAZINE 25MG TABLET	\$1,197	68.0%
00007506201	THORAZINE 25MG/ML VIAL	\$9,916	83.7%
00007504744	THORAZINE 30MG/ML LIQ CONC	\$18,892	77.3%
00007507620	THORAZINE 50MG TABLET	\$523,592	95.7%
00007507630	THORAZINE 50MG TABLET	\$2,173	74.4%
00173069100	TRIZIVIR TABLET	\$151,276,862	79.3%
00173069120	TRIZIVIR TABLET	\$1,493,793	90.8%
00173056502	VALTREX 1GM CAPLET	\$6,027,190	88.3%
00173093303	VALTREX 500MG CAPLET	\$10,479,915	86.3%
00173093308	VALTREX 500MG CAPLET	\$6,386,918	88.5%
00173032198	VENTOLIN 90MCG INH REFILL	\$228,429	92.7%
00173068200	VENTOLIN HFA 90 MCG INHALER	\$89,584	97.9%
00173038901	VENTOLIN ROTACAPS 200MCG	\$388,151	92.8%
00173038902	VENTOLIN ROTACAPS 200MCG	\$59,029	95.3%
00173038903	VENTOLIN ROTACAPS 200MCG	\$11,476	70.5%
00173017855	WELLBUTRIN 100MG TABLET	\$2,194,205	75.8%
00173017755	WELLBUTRIN 75MG TABLET	\$2,121,929	74.8%
00173094755	WELLBUTRIN SR 100MG TAB SA	\$13,975,288	74.7%
00173013555	WELLBUTRIN SR 150MG TAB SA	\$47,864,903	77.4%

Table E.1 continued

NDC	Drug detail	Expenditures reported in Plaintiff Exhibit B ²	Percentage of sales units "at or about" WAC
00173072200	WELLBUTRIN SR 200MG TAB SA	\$6,091,519	84.6%
00173073001	WELLBUTRIN XL 150MG TABLET	\$5,281,979	86.1%
00173073101	WELLBUTRIN XL 300MG TABLET	\$6,708,345	86.0%
00173034414	ZANTAC 150MG TABLET	\$14,027,260	88.0%
00173038354	ZANTAC 15MG/ML SYRUP	\$11,275,320	77.4%
00173066400	ZIAGEN 20 MG/ML SOLUTION	\$2,062,523	87.7%
00173066101	ZIAGEN 300MG TABLET	\$79,649,369	75.0%
00173044600	ZOFRAN 4MG TABLET	\$7,562,133	75.3%
00173044604	ZOFRAN 4MG TABLET	\$156,561	92.9%
00173048900	ZOFRAN 4MG/5ML ORAL SOLN	\$585,298	66.4%
00173044700	ZOFRAN 8MG TABLET	\$21,088,905	76.1%
00173044704	ZOFRAN 8MG TABLET	\$766,926	91.7%
00173056900	ZOFRAN ODT 4MG TABLET	\$701,567	70.8%
00173057000	ZOFRAN ODT 8MG TABLET	\$1,717,036	76.8%
00173095396	ZOVIRAX 200MG/5ML SUSP	\$142,697	78.5%
00173099394	ZOVIRAX 5% OINTMENT	\$10,934,049	79.8%
00173055601	ZYBAN 150MG TABLET SA	\$2,227,349	85.4%
00173055602	ZYBAN 150MG TABLET SA	\$980,406	81.6%

Table E.2: Refined Devor methodology calculation of GSK NDCs with 50% or less of the units sold “at or about” WAC¹

NDC	Drug detail	Expenditures reported in Plaintiff Exhibit B ²	Percentage of sales units “at or about” WAC
00029604420	AMOXIL 200MG TABLET CHEW	\$3,287	45.1%
00029315918	AVANDIA 4MG TABLET	\$6,963,246	44.9%
00173042702	ZANTAC 150MG EFFERDOSE TAB	\$262,207	49.7%

¹ This is a NDC-by-NDC summary for the years 1997-2005 for which information is available.

² I obtained the expenditure information directly from Exhibit B of Plaintiffs’ Revised First Amended Consolidated Complaint. Because these expenditures serve illustrative purposes only, I have not independently verified their accuracy.

Attachment F

**Adjustments to Mr. Devor's calculation of percentage of
sales "at or about" WAC for 208 GSK NDCs at issue**

NDC-by-NDC, year-by-year results

Table F.1: Year-by-year breakdown of refined Devor methodology calculation of GSK NDCs with more than 50% of the units sold during the relevant period “at or about” WAC

NDC	Year	Drug detail	Percentage of sales units “at or about” WAC
00173067200	1999	AGENERASE 150MG CAPSULE	56.2%
00173067200	2000	AGENERASE 150MG CAPSULE	81.0%
00173067200	2001	AGENERASE 150MG CAPSULE	78.5%
00173067200	2002	AGENERASE 150MG CAPSULE	77.8%
00173067200	2003	AGENERASE 150MG CAPSULE	80.6%
00173067200	2004	AGENERASE 150MG CAPSULE	72.7%
00173067200	2005	AGENERASE 150MG CAPSULE	-51.5%
00173068700	1999	AGENERASE 15MG/ML ORAL SOLN	54.6%
00173068700	2000	AGENERASE 15MG/ML ORAL SOLN	86.6%
00173068700	2001	AGENERASE 15MG/ML ORAL SOLN	85.8%
00173068700	2002	AGENERASE 15MG/ML ORAL SOLN	88.6%
00173068700	2003	AGENERASE 15MG/ML ORAL SOLN	89.6%
00173068700	2004	AGENERASE 15MG/ML ORAL SOLN	88.7%
00173068700	2005	AGENERASE 15MG/ML ORAL SOLN	96.5%
00173067900	1999	AGENERASE 50MG CAPSULE	52.7%
00173067900	2000	AGENERASE 50MG CAPSULE	72.8%
00173067900	2001	AGENERASE 50MG CAPSULE	74.3%
00173067900	2002	AGENERASE 50MG CAPSULE	84.3%
00173067900	2003	AGENERASE 50MG CAPSULE	58.1%
00173067900	2004	AGENERASE 50MG CAPSULE	62.7%
00173067900	2005	AGENERASE 50MG CAPSULE	90.0%
00007550040	1997	ALBENZA 200MG TABLET	92.7%
00007550040	1998	ALBENZA 200MG TABLET	85.8%
00007550040	1999	ALBENZA 200MG TABLET	78.5%
00007550040	2000	ALBENZA 200MG TABLET	54.1%
00007550040	2001	ALBENZA 200MG TABLET	73.3%
00007550040	2002	ALBENZA 200MG TABLET	76.9%
00007550040	2003	ALBENZA 200MG TABLET	81.2%
00007550040	2004	ALBENZA 200MG TABLET	88.2%
00007550040	2005	ALBENZA 200MG TABLET	99.6%
00173056100	1998	AMERGE 1MG TABLET	94.6%
00173056100	1999	AMERGE 1MG TABLET	69.6%
00173056100	2000	AMERGE 1MG TABLET	88.2%
00173056100	2001	AMERGE 1MG TABLET	90.5%
00173056100	2002	AMERGE 1MG TABLET	90.8%
00173056100	2003	AMERGE 1MG TABLET	92.1%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00173056100	2004	AMERGE 1MG TABLET	86.6%
00173056100	2005	AMERGE 1MG TABLET	92.0%
00173056200	1998	AMERGE 2.5MG TABLET	90.2%
00173056200	1999	AMERGE 2.5MG TABLET	60.8%
00173056200	2000	AMERGE 2.5MG TABLET	82.2%
00173056200	2001	AMERGE 2.5MG TABLET	85.6%
00173056200	2002	AMERGE 2.5MG TABLET	87.5%
00173056200	2003	AMERGE 2.5MG TABLET	89.1%
00173056200	2004	AMERGE 2.5MG TABLET	85.3%
00173056200	2005	AMERGE 2.5MG TABLET	89.2%
00029604412	1999	AMOXIL 200MG TABLET CHEW	94.4%
00029604412	2000	AMOXIL 200MG TABLET CHEW	91.6%
00029604412	2001	AMOXIL 200MG TABLET CHEW	90.6%
00029604412	2002	AMOXIL 200MG TABLET CHEW	88.4%
00029604412	2003	AMOXIL 200MG TABLET CHEW	89.9%
00029604412	2004	AMOXIL 200MG TABLET CHEW	89.8%
00029604412	2005	AMOXIL 200MG TABLET CHEW	89.1%
00029604854	1999	AMOXIL 200MG/5ML SUSPENSION	94.3%
00029604854	2000	AMOXIL 200MG/5ML SUSPENSION	92.4%
00029604854	2001	AMOXIL 200MG/5ML SUSPENSION	88.3%
00029604854	2002	AMOXIL 200MG/5ML SUSPENSION	95.0%
00029604854	2003	AMOXIL 200MG/5ML SUSPENSION	89.1%
00029604854	2004	AMOXIL 200MG/5ML SUSPENSION	78.0%
00029604854	2005	AMOXIL 200MG/5ML SUSPENSION	87.2%
00029604855	1999	AMOXIL 200MG/5ML SUSPENSION	94.6%
00029604855	2000	AMOXIL 200MG/5ML SUSPENSION	92.9%
00029604855	2001	AMOXIL 200MG/5ML SUSPENSION	89.5%
00029604855	2002	AMOXIL 200MG/5ML SUSPENSION	95.4%
00029604855	2003	AMOXIL 200MG/5ML SUSPENSION	90.4%
00029604855	2004	AMOXIL 200MG/5ML SUSPENSION	79.7%
00029604855	2005	AMOXIL 200MG/5ML SUSPENSION	85.7%
00029604859	1999	AMOXIL 200MG/5ML SUSPENSION	94.6%
00029604859	2000	AMOXIL 200MG/5ML SUSPENSION	92.8%
00029604859	2001	AMOXIL 200MG/5ML SUSPENSION	91.2%
00029604859	2002	AMOXIL 200MG/5ML SUSPENSION	96.7%
00029604859	2003	AMOXIL 200MG/5ML SUSPENSION	91.5%
00029604859	2004	AMOXIL 200MG/5ML SUSPENSION	76.6%
00029604859	2005	AMOXIL 200MG/5ML SUSPENSION	82.4%
00029604512	1999	AMOXIL 400 MG TABLET CHEW	94.8%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00029604512	2000	AMOXIL 400 MG TABLET CHEW	92.9%
00029604512	2001	AMOXIL 400 MG TABLET CHEW	91.9%
00029604512	2002	AMOXIL 400 MG TABLET CHEW	89.8%
00029604512	2003	AMOXIL 400 MG TABLET CHEW	72.7%
00029604512	2004	AMOXIL 400 MG TABLET CHEW	66.8%
00029604512	2005	AMOXIL 400 MG TABLET CHEW	81.3%
00029604520	1999	AMOXIL 400MG TABLET CHEW	94.6%
00029604520	2000	AMOXIL 400MG TABLET CHEW	92.4%
00029604520	2001	AMOXIL 400MG TABLET CHEW	88.7%
00029604520	2002	AMOXIL 400MG TABLET CHEW	85.5%
00029604520	2003	AMOXIL 400MG TABLET CHEW	52.8%
00029604520	2004	AMOXIL 400MG TABLET CHEW	47.1%
00029604954	1999	AMOXIL 400MG/5ML SUSPENSION	94.4%
00029604954	2000	AMOXIL 400MG/5ML SUSPENSION	92.4%
00029604954	2001	AMOXIL 400MG/5ML SUSPENSION	87.4%
00029604954	2002	AMOXIL 400MG/5ML SUSPENSION	93.1%
00029604954	2003	AMOXIL 400MG/5ML SUSPENSION	84.4%
00029604954	2004	AMOXIL 400MG/5ML SUSPENSION	60.5%
00029604954	2005	AMOXIL 400MG/5ML SUSPENSION	73.1%
00029604612	1998	AMOXIL 500MG TABLET	99.9%
00029604612	1999	AMOXIL 500MG TABLET	94.3%
00029604612	2000	AMOXIL 500MG TABLET	93.2%
00029604612	2001	AMOXIL 500MG TABLET	93.2%
00029604612	2002	AMOXIL 500MG TABLET	99.3%
00029604612	2003	AMOXIL 500MG TABLET	92.8%
00029604612	2004	AMOXIL 500MG TABLET	82.4%
00029604620	1998	AMOXIL 500MG TABLET	99.7%
00029604620	1999	AMOXIL 500MG TABLET	94.4%
00029604620	2000	AMOXIL 500MG TABLET	92.8%
00029604620	2001	AMOXIL 500MG TABLET	92.2%
00029604620	2002	AMOXIL 500MG TABLET	93.8%
00029604620	2003	AMOXIL 500MG TABLET	82.3%
00029604620	2004	AMOXIL 500MG TABLET	79.9%
00029604620	2005	AMOXIL 500MG TABLET	64.4%
00029604712	1998	AMOXIL 875MG TABLET	99.9%
00029604712	1999	AMOXIL 875MG TABLET	94.4%
00029604712	2000	AMOXIL 875MG TABLET	92.9%
00029604712	2001	AMOXIL 875MG TABLET	98.5%
00029604712	2002	AMOXIL 875MG TABLET	92.8%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00029604712	2003	AMOXIL 875MG TABLET	79.8%
00029604712	2004	AMOXIL 875MG TABLET	50.7%
00029604720	1998	AMOXIL 875MG TABLET	99.9%
00029604720	1999	AMOXIL 875MG TABLET	94.8%
00029604720	2000	AMOXIL 875MG TABLET	93.0%
00029604720	2001	AMOXIL 875MG TABLET	98.1%
00029604720	2002	AMOXIL 875MG TABLET	94.3%
00029604720	2003	AMOXIL 875MG TABLET	79.0%
00029604720	2004	AMOXIL 875MG TABLET	67.1%
00029604720	2005	AMOXIL 875MG TABLET	69.8%
00029604725	1998	AMOXIL 875MG TABLET	99.9%
00029604725	1999	AMOXIL 875MG TABLET	94.8%
00029604725	2000	AMOXIL 875MG TABLET	92.9%
00029604725	2001	AMOXIL 875MG TABLET	91.1%
00029604725	2002	AMOXIL 875MG TABLET	87.7%
00029604725	2003	AMOXIL 875MG TABLET	70.7%
00029604725	2004	AMOXIL 875MG TABLET	51.9%
00029608522	1997	AUGMENTIN 125-31.25 SUSPEN	77.2%
00029608522	1998	AUGMENTIN 125-31.25 SUSPEN	79.8%
00029608522	1999	AUGMENTIN 125-31.25 SUSPEN	79.3%
00029608522	2000	AUGMENTIN 125-31.25 SUSPEN	86.7%
00029608522	2001	AUGMENTIN 125-31.25 SUSPEN	87.1%
00029608522	2002	AUGMENTIN 125-31.25 SUSPEN	90.2%
00029608522	2003	AUGMENTIN 125-31.25 SUSPEN	91.2%
00029608522	2004	AUGMENTIN 125-31.25 SUSPEN	87.9%
00029608522	2005	AUGMENTIN 125-31.25 SUSPEN	90.4%
00029608523	1997	AUGMENTIN 125-31.25 SUSPEN	94.1%
00029608523	1998	AUGMENTIN 125-31.25 SUSPEN	88.5%
00029608523	1999	AUGMENTIN 125-31.25 SUSPEN	85.0%
00029608523	2000	AUGMENTIN 125-31.25 SUSPEN	84.9%
00029608523	2001	AUGMENTIN 125-31.25 SUSPEN	90.7%
00029608523	2002	AUGMENTIN 125-31.25 SUSPEN	93.6%
00029608523	2003	AUGMENTIN 125-31.25 SUSPEN	93.3%
00029608523	2004	AUGMENTIN 125-31.25 SUSPEN	86.8%
00029608523	2005	AUGMENTIN 125-31.25 SUSPEN	89.9%
00029608539	1997	AUGMENTIN 125-31.25 SUSPEN	64.8%
00029608539	1998	AUGMENTIN 125-31.25 SUSPEN	61.9%
00029608539	1999	AUGMENTIN 125-31.25 SUSPEN	64.5%
00029608539	2000	AUGMENTIN 125-31.25 SUSPEN	70.6%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00029608539	2001	AUGMENTIN 125-31.25 SUSPEN	65.7%
00029608539	2002	AUGMENTIN 125-31.25 SUSPEN	67.5%
00029608539	2003	AUGMENTIN 125-31.25 SUSPEN	74.1%
00029608539	2004	AUGMENTIN 125-31.25 SUSPEN	55.3%
00029608539	2005	AUGMENTIN 125-31.25 SUSPEN	63.2%
00029607347	1997	AUGMENTIN 125-31.25 TAB CHEW	89.0%
00029607347	1998	AUGMENTIN 125-31.25 TAB CHEW	84.2%
00029607347	1999	AUGMENTIN 125-31.25 TAB CHEW	79.1%
00029607347	2000	AUGMENTIN 125-31.25 TAB CHEW	77.1%
00029607347	2001	AUGMENTIN 125-31.25 TAB CHEW	77.8%
00029607347	2002	AUGMENTIN 125-31.25 TAB CHEW	82.3%
00029607347	2003	AUGMENTIN 125-31.25 TAB CHEW	78.5%
00029607347	2004	AUGMENTIN 125-31.25 TAB CHEW	83.0%
00029607347	2005	AUGMENTIN 125-31.25 TAB CHEW	89.4%
00029608729	1997	AUGMENTIN 200-28.5 SUSPEN	94.5%
00029608729	1998	AUGMENTIN 200-28.5 SUSPEN	84.3%
00029608729	1999	AUGMENTIN 200-28.5 SUSPEN	82.5%
00029608729	2000	AUGMENTIN 200-28.5 SUSPEN	90.0%
00029608729	2001	AUGMENTIN 200-28.5 SUSPEN	91.8%
00029608729	2002	AUGMENTIN 200-28.5 SUSPEN	89.9%
00029608729	2003	AUGMENTIN 200-28.5 SUSPEN	86.0%
00029608729	2004	AUGMENTIN 200-28.5 SUSPEN	54.6%
00029608729	2005	AUGMENTIN 200-28.5 SUSPEN	74.1%
00029608739	1997	AUGMENTIN 200-28.5 SUSPEN	94.1%
00029608739	1998	AUGMENTIN 200-28.5 SUSPEN	85.2%
00029608739	1999	AUGMENTIN 200-28.5 SUSPEN	83.7%
00029608739	2000	AUGMENTIN 200-28.5 SUSPEN	92.7%
00029608739	2001	AUGMENTIN 200-28.5 SUSPEN	93.1%
00029608739	2002	AUGMENTIN 200-28.5 SUSPEN	91.7%
00029608739	2003	AUGMENTIN 200-28.5 SUSPEN	86.3%
00029608739	2004	AUGMENTIN 200-28.5 SUSPEN	62.3%
00029608739	2005	AUGMENTIN 200-28.5 SUSPEN	74.6%
00029608751	1997	AUGMENTIN 200-28.5 SUSPEN	94.9%
00029608751	1998	AUGMENTIN 200-28.5 SUSPEN	86.7%
00029608751	1999	AUGMENTIN 200-28.5 SUSPEN	84.5%
00029608751	2000	AUGMENTIN 200-28.5 SUSPEN	89.5%
00029608751	2001	AUGMENTIN 200-28.5 SUSPEN	93.3%
00029608751	2002	AUGMENTIN 200-28.5 SUSPEN	91.7%
00029608751	2003	AUGMENTIN 200-28.5 SUSPEN	74.8%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00029608751	2004	AUGMENTIN 200-28.5 SUSPEN	47.6%
00029608751	2005	AUGMENTIN 200-28.5 SUSPEN	60.6%
00029607112	1997	AUGMENTIN 200-28.5 TAB CHEW	94.5%
00029607112	1998	AUGMENTIN 200-28.5 TAB CHEW	86.4%
00029607112	1999	AUGMENTIN 200-28.5 TAB CHEW	83.5%
00029607112	2000	AUGMENTIN 200-28.5 TAB CHEW	90.0%
00029607112	2001	AUGMENTIN 200-28.5 TAB CHEW	88.3%
00029607112	2002	AUGMENTIN 200-28.5 TAB CHEW	88.2%
00029607112	2003	AUGMENTIN 200-28.5 TAB CHEW	73.4%
00029607112	2004	AUGMENTIN 200-28.5 TAB CHEW	70.7%
00029607112	2005	AUGMENTIN 200-28.5 TAB CHEW	60.1%
00029607527	1997	AUGMENTIN 250-125 TABLET	73.2%
00029607527	1998	AUGMENTIN 250-125 TABLET	64.9%
00029607527	1999	AUGMENTIN 250-125 TABLET	67.0%
00029607527	2000	AUGMENTIN 250-125 TABLET	66.9%
00029607527	2001	AUGMENTIN 250-125 TABLET	67.7%
00029607527	2002	AUGMENTIN 250-125 TABLET	75.4%
00029607527	2003	AUGMENTIN 250-125 TABLET	75.6%
00029607527	2004	AUGMENTIN 250-125 TABLET	73.1%
00029607527	2005	AUGMENTIN 250-125 TABLET	80.8%
00029609022	1997	AUGMENTIN 250-62.5 SUSPEN	69.5%
00029609022	1998	AUGMENTIN 250-62.5 SUSPEN	74.7%
00029609022	1999	AUGMENTIN 250-62.5 SUSPEN	75.5%
00029609022	2000	AUGMENTIN 250-62.5 SUSPEN	76.6%
00029609022	2001	AUGMENTIN 250-62.5 SUSPEN	81.2%
00029609022	2002	AUGMENTIN 250-62.5 SUSPEN	89.7%
00029609022	2003	AUGMENTIN 250-62.5 SUSPEN	87.1%
00029609022	2004	AUGMENTIN 250-62.5 SUSPEN	84.4%
00029609022	2005	AUGMENTIN 250-62.5 SUSPEN	89.0%
00029609023	1997	AUGMENTIN 250-62.5 SUSPEN	88.5%
00029609023	1998	AUGMENTIN 250-62.5 SUSPEN	86.7%
00029609023	1999	AUGMENTIN 250-62.5 SUSPEN	84.5%
00029609023	2000	AUGMENTIN 250-62.5 SUSPEN	93.5%
00029609023	2001	AUGMENTIN 250-62.5 SUSPEN	92.5%
00029609023	2002	AUGMENTIN 250-62.5 SUSPEN	96.0%
00029609023	2003	AUGMENTIN 250-62.5 SUSPEN	91.9%
00029609023	2004	AUGMENTIN 250-62.5 SUSPEN	91.7%
00029609023	2005	AUGMENTIN 250-62.5 SUSPEN	93.7%
00029609039	1997	AUGMENTIN 250-62.5 SUSPEN	52.7%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00029609039	1998	AUGMENTIN 250-62.5 SUSPEN	48.7%
00029609039	1999	AUGMENTIN 250-62.5 SUSPEN	59.0%
00029609039	2000	AUGMENTIN 250-62.5 SUSPEN	67.6%
00029609039	2001	AUGMENTIN 250-62.5 SUSPEN	62.9%
00029609039	2002	AUGMENTIN 250-62.5 SUSPEN	74.2%
00029609039	2003	AUGMENTIN 250-62.5 SUSPEN	78.2%
00029609039	2004	AUGMENTIN 250-62.5 SUSPEN	58.3%
00029609039	2005	AUGMENTIN 250-62.5 SUSPEN	70.9%
00029607447	1997	AUGMENTIN 250-62.5 TAB CHEW	83.5%
00029607447	1998	AUGMENTIN 250-62.5 TAB CHEW	82.6%
00029607447	1999	AUGMENTIN 250-62.5 TAB CHEW	80.9%
00029607447	2000	AUGMENTIN 250-62.5 TAB CHEW	90.3%
00029607447	2001	AUGMENTIN 250-62.5 TAB CHEW	92.0%
00029607447	2002	AUGMENTIN 250-62.5 TAB CHEW	93.3%
00029607447	2003	AUGMENTIN 250-62.5 TAB CHEW	93.9%
00029607447	2004	AUGMENTIN 250-62.5 TAB CHEW	89.7%
00029607447	2005	AUGMENTIN 250-62.5 TAB CHEW	93.6%
00029609229	1997	AUGMENTIN 400-57 SUSPEN	92.9%
00029609229	1998	AUGMENTIN 400-57 SUSPEN	83.7%
00029609229	1999	AUGMENTIN 400-57 SUSPEN	82.0%
00029609229	2000	AUGMENTIN 400-57 SUSPEN	84.8%
00029609229	2001	AUGMENTIN 400-57 SUSPEN	90.2%
00029609229	2002	AUGMENTIN 400-57 SUSPEN	88.3%
00029609229	2003	AUGMENTIN 400-57 SUSPEN	72.1%
00029609229	2004	AUGMENTIN 400-57 SUSPEN	30.1%
00029609229	2005	AUGMENTIN 400-57 SUSPEN	54.5%
00029609239	1997	AUGMENTIN 400-57 SUSPEN	93.3%
00029609239	1998	AUGMENTIN 400-57 SUSPEN	85.2%
00029609239	1999	AUGMENTIN 400-57 SUSPEN	84.4%
00029609239	2000	AUGMENTIN 400-57 SUSPEN	88.3%
00029609239	2001	AUGMENTIN 400-57 SUSPEN	95.0%
00029609239	2002	AUGMENTIN 400-57 SUSPEN	93.3%
00029609239	2003	AUGMENTIN 400-57 SUSPEN	78.5%
00029609239	2004	AUGMENTIN 400-57 SUSPEN	43.7%
00029609239	2005	AUGMENTIN 400-57 SUSPEN	60.2%
00029609251	1997	AUGMENTIN 400-57 SUSPEN	94.1%
00029609251	1998	AUGMENTIN 400-57 SUSPEN	85.6%
00029609251	1999	AUGMENTIN 400-57 SUSPEN	82.1%
00029609251	2000	AUGMENTIN 400-57 SUSPEN	87.0%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00029609251	2001	AUGMENTIN 400-57 SUSPEN	92.8%
00029609251	2002	AUGMENTIN 400-57 SUSPEN	-22.2%
00029609251	2003	AUGMENTIN 400-57 SUSPEN	58.1%
00029609251	2004	AUGMENTIN 400-57 SUSPEN	29.4%
00029609251	2005	AUGMENTIN 400-57 SUSPEN	52.7%
00029607212	1997	AUGMENTIN 400-57 TAB CHEW	95.1%
00029607212	1998	AUGMENTIN 400-57 TAB CHEW	87.6%
00029607212	1999	AUGMENTIN 400-57 TAB CHEW	85.1%
00029607212	2000	AUGMENTIN 400-57 TAB CHEW	88.7%
00029607212	2001	AUGMENTIN 400-57 TAB CHEW	91.8%
00029607212	2002	AUGMENTIN 400-57 TAB CHEW	94.9%
00029607212	2003	AUGMENTIN 400-57 TAB CHEW	92.8%
00029607212	2004	AUGMENTIN 400-57 TAB CHEW	76.8%
00029607212	2005	AUGMENTIN 400-57 TAB CHEW	84.4%
00029608012	1997	AUGMENTIN 500-125 TABLET	88.3%
00029608012	1998	AUGMENTIN 500-125 TABLET	76.8%
00029608012	1999	AUGMENTIN 500-125 TABLET	79.9%
00029608012	2000	AUGMENTIN 500-125 TABLET	84.0%
00029608012	2001	AUGMENTIN 500-125 TABLET	82.0%
00029608012	2002	AUGMENTIN 500-125 TABLET	86.9%
00029608012	2003	AUGMENTIN 500-125 TABLET	2.3%
00029608012	2004	AUGMENTIN 500-125 TABLET	32.2%
00029608012	2005	AUGMENTIN 500-125 TABLET	66.9%
00029608612	1997	AUGMENTIN 875-125 TABLET	93.5%
00029608612	1998	AUGMENTIN 875-125 TABLET	81.5%
00029608612	1999	AUGMENTIN 875-125 TABLET	80.9%
00029608612	2000	AUGMENTIN 875-125 TABLET	87.4%
00029608612	2001	AUGMENTIN 875-125 TABLET	85.8%
00029608612	2002	AUGMENTIN 875-125 TABLET	89.5%
00029608612	2003	AUGMENTIN 875-125 TABLET	1.4%
00029608612	2004	AUGMENTIN 875-125 TABLET	36.4%
00029608612	2005	AUGMENTIN 875-125 TABLET	59.2%
00029609422	2001	AUGMENTIN ES-600 SUSPENSION	99.6%
00029609422	2002	AUGMENTIN ES-600 SUSPENSION	97.7%
00029609422	2003	AUGMENTIN ES-600 SUSPENSION	96.3%
00029609424	2003	AUGMENTIN ES-600 SUSPENSION	96.9%
00029609424	2004	AUGMENTIN ES-600 SUSPENSION	93.1%
00029609424	2005	AUGMENTIN ES-600 SUSPENSION	-26.8%
00029609429	2001	AUGMENTIN ES-600 SUSPENSION	99.6%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00029609429	2002	AUGMENTIN ES-600 SUSPENSION	97.6%
00029609429	2003	AUGMENTIN ES-600 SUSPENSION	96.3%
00029609439	2001	AUGMENTIN ES-600 SUSPENSION	99.8%
00029609439	2002	AUGMENTIN ES-600 SUSPENSION	97.8%
00029609439	2003	AUGMENTIN ES-600 SUSPENSION	95.5%
00029609439	2004	AUGMENTIN ES-600 SUSPENSION	92.3%
00029609439	2005	AUGMENTIN ES-600 SUSPENSION	-16.7%
00029609445	2003	AUGMENTIN ES-600 SUSPENSION	97.7%
00029609445	2004	AUGMENTIN ES-600 SUSPENSION	94.8%
00029609445	2005	AUGMENTIN ES-600 SUSPENSION	-22.6%
00029609451	2001	AUGMENTIN ES-600 SUSPENSION	99.7%
00029609451	2002	AUGMENTIN ES-600 SUSPENSION	97.9%
00029609451	2003	AUGMENTIN ES-600 SUSPENSION	96.5%
00029609628	2002	AUGMENTIN XR 1000-62.5 TAB	99.9%
00029609628	2003	AUGMENTIN XR 1000-62.5 TAB	96.7%
00029609640	2002	AUGMENTIN XR 1000-62.5 TAB	100.0%
00029609640	2003	AUGMENTIN XR 1000-62.5 TAB	99.1%
00029609648	2003	AUGMENTIN XR 1000-62.5 TAB	97.0%
00029609648	2004	AUGMENTIN XR 1000-62.5 TAB	93.2%
00029609648	2005	AUGMENTIN XR 1000-62.5 TAB	92.2%
00029609660	2003	AUGMENTIN XR 1000-62.5 TAB	99.5%
00029609660	2004	AUGMENTIN XR 1000-62.5 TAB	97.6%
00029609660	2005	AUGMENTIN XR 1000-62.5 TAB	97.8%
00029315818	1999	AVANDIA 2MG TABLET	92.7%
00029315818	2000	AVANDIA 2MG TABLET	81.5%
00029315818	2001	AVANDIA 2MG TABLET	75.9%
00029315818	2002	AVANDIA 2MG TABLET	73.9%
00029315818	2003	AVANDIA 2MG TABLET	73.2%
00029315818	2004	AVANDIA 2MG TABLET	60.4%
00029315818	2005	AVANDIA 2MG TABLET	74.9%
00029315913	1999	AVANDIA 4MG TABLET	95.8%
00029315913	2000	AVANDIA 4MG TABLET	87.9%
00029315913	2001	AVANDIA 4MG TABLET	80.0%
00029315913	2002	AVANDIA 4MG TABLET	83.4%
00029315913	2003	AVANDIA 4MG TABLET	75.1%
00029315913	2004	AVANDIA 4MG TABLET	75.7%
00029315913	2005	AVANDIA 4MG TABLET	82.8%
00029315920	1999	AVANDIA 4MG TABLET	95.3%
00029315920	2000	AVANDIA 4MG TABLET	88.3%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00029315920	2001	AVANDIA 4MG TABLET	81.5%
00029315920	2002	AVANDIA 4MG TABLET	79.2%
00029315920	2003	AVANDIA 4MG TABLET	75.0%
00029315920	2004	AVANDIA 4MG TABLET	64.0%
00029315920	2005	AVANDIA 4MG TABLET	69.5%
00029316013	1999	AVANDIA 8MG TABLET	96.8%
00029316013	2000	AVANDIA 8MG TABLET	94.5%
00029316013	2001	AVANDIA 8MG TABLET	90.6%
00029316013	2002	AVANDIA 8MG TABLET	92.0%
00029316013	2003	AVANDIA 8MG TABLET	84.2%
00029316013	2004	AVANDIA 8MG TABLET	73.1%
00029316013	2005	AVANDIA 8MG TABLET	78.0%
00029316020	1999	AVANDIA 8MG TABLET	93.9%
00029316020	2000	AVANDIA 8MG TABLET	79.2%
00029316020	2001	AVANDIA 8MG TABLET	71.2%
00029316020	2002	AVANDIA 8MG TABLET	65.3%
00029316020	2003	AVANDIA 8MG TABLET	64.9%
00029316020	2004	AVANDIA 8MG TABLET	47.8%
00029316020	2005	AVANDIA 8MG TABLET	52.7%
00029152722	1998	BACTROBAN 2% CREAM	98.2%
00029152722	1999	BACTROBAN 2% CREAM	95.6%
00029152722	2000	BACTROBAN 2% CREAM	94.0%
00029152722	2001	BACTROBAN 2% CREAM	95.8%
00029152722	2002	BACTROBAN 2% CREAM	90.0%
00029152722	2003	BACTROBAN 2% CREAM	82.1%
00029152722	2004	BACTROBAN 2% CREAM	80.8%
00029152722	2005	BACTROBAN 2% CREAM	86.7%
00029152725	1998	BACTROBAN 2% CREAM	98.3%
00029152725	1999	BACTROBAN 2% CREAM	96.6%
00029152725	2000	BACTROBAN 2% CREAM	96.1%
00029152725	2001	BACTROBAN 2% CREAM	96.3%
00029152725	2002	BACTROBAN 2% CREAM	90.1%
00029152725	2003	BACTROBAN 2% CREAM	93.0%
00029152725	2004	BACTROBAN 2% CREAM	86.0%
00029152725	2005	BACTROBAN 2% CREAM	91.6%
00029152522	1997	BACTROBAN 2% OINTMENT	78.3%
00029152522	1998	BACTROBAN 2% OINTMENT	68.1%
00029152522	1999	BACTROBAN 2% OINTMENT	62.8%
00029152522	2000	BACTROBAN 2% OINTMENT	71.9%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00029152525	1997	BACTROBAN 2% OINTMENT	91.9%
00029152525	1998	BACTROBAN 2% OINTMENT	85.4%
00029152525	1999	BACTROBAN 2% OINTMENT	84.1%
00029152525	2000	BACTROBAN 2% OINTMENT	88.5%
00029152544	2000	BACTROBAN 2% OINTMENT	87.1%
00029152544	2001	BACTROBAN 2% OINTMENT	72.9%
00029152544	2002	BACTROBAN 2% OINTMENT	67.4%
00029152544	2003	BACTROBAN 2% OINTMENT	68.6%
00029152544	2004	BACTROBAN 2% OINTMENT	25.6%
00029152544	2005	BACTROBAN 2% OINTMENT	43.2%
00029152611	1997	BACTROBAN NASAL 2% OINTMENT	97.8%
00029152611	1998	BACTROBAN NASAL 2% OINTMENT	80.6%
00029152611	1999	BACTROBAN NASAL 2% OINTMENT	79.0%
00029152611	2000	BACTROBAN NASAL 2% OINTMENT	81.4%
00029152611	2001	BACTROBAN NASAL 2% OINTMENT	54.4%
00029152611	2002	BACTROBAN NASAL 2% OINTMENT	58.1%
00029152611	2003	BACTROBAN NASAL 2% OINTMENT	60.9%
00029152611	2004	BACTROBAN NASAL 2% OINTMENT	55.1%
00029152611	2005	BACTROBAN NASAL 2% OINTMENT	50.4%
00173031288	1997	BECLOVENT INHALER	60.6%
00173031288	1998	BECLOVENT INHALER	60.8%
00173031288	1999	BECLOVENT INHALER	57.1%
00173031288	2000	BECLOVENT INHALER	29.9%
00173031288	2001	BECLOVENT INHALER	-23328.7%
00173031288	2002	BECLOVENT INHALER	-50.0%
00173038879	1997	BECONASE AQ 0.042% SPRAY	76.9%
00173038879	1998	BECONASE AQ 0.042% SPRAY	82.0%
00173038879	1999	BECONASE AQ 0.042% SPRAY	76.2%
00173038879	2000	BECONASE AQ 0.042% SPRAY	79.0%
00173038879	2001	BECONASE AQ 0.042% SPRAY	81.1%
00173038879	2002	BECONASE AQ 0.042% SPRAY	83.2%
00173038879	2003	BECONASE AQ 0.042% SPRAY	87.2%
00173038879	2004	BECONASE AQ 0.042% SPRAY	88.0%
00173038879	2005	BECONASE AQ 0.042% SPRAY	89.2%
00173039501	1997	CEFTIN 125MG TABLET	83.3%
00173039501	1998	CEFTIN 125MG TABLET	79.9%
00173039501	1999	CEFTIN 125MG TABLET	62.3%
00173039501	2000	CEFTIN 125MG TABLET	53.0%
00173039501	2002	CEFTIN 125MG TABLET	64.8%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00173040600	1997	CEFTIN 125MG/5ML ORAL SUSP	93.1%
00173040600	1998	CEFTIN 125MG/5ML ORAL SUSP	92.9%
00173040600	1999	CEFTIN 125MG/5ML ORAL SUSP	88.8%
00173040600	2000	CEFTIN 125MG/5ML ORAL SUSP	83.7%
00173040600	2002	CEFTIN 125MG/5ML ORAL SUSP	92.9%
00173040600	2003	CEFTIN 125MG/5ML ORAL SUSP	90.0%
00173040600	2004	CEFTIN 125MG/5ML ORAL SUSP	81.5%
00173038700	1997	CEFTIN 250MG TABLET	85.1%
00173038700	1998	CEFTIN 250MG TABLET	92.8%
00173038700	1999	CEFTIN 250MG TABLET	80.8%
00173038700	2000	CEFTIN 250MG TABLET	85.2%
00173038700	2002	CEFTIN 250MG TABLET	88.3%
00173038700	2003	CEFTIN 250MG TABLET	54.2%
00173038700	2004	CEFTIN 250MG TABLET	66.6%
00173038700	2005	CEFTIN 250MG TABLET	79.2%
00173038742	1997	CEFTIN 250MG TABLET	92.0%
00173038742	1998	CEFTIN 250MG TABLET	90.1%
00173038742	1999	CEFTIN 250MG TABLET	88.8%
00173038742	2000	CEFTIN 250MG TABLET	88.1%
00173038742	2002	CEFTIN 250MG TABLET	72.3%
00173038742	2003	CEFTIN 250MG TABLET	-87.9%
00173038742	2004	CEFTIN 250MG TABLET	40.9%
00173055400	1997	CEFTIN 250MG/5ML ORAL SUSP	87.2%
00173055400	1998	CEFTIN 250MG/5ML ORAL SUSP	93.0%
00173055400	1999	CEFTIN 250MG/5ML ORAL SUSP	86.5%
00173055400	2000	CEFTIN 250MG/5ML ORAL SUSP	77.5%
00173055400	2002	CEFTIN 250MG/5ML ORAL SUSP	82.8%
00173055400	2003	CEFTIN 250MG/5ML ORAL SUSP	92.0%
00173055400	2004	CEFTIN 250MG/5ML ORAL SUSP	77.2%
00173055500	1997	CEFTIN 250MG/5ML ORAL SUSP	95.9%
00173055500	1998	CEFTIN 250MG/5ML ORAL SUSP	96.6%
00173055500	1999	CEFTIN 250MG/5ML ORAL SUSP	95.0%
00173055500	2000	CEFTIN 250MG/5ML ORAL SUSP	91.4%
00173055500	2002	CEFTIN 250MG/5ML ORAL SUSP	94.5%
00173055500	2003	CEFTIN 250MG/5ML ORAL SUSP	93.0%
00173055500	2004	CEFTIN 250MG/5ML ORAL SUSP	87.3%
00173039400	1997	CEFTIN 500MG TABLET	97.1%
00173039400	1998	CEFTIN 500MG TABLET	93.9%
00173039400	1999	CEFTIN 500MG TABLET	90.1%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00173039400	2000	CEFTIN 500MG TABLET	86.3%
00173039400	2002	CEFTIN 500MG TABLET	89.0%
00173039400	2003	CEFTIN 500MG TABLET	55.7%
00173039400	2004	CEFTIN 500MG TABLET	83.4%
00173039400	2005	CEFTIN 500MG TABLET	86.4%
00173039442	1997	CEFTIN 500MG TABLET	83.0%
00173039442	1998	CEFTIN 500MG TABLET	82.5%
00173039442	1999	CEFTIN 500MG TABLET	76.6%
00173039442	2000	CEFTIN 500MG TABLET	78.4%
00173039442	2002	CEFTIN 500MG TABLET	80.8%
00173039442	2003	CEFTIN 500MG TABLET	-46.5%
00173039442	2004	CEFTIN 500MG TABLET	54.0%
00173039442	2005	CEFTIN 500MG TABLET	65.8%
58437000218	1997	CIMETIDINE 400MG TABLET	92.4%
58437000218	1998	CIMETIDINE 400MG TABLET	99.7%
58437000218	1999	CIMETIDINE 400MG TABLET	99.9%
58437000218	2000	CIMETIDINE 400MG TABLET	100.0%
58437000218	2001	CIMETIDINE 400MG TABLET	100.0%
58437000218	2002	CIMETIDINE 400MG TABLET	98.8%
58437000218	2003	CIMETIDINE 400MG TABLET	92.4%
58437000218	2004	CIMETIDINE 400MG TABLET	68.3%
58437000218	2005	CIMETIDINE 400MG TABLET	100.0%
58437000225	1997	CIMETIDINE 400MG TABLET	87.2%
58437000225	1998	CIMETIDINE 400MG TABLET	100.0%
00173059500	1997	COMBIVIR TABLET	82.6%
00173059500	1998	COMBIVIR TABLET	81.6%
00173059500	1999	COMBIVIR TABLET	54.0%
00173059500	2000	COMBIVIR TABLET	75.4%
00173059500	2001	COMBIVIR TABLET	74.2%
00173059500	2002	COMBIVIR TABLET	73.6%
00173059500	2003	COMBIVIR TABLET	75.8%
00173059500	2004	COMBIVIR TABLET	73.3%
00173059500	2005	COMBIVIR TABLET	74.8%
00007336003	1997	COMPAZINE 2.5MG SUPPOSITORY	85.0%
00007336003	1998	COMPAZINE 2.5MG SUPPOSITORY	70.0%
00007336003	1999	COMPAZINE 2.5MG SUPPOSITORY	87.6%
00007336003	2000	COMPAZINE 2.5MG SUPPOSITORY	78.5%
00007336003	2001	COMPAZINE 2.5MG SUPPOSITORY	73.2%
00007336003	2002	COMPAZINE 2.5MG SUPPOSITORY	78.7%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00007336003	2003	COMPAZINE 2.5MG SUPPOSITORY	69.9%
00007336003	2004	COMPAZINE 2.5MG SUPPOSITORY	74.8%
00007336103	1997	COMPAZINE 5MG SUPPOSITORY	80.5%
00007336103	1998	COMPAZINE 5MG SUPPOSITORY	71.5%
00007336103	1999	COMPAZINE 5MG SUPPOSITORY	78.6%
00007336103	2000	COMPAZINE 5MG SUPPOSITORY	50.8%
00007336103	2001	COMPAZINE 5MG SUPPOSITORY	42.9%
00007336103	2002	COMPAZINE 5MG SUPPOSITORY	73.6%
00007336103	2003	COMPAZINE 5MG SUPPOSITORY	34.9%
00007336344	1997	COMPAZINE 5MG/5ML SYRUP	72.9%
00007336344	1998	COMPAZINE 5MG/5ML SYRUP	77.0%
00007336344	1999	COMPAZINE 5MG/5ML SYRUP	79.2%
00007336344	2000	COMPAZINE 5MG/5ML SYRUP	46.9%
00007336344	2001	COMPAZINE 5MG/5ML SYRUP	19.1%
00007336344	2002	COMPAZINE 5MG/5ML SYRUP	-2735.9%
00007334615	1997	COMPAZINE SPANSULE 15MG	85.1%
00007334615	1998	COMPAZINE SPANSULE 15MG	92.8%
00007334615	1999	COMPAZINE SPANSULE 15MG	91.4%
00007334615	2000	COMPAZINE SPANSULE 15MG	74.9%
00007334615	2001	COMPAZINE SPANSULE 15MG	61.2%
00007334615	2002	COMPAZINE SPANSULE 15MG	-3121.5%
00007414120	1997	COREG 12.5MG TABLET	98.5%
00007414120	1998	COREG 12.5MG TABLET	95.3%
00007414120	1999	COREG 12.5MG TABLET	94.1%
00007414120	2000	COREG 12.5MG TABLET	89.7%
00007414120	2001	COREG 12.5MG TABLET	88.0%
00007414120	2002	COREG 12.5MG TABLET	80.9%
00007414120	2003	COREG 12.5MG TABLET	77.8%
00007414120	2004	COREG 12.5MG TABLET	75.3%
00007414120	2005	COREG 12.5MG TABLET	77.4%
00007414220	1997	COREG 25MG TABLET	97.5%
00007414220	1998	COREG 25MG TABLET	95.1%
00007414220	1999	COREG 25MG TABLET	92.7%
00007414220	2000	COREG 25MG TABLET	87.9%
00007414220	2001	COREG 25MG TABLET	86.3%
00007414220	2002	COREG 25MG TABLET	79.8%
00007414220	2003	COREG 25MG TABLET	76.9%
00007414220	2004	COREG 25MG TABLET	75.2%
00007414220	2005	COREG 25MG TABLET	74.9%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00007413920	1997	COREG 3.125MG TABLET	97.9%
00007413920	1998	COREG 3.125MG TABLET	95.4%
00007413920	1999	COREG 3.125MG TABLET	94.5%
00007413920	2000	COREG 3.125MG TABLET	89.7%
00007413920	2001	COREG 3.125MG TABLET	89.0%
00007413920	2002	COREG 3.125MG TABLET	85.2%
00007413920	2003	COREG 3.125MG TABLET	79.3%
00007413920	2004	COREG 3.125MG TABLET	73.4%
00007413920	2005	COREG 3.125MG TABLET	76.6%
00007413955	2002	COREG 3.125MG TABLET	94.6%
00007414020	1997	COREG 6.25MG TABLET	98.1%
00007414020	1998	COREG 6.25MG TABLET	94.7%
00007414020	1999	COREG 6.25MG TABLET	94.0%
00007414020	2000	COREG 6.25MG TABLET	89.4%
00007414020	2001	COREG 6.25MG TABLET	88.2%
00007414020	2002	COREG 6.25MG TABLET	82.2%
00007414020	2003	COREG 6.25MG TABLET	78.7%
00007414020	2004	COREG 6.25MG TABLET	75.0%
00007414020	2005	COREG 6.25MG TABLET	76.0%
00173020155	1997	DARAPRIM 25MG TABLET	77.1%
00173020155	1998	DARAPRIM 25MG TABLET	75.2%
00173020155	1999	DARAPRIM 25MG TABLET	71.6%
00173020155	2000	DARAPRIM 25MG TABLET	74.4%
00173020155	2001	DARAPRIM 25MG TABLET	65.5%
00173020155	2002	DARAPRIM 25MG TABLET	65.4%
00173020155	2003	DARAPRIM 25MG TABLET	60.3%
00173020155	2004	DARAPRIM 25MG TABLET	62.4%
00173020155	2005	DARAPRIM 25MG TABLET	76.1%
00007351920	1997	DEXEDRINE 5MG TABLET	93.1%
00007351920	1998	DEXEDRINE 5MG TABLET	91.8%
00007351920	1999	DEXEDRINE 5MG TABLET	92.7%
00007351920	2000	DEXEDRINE 5MG TABLET	87.5%
00007351920	2001	DEXEDRINE 5MG TABLET	91.7%
00007351920	2002	DEXEDRINE 5MG TABLET	87.9%
00007351920	2003	DEXEDRINE 5MG TABLET	86.8%
00007351920	2004	DEXEDRINE 5MG TABLET	87.4%
00007351920	2005	DEXEDRINE 5MG TABLET	89.7%
00007351320	1999	DEXEDRINE SPANSULE 10MG	92.2%
00007351320	2000	DEXEDRINE SPANSULE 10MG	90.2%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00007351320	2001	DEXEDRINE SPANSULE 10MG	92.5%
00007351320	2002	DEXEDRINE SPANSULE 10MG	84.5%
00007351320	2003	DEXEDRINE SPANSULE 10MG	86.6%
00007351320	2004	DEXEDRINE SPANSULE 10MG	88.2%
00007351320	2005	DEXEDRINE SPANSULE 10MG	88.1%
00007351420	1999	DEXEDRINE SPANSULE 15MG	93.7%
00007351420	2000	DEXEDRINE SPANSULE 15MG	88.4%
00007351420	2001	DEXEDRINE SPANSULE 15MG	93.9%
00007351420	2002	DEXEDRINE SPANSULE 15MG	67.8%
00007351420	2003	DEXEDRINE SPANSULE 15MG	88.5%
00007351420	2004	DEXEDRINE SPANSULE 15MG	91.2%
00007351420	2005	DEXEDRINE SPANSULE 15MG	90.8%
00007351220	1999	DEXEDRINE SPANSULE 5MG	91.2%
00007351220	2000	DEXEDRINE SPANSULE 5MG	84.3%
00007351220	2001	DEXEDRINE SPANSULE 5MG	85.6%
00007351220	2002	DEXEDRINE SPANSULE 5MG	70.2%
00007351220	2003	DEXEDRINE SPANSULE 5MG	78.1%
00007351220	2004	DEXEDRINE SPANSULE 5MG	87.2%
00007351220	2005	DEXEDRINE SPANSULE 5MG	86.8%
00007365022	1997	DYAZIDE 37.5/25 CAPSULE	92.3%
00007365022	1998	DYAZIDE 37.5/25 CAPSULE	89.2%
00007365022	1999	DYAZIDE 37.5/25 CAPSULE	95.0%
00007365022	2000	DYAZIDE 37.5/25 CAPSULE	98.6%
00007365022	2001	DYAZIDE 37.5/25 CAPSULE	97.9%
00007365022	2002	DYAZIDE 37.5/25 CAPSULE	96.9%
00007365022	2003	DYAZIDE 37.5/25 CAPSULE	95.4%
00007365022	2004	DYAZIDE 37.5/25 CAPSULE	96.7%
00007365022	2005	DYAZIDE 37.5/25 CAPSULE	99.2%
00007365030	1997	DYAZIDE 37.5/25 CAPSULE	93.5%
00007365030	1998	DYAZIDE 37.5/25 CAPSULE	92.7%
00007365030	1999	DYAZIDE 37.5/25 CAPSULE	93.5%
00007365030	2000	DYAZIDE 37.5/25 CAPSULE	89.3%
00007365030	2001	DYAZIDE 37.5/25 CAPSULE	91.2%
00007365030	2002	DYAZIDE 37.5/25 CAPSULE	89.0%
00007365030	2003	DYAZIDE 37.5/25 CAPSULE	87.8%
00007365030	2004	DYAZIDE 37.5/25 CAPSULE	92.2%
00007365030	2005	DYAZIDE 37.5/25 CAPSULE	90.4%
00173047100	1997	EPIVIR 10MG/ML ORAL SOLN	82.2%
00173047100	1998	EPIVIR 10MG/ML ORAL SOLN	88.8%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00173047100	1999	EPIVIR 10MG/ML ORAL SOLN	73.0%
00173047100	2000	EPIVIR 10MG/ML ORAL SOLN	86.8%
00173047100	2001	EPIVIR 10MG/ML ORAL SOLN	88.6%
00173047100	2002	EPIVIR 10MG/ML ORAL SOLN	85.8%
00173047100	2003	EPIVIR 10MG/ML ORAL SOLN	86.2%
00173047100	2004	EPIVIR 10MG/ML ORAL SOLN	87.5%
00173047100	2005	EPIVIR 10MG/ML ORAL SOLN	86.7%
00173047001	1997	EPIVIR 150MG TABLET	79.1%
00173047001	1998	EPIVIR 150MG TABLET	78.7%
00173047001	1999	EPIVIR 150MG TABLET	58.5%
00173047001	2000	EPIVIR 150MG TABLET	77.1%
00173047001	2001	EPIVIR 150MG TABLET	76.4%
00173047001	2002	EPIVIR 150MG TABLET	74.5%
00173047001	2003	EPIVIR 150MG TABLET	76.1%
00173047001	2004	EPIVIR 150MG TABLET	73.2%
00173047001	2005	EPIVIR 150MG TABLET	73.7%
00173071400	2002	EPIVIR 300 MG TABLET	97.7%
00173071400	2003	EPIVIR 300 MG TABLET	83.0%
00173071400	2004	EPIVIR 300 MG TABLET	76.1%
00173071400	2005	EPIVIR 300 MG TABLET	74.9%
00173066200	1998	EPIVIR HBV 100MG TABLET	100.0%
00173066200	1999	EPIVIR HBV 100MG TABLET	57.5%
00173066200	2000	EPIVIR HBV 100MG TABLET	95.2%
00173066200	2001	EPIVIR HBV 100MG TABLET	94.1%
00173066200	2002	EPIVIR HBV 100MG TABLET	93.6%
00173066200	2003	EPIVIR HBV 100MG TABLET	88.2%
00173066200	2004	EPIVIR HBV 100MG TABLET	90.2%
00173066200	2005	EPIVIR HBV 100MG TABLET	88.8%
00173066300	1999	EPIVIR HBV 25MG/5ML SOLN	78.6%
00173066300	2000	EPIVIR HBV 25MG/5ML SOLN	80.6%
00173066300	2001	EPIVIR HBV 25MG/5ML SOLN	85.0%
00173066300	2002	EPIVIR HBV 25MG/5ML SOLN	90.7%
00173066300	2003	EPIVIR HBV 25MG/5ML SOLN	89.1%
00173066300	2004	EPIVIR HBV 25MG/5ML SOLN	89.9%
00173066300	2005	EPIVIR HBV 25MG/5ML SOLN	88.8%
00007400720	1997	ESKALITH 300MG CAPSULE	91.8%
00007400720	1998	ESKALITH 300MG CAPSULE	98.5%
00007400720	1999	ESKALITH 300MG CAPSULE	97.5%
00007400720	2000	ESKALITH 300MG CAPSULE	98.9%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00007400720	2001	ESKALITH 300MG CAPSULE	97.4%
00007400720	2002	ESKALITH 300MG CAPSULE	98.0%
00007400720	2003	ESKALITH 300MG CAPSULE	84.1%
00007400720	2004	ESKALITH 300MG CAPSULE	91.4%
00007400720	2005	ESKALITH 300MG CAPSULE	92.8%
00007401020	1997	ESKALITH CR 450MG TABLET SA	85.3%
00007401020	1998	ESKALITH CR 450MG TABLET SA	81.1%
00007401020	1999	ESKALITH CR 450MG TABLET SA	90.6%
00007401020	2000	ESKALITH CR 450MG TABLET SA	91.8%
00007401020	2001	ESKALITH CR 450MG TABLET SA	90.4%
00007401020	2002	ESKALITH CR 450MG TABLET SA	86.4%
00007401020	2003	ESKALITH CR 450MG TABLET SA	86.8%
00007401020	2004	ESKALITH CR 450MG TABLET SA	73.6%
00007401020	2005	ESKALITH CR 450MG TABLET SA	76.8%
00173045301	1997	FLONASE 0.05% NASAL SPRAY	94.2%
00173045301	1998	FLONASE 0.05% NASAL SPRAY	80.6%
00173045301	1999	FLONASE 0.05% NASAL SPRAY	51.8%
00173045301	2000	FLONASE 0.05% NASAL SPRAY	70.5%
00173045301	2001	FLONASE 0.05% NASAL SPRAY	68.6%
00173045301	2002	FLONASE 0.05% NASAL SPRAY	61.4%
00173045301	2003	FLONASE 0.05% NASAL SPRAY	70.4%
00173045301	2004	FLONASE 0.05% NASAL SPRAY	67.2%
00173045301	2005	FLONASE 0.05% NASAL SPRAY	72.5%
00173050900	1998	FLOVENT 100MCG ROTADISK	94.3%
00173050900	1999	FLOVENT 100MCG ROTADISK	64.2%
00173050900	2000	FLOVENT 100MCG ROTADISK	88.2%
00173050900	2001	FLOVENT 100MCG ROTADISK	89.6%
00173050900	2002	FLOVENT 100MCG ROTADISK	90.9%
00173050900	2003	FLOVENT 100MCG ROTADISK	87.1%
00173050900	2004	FLOVENT 100MCG ROTADISK	74.9%
00173050900	2005	FLOVENT 100MCG ROTADISK	-275.0%
00173049400	1997	FLOVENT 110MCG INHALER	91.0%
00173049400	1998	FLOVENT 110MCG INHALER	76.8%
00173049400	1999	FLOVENT 110MCG INHALER	48.1%
00173049400	2000	FLOVENT 110MCG INHALER	70.5%
00173049400	2001	FLOVENT 110MCG INHALER	68.9%
00173049400	2002	FLOVENT 110MCG INHALER	69.8%
00173049400	2003	FLOVENT 110MCG INHALER	68.4%
00173049400	2004	FLOVENT 110MCG INHALER	66.1%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00173049400	2005	FLOVENT 110MCG INHALER	65.2%
00173049500	1997	FLOVENT 220MCG INHALER	83.9%
00173049500	1998	FLOVENT 220MCG INHALER	67.5%
00173049500	1999	FLOVENT 220MCG INHALER	37.9%
00173049500	2000	FLOVENT 220MCG INHALER	53.2%
00173049500	2001	FLOVENT 220MCG INHALER	56.2%
00173049500	2002	FLOVENT 220MCG INHALER	54.6%
00173049500	2003	FLOVENT 220MCG INHALER	52.9%
00173049500	2004	FLOVENT 220MCG INHALER	50.1%
00173049500	2005	FLOVENT 220MCG INHALER	43.0%
00173050400	1998	FLOVENT 250MCG ROTADISK	91.3%
00173050400	1999	FLOVENT 250MCG ROTADISK	64.4%
00173050400	2000	FLOVENT 250MCG ROTADISK	76.9%
00173050400	2001	FLOVENT 250MCG ROTADISK	81.6%
00173050400	2002	FLOVENT 250MCG ROTADISK	82.3%
00173050400	2003	FLOVENT 250MCG ROTADISK	82.6%
00173050400	2004	FLOVENT 250MCG ROTADISK	62.7%
00173049100	1997	FLOVENT 44MCG INHALER	94.9%
00173049100	1998	FLOVENT 44MCG INHALER	86.0%
00173049100	1999	FLOVENT 44MCG INHALER	56.2%
00173049100	2000	FLOVENT 44MCG INHALER	82.3%
00173049100	2001	FLOVENT 44MCG INHALER	78.7%
00173049100	2002	FLOVENT 44MCG INHALER	75.4%
00173049100	2003	FLOVENT 44MCG INHALER	74.3%
00173049100	2004	FLOVENT 44MCG INHALER	73.1%
00173049100	2005	FLOVENT 44MCG INHALER	70.4%
00173051100	1998	FLOVENT 50 MCG ROTADISK	96.6%
00173051100	1999	FLOVENT 50 MCG ROTADISK	67.9%
00173051100	2000	FLOVENT 50 MCG ROTADISK	79.2%
00173051100	2001	FLOVENT 50 MCG ROTADISK	92.3%
00173051100	2002	FLOVENT 50 MCG ROTADISK	93.7%
00173051100	2003	FLOVENT 50 MCG ROTADISK	90.4%
00173051100	2004	FLOVENT 50 MCG ROTADISK	80.7%
00007420105	1997	HYCANTIN 4MG VIAL	97.9%
00007420105	1998	HYCANTIN 4MG VIAL	94.2%
00007420105	1999	HYCANTIN 4MG VIAL	92.5%
00007420105	2000	HYCANTIN 4MG VIAL	95.2%
00007420105	2001	HYCANTIN 4MG VIAL	94.8%
00007420105	2002	HYCANTIN 4MG VIAL	88.0%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00007420105	2003	HYCANTIN 4MG VIAL	84.3%
00007420105	2004	HYCANTIN 4MG VIAL	50.8%
00007420105	2005	HYCANTIN 4MG VIAL	48.5%
00173045003	2000	IMITREX 100MG TABLET	99.6%
00173045003	2001	IMITREX 100MG TABLET	90.6%
00173045003	2002	IMITREX 100MG TABLET	88.6%
00173045003	2003	IMITREX 100MG TABLET	84.9%
00173073701	2004	IMITREX 100MG TABLET	84.9%
00173073701	2005	IMITREX 100MG TABLET	88.0%
00173052300	1997	IMITREX 20MG NASAL SPRAY	99.6%
00173052300	1998	IMITREX 20MG NASAL SPRAY	90.3%
00173052300	1999	IMITREX 20MG NASAL SPRAY	57.1%
00173052300	2000	IMITREX 20MG NASAL SPRAY	74.7%
00173052300	2001	IMITREX 20MG NASAL SPRAY	83.5%
00173052300	2002	IMITREX 20MG NASAL SPRAY	83.5%
00173052300	2003	IMITREX 20MG NASAL SPRAY	82.9%
00173052300	2004	IMITREX 20MG NASAL SPRAY	77.9%
00173052300	2005	IMITREX 20MG NASAL SPRAY	83.2%
00173073500	2004	IMITREX 25 MG TABLET	80.5%
00173073500	2005	IMITREX 25 MG TABLET	82.8%
00173046002	1997	IMITREX 25MG TABLET	93.6%
00173046002	1998	IMITREX 25MG TABLET	80.5%
00173046002	1999	IMITREX 25MG TABLET	52.3%
00173046002	2000	IMITREX 25MG TABLET	70.2%
00173046002	2001	IMITREX 25MG TABLET	78.2%
00173046002	2002	IMITREX 25MG TABLET	76.6%
00173046002	2003	IMITREX 25MG TABLET	75.2%
00173045900	1997	IMITREX 50MG TABLET	92.5%
00173045900	1998	IMITREX 50MG TABLET	81.2%
00173045900	1999	IMITREX 50MG TABLET	56.1%
00173045900	2000	IMITREX 50MG TABLET	78.5%
00173045900	2001	IMITREX 50MG TABLET	82.4%
00173045900	2002	IMITREX 50MG TABLET	80.0%
00173045900	2003	IMITREX 50MG TABLET	74.7%
00173073601	2004	IMITREX 50MG TABLET	79.3%
00173073601	2005	IMITREX 50MG TABLET	80.6%
00173052400	1997	IMITREX 5MG NASAL SPRAY	99.4%
00173052400	1998	IMITREX 5MG NASAL SPRAY	76.1%
00173052400	1999	IMITREX 5MG NASAL SPRAY	62.1%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00173052400	2000	IMITREX 5MG NASAL SPRAY	70.7%
00173052400	2001	IMITREX 5MG NASAL SPRAY	83.6%
00173052400	2002	IMITREX 5MG NASAL SPRAY	82.4%
00173052400	2003	IMITREX 5MG NASAL SPRAY	83.1%
00173052400	2004	IMITREX 5MG NASAL SPRAY	80.2%
00173052400	2005	IMITREX 5MG NASAL SPRAY	83.5%
00173047800	1997	IMITREX 6MG/0.5ML KIT REFL	91.8%
00173047800	1998	IMITREX 6MG/0.5ML KIT REFL	79.8%
00173047800	1999	IMITREX 6MG/0.5ML KIT REFL	53.0%
00173047800	2000	IMITREX 6MG/0.5ML KIT REFL	76.2%
00173047800	2001	IMITREX 6MG/0.5ML KIT REFL	78.6%
00173047800	2002	IMITREX 6MG/0.5ML KIT REFL	78.1%
00173047800	2003	IMITREX 6MG/0.5ML KIT REFL	77.9%
00173047800	2004	IMITREX 6MG/0.5ML KIT REFL	71.8%
00173047800	2005	IMITREX 6MG/0.5ML KIT REFL	78.7%
00173047900	1997	IMITREX 6MG/0.5ML SYRNG KIT	92.1%
00173047900	1998	IMITREX 6MG/0.5ML SYRNG KIT	67.4%
00173047900	1999	IMITREX 6MG/0.5ML SYRNG KIT	44.5%
00173047900	2000	IMITREX 6MG/0.5ML SYRNG KIT	69.6%
00173047900	2001	IMITREX 6MG/0.5ML SYRNG KIT	74.7%
00173047900	2002	IMITREX 6MG/0.5ML SYRNG KIT	77.1%
00173047900	2003	IMITREX 6MG/0.5ML SYRNG KIT	73.8%
00173047900	2004	IMITREX 6MG/0.5ML SYRNG KIT	72.9%
00173047900	2005	IMITREX 6MG/0.5ML SYRNG KIT	76.7%
00173064255	1997	LAMICTAL 100MG TABLET	92.5%
00173064255	1998	LAMICTAL 100MG TABLET	92.5%
00173064255	1999	LAMICTAL 100MG TABLET	63.7%
00173064255	2000	LAMICTAL 100MG TABLET	83.9%
00173064255	2001	LAMICTAL 100MG TABLET	85.6%
00173064255	2002	LAMICTAL 100MG TABLET	86.4%
00173064255	2003	LAMICTAL 100MG TABLET	83.8%
00173064255	2004	LAMICTAL 100MG TABLET	83.5%
00173064255	2005	LAMICTAL 100MG TABLET	89.4%
00173064360	1997	LAMICTAL 150MG TABLET	91.8%
00173064360	1998	LAMICTAL 150MG TABLET	92.9%
00173064360	1999	LAMICTAL 150MG TABLET	62.5%
00173064360	2000	LAMICTAL 150MG TABLET	85.3%
00173064360	2001	LAMICTAL 150MG TABLET	87.1%
00173064360	2002	LAMICTAL 150MG TABLET	88.3%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00173064360	2003	LAMICTAL 150MG TABLET	83.3%
00173064360	2004	LAMICTAL 150MG TABLET	84.7%
00173064360	2005	LAMICTAL 150MG TABLET	90.9%
00173064460	1997	LAMICTAL 200MG TABLET	91.9%
00173064460	1998	LAMICTAL 200MG TABLET	92.5%
00173064460	1999	LAMICTAL 200MG TABLET	63.1%
00173064460	2000	LAMICTAL 200MG TABLET	84.5%
00173064460	2001	LAMICTAL 200MG TABLET	88.2%
00173064460	2002	LAMICTAL 200MG TABLET	89.0%
00173064460	2003	LAMICTAL 200MG TABLET	84.8%
00173064460	2004	LAMICTAL 200MG TABLET	84.8%
00173064460	2005	LAMICTAL 200MG TABLET	91.5%
00173052700	1998	LAMICTAL 25MG DISPER TABLET	99.9%
00173052700	1999	LAMICTAL 25MG DISPER TABLET	73.6%
00173052700	2000	LAMICTAL 25MG DISPER TABLET	89.5%
00173052700	2001	LAMICTAL 25MG DISPER TABLET	90.8%
00173052700	2002	LAMICTAL 25MG DISPER TABLET	93.4%
00173052700	2003	LAMICTAL 25MG DISPER TABLET	88.6%
00173052700	2004	LAMICTAL 25MG DISPER TABLET	88.5%
00173052700	2005	LAMICTAL 25MG DISPER TABLET	91.6%
00173063302	1997	LAMICTAL 25MG TABLET	92.3%
00173063302	1998	LAMICTAL 25MG TABLET	92.3%
00173063302	1999	LAMICTAL 25MG TABLET	63.0%
00173063302	2000	LAMICTAL 25MG TABLET	81.9%
00173063302	2001	LAMICTAL 25MG TABLET	86.1%
00173063302	2002	LAMICTAL 25MG TABLET	87.3%
00173063302	2003	LAMICTAL 25MG TABLET	81.8%
00173063302	2004	LAMICTAL 25MG TABLET	79.1%
00173063302	2005	LAMICTAL 25MG TABLET	88.1%
00173052600	1998	LAMICTAL 5MG DISPER TABLET	99.8%
00173052600	1999	LAMICTAL 5MG DISPER TABLET	69.7%
00173052600	2000	LAMICTAL 5MG DISPER TABLET	89.6%
00173052600	2001	LAMICTAL 5MG DISPER TABLET	90.4%
00173052600	2002	LAMICTAL 5MG DISPER TABLET	92.5%
00173052600	2003	LAMICTAL 5MG DISPER TABLET	89.5%
00173052600	2004	LAMICTAL 5MG DISPER TABLET	88.4%
00173052600	2005	LAMICTAL 5MG DISPER TABLET	92.2%
00173024255	1997	LANOXIN 125MCG TABLET	39.9%
00173024255	1998	LANOXIN 125MCG TABLET	64.4%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00173024255	1999	LANOXIN 125MCG TABLET	76.5%
00173024255	2000	LANOXIN 125MCG TABLET	63.9%
00173024255	2001	LANOXIN 125MCG TABLET	48.8%
00173024255	2002	LANOXIN 125MCG TABLET	61.8%
00173024255	2003	LANOXIN 125MCG TABLET	57.4%
00173024255	2004	LANOXIN 125MCG TABLET	53.9%
00173024255	2005	LANOXIN 125MCG TABLET	62.0%
00173024275	1997	LANOXIN 125MCG TABLET	83.0%
00173024275	1998	LANOXIN 125MCG TABLET	83.9%
00173024275	1999	LANOXIN 125MCG TABLET	79.9%
00173024275	2000	LANOXIN 125MCG TABLET	79.1%
00173024275	2001	LANOXIN 125MCG TABLET	81.5%
00173024275	2002	LANOXIN 125MCG TABLET	75.5%
00173024275	2003	LANOXIN 125MCG TABLET	70.7%
00173024275	2004	LANOXIN 125MCG TABLET	64.6%
00173024275	2005	LANOXIN 125MCG TABLET	60.8%
00173024955	1997	LANOXIN 250MCG TABLET	48.3%
00173024955	1998	LANOXIN 250MCG TABLET	78.2%
00173024955	1999	LANOXIN 250MCG TABLET	67.0%
00173024955	2000	LANOXIN 250MCG TABLET	57.2%
00173024955	2001	LANOXIN 250MCG TABLET	36.1%
00173024955	2002	LANOXIN 250MCG TABLET	61.3%
00173024955	2003	LANOXIN 250MCG TABLET	57.2%
00173024955	2004	LANOXIN 250MCG TABLET	64.8%
00173024955	2005	LANOXIN 250MCG TABLET	65.8%
00173024975	1997	LANOXIN 250MCG TABLET	64.8%
00173024975	1998	LANOXIN 250MCG TABLET	66.8%
00173024975	1999	LANOXIN 250MCG TABLET	58.7%
00173024975	2000	LANOXIN 250MCG TABLET	50.2%
00173024975	2001	LANOXIN 250MCG TABLET	51.8%
00173024975	2002	LANOXIN 250MCG TABLET	54.8%
00173024975	2003	LANOXIN 250MCG TABLET	48.8%
00173024975	2004	LANOXIN 250MCG TABLET	46.6%
00173024975	2005	LANOXIN 250MCG TABLET	41.6%
00173024980	1997	LANOXIN 250MCG TABLET	92.0%
00173024980	1998	LANOXIN 250MCG TABLET	92.7%
00173024980	1999	LANOXIN 250MCG TABLET	90.2%
00173024980	2000	LANOXIN 250MCG TABLET	95.1%
00173024980	2001	LANOXIN 250MCG TABLET	88.0%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00173024980	2002	LANOXIN 250MCG TABLET	79.1%
00173024980	2003	LANOXIN 250MCG TABLET	81.1%
00173024980	2004	LANOXIN 250MCG TABLET	76.8%
00173024980	2005	LANOXIN 250MCG TABLET	72.2%
00173026427	1997	LANOXIN 50MCG/ML ELIXIR	67.0%
00173026427	1998	LANOXIN 50MCG/ML ELIXIR	61.9%
00173026427	1999	LANOXIN 50MCG/ML ELIXIR	55.0%
00173026427	2000	LANOXIN 50MCG/ML ELIXIR	69.5%
00173026427	2001	LANOXIN 50MCG/ML ELIXIR	78.1%
00173026427	2002	LANOXIN 50MCG/ML ELIXIR	74.3%
00173026427	2003	LANOXIN 50MCG/ML ELIXIR	80.2%
00173026427	2004	LANOXIN 50MCG/ML ELIXIR	80.9%
00173026427	2005	LANOXIN 50MCG/ML ELIXIR	71.3%
00173063535	1997	LEUKERAN 2MG TABLET	90.5%
00173063535	1998	LEUKERAN 2MG TABLET	91.2%
00173063535	1999	LEUKERAN 2MG TABLET	70.1%
00173063535	2000	LEUKERAN 2MG TABLET	87.2%
00173063535	2001	LEUKERAN 2MG TABLET	88.0%
00173063535	2002	LEUKERAN 2MG TABLET	87.5%
00173063535	2003	LEUKERAN 2MG TABLET	88.0%
00173063535	2004	LEUKERAN 2MG TABLET	90.7%
00173063535	2005	LEUKERAN 2MG TABLET	90.6%
00173069000	2000	LOTRONEX 1MG TABLET	97.1%
00173069000	2001	LOTRONEX 1MG TABLET	97.0%
00173069000	2002	LOTRONEX 1MG TABLET	100.0%
00173069005	2002	LOTRONEX 1MG TABLET	100.0%
00173069005	2003	LOTRONEX 1MG TABLET	95.0%
00173069005	2004	LOTRONEX 1MG TABLET	97.0%
00173069005	2005	LOTRONEX 1MG TABLET	99.9%
00173066518	1997	MEPRON 750MG/5ML SUSPENSION	82.0%
00173066518	1998	MEPRON 750MG/5ML SUSPENSION	78.3%
00173066518	1999	MEPRON 750MG/5ML SUSPENSION	62.3%
00173066518	2000	MEPRON 750MG/5ML SUSPENSION	79.7%
00173066518	2001	MEPRON 750MG/5ML SUSPENSION	76.4%
00173066518	2002	MEPRON 750MG/5ML SUSPENSION	77.8%
00173066518	2003	MEPRON 750MG/5ML SUSPENSION	81.6%
00173066518	2004	MEPRON 750MG/5ML SUSPENSION	80.7%
00173066518	2005	MEPRON 750MG/5ML SUSPENSION	83.2%
00007447120	1997	PARNATE 10MG TABLET	89.7%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00007447120	1998	PARNATE 10MG TABLET	80.0%
00007447120	1999	PARNATE 10MG TABLET	93.0%
00007447120	2000	PARNATE 10MG TABLET	95.0%
00007447120	2001	PARNATE 10MG TABLET	93.1%
00007447120	2002	PARNATE 10MG TABLET	92.1%
00007447120	2003	PARNATE 10MG TABLET	93.6%
00007447120	2004	PARNATE 10MG TABLET	96.0%
00007447120	2005	PARNATE 10MG TABLET	99.6%
00029321013	1997	PAXIL 10MG TABLET	93.3%
00029321013	1998	PAXIL 10MG TABLET	86.5%
00029321013	1999	PAXIL 10MG TABLET	83.2%
00029321013	2000	PAXIL 10MG TABLET	80.0%
00029321013	2001	PAXIL 10MG TABLET	83.6%
00029321013	2002	PAXIL 10MG TABLET	83.1%
00029321013	2003	PAXIL 10MG TABLET	75.3%
00029321013	2004	PAXIL 10MG TABLET	70.9%
00029321013	2005	PAXIL 10MG TABLET	90.4%
00029321548	1998	PAXIL 10MG/5ML SUSPENSION	92.5%
00029321548	1999	PAXIL 10MG/5ML SUSPENSION	83.2%
00029321548	2000	PAXIL 10MG/5ML SUSPENSION	84.9%
00029321548	2001	PAXIL 10MG/5ML SUSPENSION	81.8%
00029321548	2002	PAXIL 10MG/5ML SUSPENSION	92.7%
00029321548	2003	PAXIL 10MG/5ML SUSPENSION	74.1%
00029321548	2004	PAXIL 10MG/5ML SUSPENSION	72.1%
00029321548	2005	PAXIL 10MG/5ML SUSPENSION	92.3%
00029321113	1997	PAXIL 20MG TABLET	80.7%
00029321113	1998	PAXIL 20MG TABLET	74.4%
00029321113	1999	PAXIL 20MG TABLET	79.3%
00029321113	2000	PAXIL 20MG TABLET	79.7%
00029321113	2001	PAXIL 20MG TABLET	75.1%
00029321113	2002	PAXIL 20MG TABLET	76.0%
00029321113	2003	PAXIL 20MG TABLET	70.9%
00029321113	2004	PAXIL 20MG TABLET	85.0%
00029321113	2005	PAXIL 20MG TABLET	91.2%
00029321120	1997	PAXIL 20MG TABLET	89.7%
00029321120	1998	PAXIL 20MG TABLET	82.6%
00029321120	1999	PAXIL 20MG TABLET	81.8%
00029321120	2000	PAXIL 20MG TABLET	77.8%
00029321120	2001	PAXIL 20MG TABLET	83.3%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00029321120	2002	PAXIL 20MG TABLET	83.0%
00029321120	2003	PAXIL 20MG TABLET	75.5%
00029321120	2004	PAXIL 20MG TABLET	62.4%
00029321120	2005	PAXIL 20MG TABLET	82.6%
00029321213	1997	PAXIL 30MG TABLET	86.1%
00029321213	1998	PAXIL 30MG TABLET	80.0%
00029321213	1999	PAXIL 30MG TABLET	80.0%
00029321213	2000	PAXIL 30MG TABLET	74.4%
00029321213	2001	PAXIL 30MG TABLET	81.1%
00029321213	2002	PAXIL 30MG TABLET	82.1%
00029321213	2003	PAXIL 30MG TABLET	72.0%
00029321213	2004	PAXIL 30MG TABLET	70.0%
00029321213	2005	PAXIL 30MG TABLET	92.0%
00029321313	1997	PAXIL 40MG TABLET	87.4%
00029321313	1998	PAXIL 40MG TABLET	76.7%
00029321313	1999	PAXIL 40MG TABLET	73.4%
00029321313	2000	PAXIL 40MG TABLET	65.0%
00029321313	2001	PAXIL 40MG TABLET	74.6%
00029321313	2002	PAXIL 40MG TABLET	77.5%
00029321313	2003	PAXIL 40MG TABLET	69.2%
00029321313	2004	PAXIL 40MG TABLET	66.4%
00029321313	2005	PAXIL 40MG TABLET	83.3%
00029320613	2002	PAXIL CR 12.5MG TABLET	91.7%
00029320613	2003	PAXIL CR 12.5MG TABLET	85.1%
00029320613	2004	PAXIL CR 12.5MG TABLET	84.8%
00029320613	2005	PAXIL CR 12.5MG TABLET	87.1%
00029320713	2002	PAXIL CR 25MG TABLET	93.9%
00029320713	2003	PAXIL CR 25MG TABLET	87.1%
00029320713	2004	PAXIL CR 25MG TABLET	86.8%
00029320713	2005	PAXIL CR 25MG TABLET	86.3%
00029320813	2002	PAXIL CR 37.5MG TABLET	93.2%
00029320813	2003	PAXIL CR 37.5MG TABLET	83.6%
00029320813	2004	PAXIL CR 37.5MG TABLET	84.1%
00029320813	2005	PAXIL CR 37.5MG TABLET	82.3%
00173080725	1997	PURINETHOL 50MG TABLET	96.0%
00173080725	1998	PURINETHOL 50MG TABLET	97.1%
00173080725	1999	PURINETHOL 50MG TABLET	73.8%
00173080725	2000	PURINETHOL 50MG TABLET	94.2%
00173080725	2001	PURINETHOL 50MG TABLET	94.6%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00173080725	2002	PURINETHOL 50MG TABLET	95.7%
00173080725	2003	PURINETHOL 50MG TABLET	94.8%
00173080765	1997	PURINETHOL 50MG TABLET	85.5%
00173080765	1998	PURINETHOL 50MG TABLET	86.7%
00173080765	1999	PURINETHOL 50MG TABLET	63.2%
00173080765	2000	PURINETHOL 50MG TABLET	86.2%
00173080765	2001	PURINETHOL 50MG TABLET	80.8%
00173080765	2002	PURINETHOL 50MG TABLET	77.0%
00173080765	2003	PURINETHOL 50MG TABLET	84.4%
00029485120	1997	RELAFEN 500MG TABLET	89.7%
00029485120	1998	RELAFEN 500MG TABLET	78.7%
00029485120	1999	RELAFEN 500MG TABLET	82.0%
00029485120	2000	RELAFEN 500MG TABLET	88.5%
00029485120	2001	RELAFEN 500MG TABLET	43.4%
00029485120	2002	RELAFEN 500MG TABLET	-8.5%
00029485120	2003	RELAFEN 500MG TABLET	17.3%
00029485120	2004	RELAFEN 500MG TABLET	80.3%
00029485120	2005	RELAFEN 500MG TABLET	79.3%
00029485220	1997	RELAFEN 750MG TABLET	92.7%
00029485220	1998	RELAFEN 750MG TABLET	82.4%
00029485220	1999	RELAFEN 750MG TABLET	85.8%
00029485220	2000	RELAFEN 750MG TABLET	87.2%
00029485220	2001	RELAFEN 750MG TABLET	75.6%
00029485220	2002	RELAFEN 750MG TABLET	70.4%
00029485220	2003	RELAFEN 750MG TABLET	68.9%
00029485220	2004	RELAFEN 750MG TABLET	78.2%
00029485220	2005	RELAFEN 750MG TABLET	88.9%
00173068101	1999	RELENZA 5 MG DISKHALER	99.2%
00173068101	2000	RELENZA 5 MG DISKHALER	98.7%
00173068101	2001	RELENZA 5 MG DISKHALER	20.1%
00173068101	2002	RELENZA 5 MG DISKHALER	-81.9%
00173068101	2003	RELENZA 5 MG DISKHALER	93.7%
00173068101	2004	RELENZA 5 MG DISKHALER	92.7%
00173068101	2005	RELENZA 5 MG DISKHALER	-1.7%
00007489020	1997	REQUIP 0.25MG TABLET	99.6%
00007489020	1998	REQUIP 0.25MG TABLET	95.4%
00007489020	1999	REQUIP 0.25MG TABLET	91.3%
00007489020	2000	REQUIP 0.25MG TABLET	90.7%
00007489020	2001	REQUIP 0.25MG TABLET	86.9%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00007489020	2002	REQUIP 0.25MG TABLET	88.4%
00007489020	2003	REQUIP 0.25MG TABLET	71.5%
00007489020	2004	REQUIP 0.25MG TABLET	76.6%
00007489020	2005	REQUIP 0.25MG TABLET	89.8%
00007489120	1997	REQUIP 0.5MG TABLET	99.4%
00007489120	1998	REQUIP 0.5MG TABLET	95.1%
00007489120	1999	REQUIP 0.5MG TABLET	92.2%
00007489120	2000	REQUIP 0.5MG TABLET	91.1%
00007489120	2001	REQUIP 0.5MG TABLET	90.2%
00007489120	2002	REQUIP 0.5MG TABLET	90.9%
00007489120	2003	REQUIP 0.5MG TABLET	75.4%
00007489120	2004	REQUIP 0.5MG TABLET	79.1%
00007489120	2005	REQUIP 0.5MG TABLET	90.4%
00007489220	1997	REQUIP 1MG TABLET	99.9%
00007489220	1998	REQUIP 1MG TABLET	95.7%
00007489220	1999	REQUIP 1MG TABLET	89.9%
00007489220	2000	REQUIP 1MG TABLET	91.0%
00007489220	2001	REQUIP 1MG TABLET	87.1%
00007489220	2002	REQUIP 1MG TABLET	84.7%
00007489220	2003	REQUIP 1MG TABLET	73.6%
00007489220	2004	REQUIP 1MG TABLET	76.1%
00007489220	2005	REQUIP 1MG TABLET	87.7%
00007489320	1997	REQUIP 2MG TABLET	99.9%
00007489320	1998	REQUIP 2MG TABLET	95.5%
00007489320	1999	REQUIP 2MG TABLET	93.7%
00007489320	2000	REQUIP 2MG TABLET	91.0%
00007489320	2001	REQUIP 2MG TABLET	86.8%
00007489320	2002	REQUIP 2MG TABLET	87.5%
00007489320	2003	REQUIP 2MG TABLET	73.4%
00007489320	2004	REQUIP 2MG TABLET	75.9%
00007489320	2005	REQUIP 2MG TABLET	84.3%
00007489520	2001	REQUIP 3MG TABLET	96.1%
00007489520	2002	REQUIP 3MG TABLET	95.2%
00007489520	2003	REQUIP 3MG TABLET	93.7%
00007489520	2004	REQUIP 3MG TABLET	92.4%
00007489520	2005	REQUIP 3MG TABLET	92.5%
00007489620	1999	REQUIP 4MG TABLET	99.8%
00007489620	2000	REQUIP 4MG TABLET	83.7%
00007489620	2001	REQUIP 4MG TABLET	93.7%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00007489620	2002	REQUIP 4MG TABLET	93.4%
00007489620	2003	REQUIP 4MG TABLET	88.3%
00007489620	2004	REQUIP 4MG TABLET	89.4%
00007489620	2005	REQUIP 4MG TABLET	91.2%
00007489420	1997	REQUIP 5MG TABLET	99.8%
00007489420	1998	REQUIP 5MG TABLET	94.8%
00007489420	1999	REQUIP 5MG TABLET	95.3%
00007489420	2000	REQUIP 5MG TABLET	89.3%
00007489420	2001	REQUIP 5MG TABLET	88.9%
00007489420	2002	REQUIP 5MG TABLET	88.6%
00007489420	2003	REQUIP 5MG TABLET	82.3%
00007489420	2004	REQUIP 5MG TABLET	84.6%
00007489420	2005	REQUIP 5MG TABLET	88.0%
00173010855	1997	RETROVIR 100MG CAPSULE	71.6%
00173010855	1998	RETROVIR 100MG CAPSULE	76.2%
00173010855	1999	RETROVIR 100MG CAPSULE	61.7%
00173010855	2000	RETROVIR 100MG CAPSULE	79.0%
00173010855	2001	RETROVIR 100MG CAPSULE	81.8%
00173010855	2002	RETROVIR 100MG CAPSULE	79.7%
00173010855	2003	RETROVIR 100MG CAPSULE	82.1%
00173010855	2004	RETROVIR 100MG CAPSULE	80.5%
00173010855	2005	RETROVIR 100MG CAPSULE	81.1%
00173011318	1997	RETROVIR 10MG/ML SYRUP	86.8%
00173011318	1998	RETROVIR 10MG/ML SYRUP	88.8%
00173011318	1999	RETROVIR 10MG/ML SYRUP	72.1%
00173011318	2000	RETROVIR 10MG/ML SYRUP	88.4%
00173011318	2001	RETROVIR 10MG/ML SYRUP	91.5%
00173011318	2002	RETROVIR 10MG/ML SYRUP	88.8%
00173011318	2003	RETROVIR 10MG/ML SYRUP	90.9%
00173011318	2004	RETROVIR 10MG/ML SYRUP	89.2%
00173011318	2005	RETROVIR 10MG/ML SYRUP	89.3%
00173050100	1997	RETROVIR 300MG TABLET	82.2%
00173050100	1998	RETROVIR 300MG TABLET	77.9%
00173050100	1999	RETROVIR 300MG TABLET	62.7%
00173050100	2000	RETROVIR 300MG TABLET	78.7%
00173050100	2001	RETROVIR 300MG TABLET	79.9%
00173050100	2002	RETROVIR 300MG TABLET	72.0%
00173050100	2003	RETROVIR 300MG TABLET	74.0%
00173050100	2004	RETROVIR 300MG TABLET	70.7%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00173050100	2005	RETROVIR 300MG TABLET	70.7%
00173010793	1997	RETROVIR IV INFUSION VIAL	97.6%
00173010793	1998	RETROVIR IV INFUSION VIAL	97.2%
00173010793	1999	RETROVIR IV INFUSION VIAL	93.9%
00173010793	2000	RETROVIR IV INFUSION VIAL	95.1%
00173010793	2001	RETROVIR IV INFUSION VIAL	97.0%
00173010793	2002	RETROVIR IV INFUSION VIAL	94.6%
00173010793	2003	RETROVIR IV INFUSION VIAL	96.7%
00173010793	2004	RETROVIR IV INFUSION VIAL	96.5%
00173010793	2005	RETROVIR IV INFUSION VIAL	96.6%
00173046400	1997	SEREVENT 21MCG INHALER	90.0%
00173046400	1998	SEREVENT 21MCG INHALER	75.6%
00173046400	1999	SEREVENT 21MCG INHALER	45.4%
00173046400	2000	SEREVENT 21MCG INHALER	64.5%
00173046400	2001	SEREVENT 21MCG INHALER	62.9%
00173046400	2002	SEREVENT 21MCG INHALER	61.4%
00173046400	2003	SEREVENT 21MCG INHALER	52.0%
00173046400	2004	SEREVENT 21MCG INHALER	-182.4%
00173046500	1997	SEREVENT 21MCG INHLR REFILL	96.6%
00173046500	1998	SEREVENT 21MCG INHLR REFILL	95.9%
00173046500	1999	SEREVENT 21MCG INHLR REFILL	73.3%
00173046500	2000	SEREVENT 21MCG INHLR REFILL	89.3%
00173046500	2001	SEREVENT 21MCG INHLR REFILL	89.2%
00173046500	2002	SEREVENT 21MCG INHLR REFILL	91.1%
00173046500	2003	SEREVENT 21MCG INHLR REFILL	82.7%
00173052100	1997	SEREVENT DISKUS 50MCG	100.0%
00173052100	1998	SEREVENT DISKUS 50MCG	84.9%
00173052100	1999	SEREVENT DISKUS 50MCG	83.3%
00173052100	2000	SEREVENT DISKUS 50MCG	79.8%
00173052100	2001	SEREVENT DISKUS 50MCG	75.0%
00173052100	2002	SEREVENT DISKUS 50MCG	74.8%
00173052100	2003	SEREVENT DISKUS 50MCG	62.7%
00173052100	2004	SEREVENT DISKUS 50MCG	52.4%
00173052100	2005	SEREVENT DISKUS 50MCG	59.5%
00108490420	1997	STELAZINE 2MG TABLET	83.7%
00108490420	1998	STELAZINE 2MG TABLET	94.0%
00108490420	1999	STELAZINE 2MG TABLET	96.0%
00108490420	2000	STELAZINE 2MG TABLET	97.1%
00108490420	2001	STELAZINE 2MG TABLET	96.9%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00108490420	2002	STELAZINE 2MG TABLET	95.4%
00108490420	2003	STELAZINE 2MG TABLET	95.8%
00108490201	1997	STELAZINE 2MG/ML VIAL	52.2%
00108490201	1998	STELAZINE 2MG/ML VIAL	84.2%
00108490201	1999	STELAZINE 2MG/ML VIAL	49.0%
00108490201	2000	STELAZINE 2MG/ML VIAL	86.5%
00108490201	2001	STELAZINE 2MG/ML VIAL	27.8%
00108490201	2002	STELAZINE 2MG/ML VIAL	32.4%
00108490201	2003	STELAZINE 2MG/ML VIAL	54.7%
00173045402	1997	TEMOVATE EMOLLIENT 0.05% CRM	87.6%
00173045402	1998	TEMOVATE EMOLLIENT 0.05% CRM	89.0%
00173045402	1999	TEMOVATE EMOLLIENT 0.05% CRM	66.9%
00173045402	2000	TEMOVATE EMOLLIENT 0.05% CRM	77.2%
00173045402	2001	TEMOVATE EMOLLIENT 0.05% CRM	50.3%
00173045402	2002	TEMOVATE EMOLLIENT 0.05% CRM	0.0%
00173045403	1997	TEMOVATE EMOLLIENT 0.05% CRM	94.0%
00173045403	1998	TEMOVATE EMOLLIENT 0.05% CRM	94.2%
00173045403	1999	TEMOVATE EMOLLIENT 0.05% CRM	76.4%
00173045403	2000	TEMOVATE EMOLLIENT 0.05% CRM	89.8%
00173045403	2001	TEMOVATE EMOLLIENT 0.05% CRM	42.1%
00173045403	2002	TEMOVATE EMOLLIENT 0.05% CRM	100.0%
00173088025	1997	THIOGUANINE TABLOID 40MG TB	70.5%
00173088025	1998	THIOGUANINE TABLOID 40MG TB	69.3%
00173088025	1999	THIOGUANINE TABLOID 40MG TB	48.3%
00173088025	2000	THIOGUANINE TABLOID 40MG TB	72.4%
00173088025	2001	THIOGUANINE TABLOID 40MG TB	72.9%
00173088025	2002	THIOGUANINE TABLOID 40MG TB	81.9%
00173088025	2003	THIOGUANINE TABLOID 40MG TB	81.4%
00173088025	2004	THIOGUANINE TABLOID 40MG TB	77.2%
00173088025	2005	THIOGUANINE TABLOID 40MG TB	79.6%
00007507103	1997	THORAZINE 100MG SUPPOSITORY	97.2%
00007507103	1998	THORAZINE 100MG SUPPOSITORY	93.5%
00007507103	1999	THORAZINE 100MG SUPPOSITORY	87.6%
00007507103	2000	THORAZINE 100MG SUPPOSITORY	94.4%
00007507103	2001	THORAZINE 100MG SUPPOSITORY	75.0%
00007507103	2002	THORAZINE 100MG SUPPOSITORY	75.8%
00007507720	1997	THORAZINE 100MG TABLET	92.9%
00007507720	1998	THORAZINE 100MG TABLET	97.1%
00007507720	1999	THORAZINE 100MG TABLET	96.5%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00007507720	2000	THORAZINE 100MG TABLET	97.4%
00007507720	2001	THORAZINE 100MG TABLET	96.4%
00007507720	2002	THORAZINE 100MG TABLET	94.9%
00007507720	2003	THORAZINE 100MG TABLET	-1466.7%
00007507244	1997	THORAZINE 10MG/5ML SYRUP	83.4%
00007507244	1998	THORAZINE 10MG/5ML SYRUP	97.2%
00007507244	1999	THORAZINE 10MG/5ML SYRUP	85.2%
00007507244	2000	THORAZINE 10MG/5ML SYRUP	96.5%
00007507244	2001	THORAZINE 10MG/5ML SYRUP	80.5%
00007507244	2002	THORAZINE 10MG/5ML SYRUP	88.1%
00007507244	2003	THORAZINE 10MG/5ML SYRUP	34.6%
00007507920	1997	THORAZINE 200MG TABLET	91.3%
00007507920	1998	THORAZINE 200MG TABLET	97.5%
00007507920	1999	THORAZINE 200MG TABLET	96.5%
00007507920	2000	THORAZINE 200MG TABLET	97.9%
00007507920	2001	THORAZINE 200MG TABLET	95.7%
00007507920	2002	THORAZINE 200MG TABLET	93.0%
00007507930	1997	THORAZINE 200MG TABLET	55.6%
00007507930	1998	THORAZINE 200MG TABLET	90.8%
00007507930	1999	THORAZINE 200MG TABLET	100.0%
00007507930	2000	THORAZINE 200MG TABLET	100.0%
00007507420	1997	THORAZINE 25MG TABLET	93.8%
00007507420	1998	THORAZINE 25MG TABLET	98.0%
00007507420	1999	THORAZINE 25MG TABLET	98.0%
00007507420	2000	THORAZINE 25MG TABLET	97.6%
00007507420	2001	THORAZINE 25MG TABLET	95.6%
00007507420	2002	THORAZINE 25MG TABLET	92.9%
00007507430	1997	THORAZINE 25MG TABLET	71.9%
00007507430	1998	THORAZINE 25MG TABLET	62.1%
00007507430	1999	THORAZINE 25MG TABLET	72.0%
00007507430	2000	THORAZINE 25MG TABLET	33.3%
00007506201	1997	THORAZINE 25MG/ML VIAL	78.2%
00007506201	1998	THORAZINE 25MG/ML VIAL	94.1%
00007506201	1999	THORAZINE 25MG/ML VIAL	85.0%
00007506201	2000	THORAZINE 25MG/ML VIAL	97.0%
00007506201	2001	THORAZINE 25MG/ML VIAL	70.7%
00007506201	2002	THORAZINE 25MG/ML VIAL	81.1%
00007506201	2003	THORAZINE 25MG/ML VIAL	81.2%
00007504744	1997	THORAZINE 30MG/ML LIQ CONC	77.3%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00007507620	1997	THORAZINE 50MG TABLET	92.2%
00007507620	1998	THORAZINE 50MG TABLET	98.2%
00007507620	1999	THORAZINE 50MG TABLET	98.2%
00007507620	2000	THORAZINE 50MG TABLET	98.4%
00007507620	2001	THORAZINE 50MG TABLET	96.9%
00007507620	2002	THORAZINE 50MG TABLET	92.3%
00007507620	2003	THORAZINE 50MG TABLET	87.6%
00007507630	1997	THORAZINE 50MG TABLET	64.8%
00007507630	1998	THORAZINE 50MG TABLET	81.4%
00007507630	1999	THORAZINE 50MG TABLET	73.8%
00007507630	2000	THORAZINE 50MG TABLET	100.0%
00173069100	2000	TRIZIVIR TABLET	93.1%
00173069100	2001	TRIZIVIR TABLET	82.0%
00173069100	2002	TRIZIVIR TABLET	77.3%
00173069100	2003	TRIZIVIR TABLET	80.5%
00173069100	2004	TRIZIVIR TABLET	77.5%
00173069100	2005	TRIZIVIR TABLET	79.7%
00173069120	2004	TRIZIVIR TABLET	95.8%
00173069120	2005	TRIZIVIR TABLET	67.4%
00173056502	2001	VALTREX 1GM CAPLET	99.8%
00173056502	2002	VALTREX 1GM CAPLET	89.8%
00173056502	2003	VALTREX 1GM CAPLET	86.2%
00173056502	2004	VALTREX 1GM CAPLET	85.8%
00173056502	2005	VALTREX 1GM CAPLET	90.6%
00173093303	1997	VALTREX 500MG CAPLET	96.0%
00173093303	1998	VALTREX 500MG CAPLET	91.0%
00173093303	1999	VALTREX 500MG CAPLET	67.2%
00173093303	2000	VALTREX 500MG CAPLET	85.5%
00173093303	2001	VALTREX 500MG CAPLET	89.9%
00173093303	2002	VALTREX 500MG CAPLET	90.3%
00173093303	2003	VALTREX 500MG CAPLET	81.6%
00173093308	2003	VALTREX 500MG CAPLET	91.9%
00173093308	2004	VALTREX 500MG CAPLET	85.9%
00173093308	2005	VALTREX 500MG CAPLET	88.3%
00173032198	1997	VENTOLIN 90MCG INH REFILL	94.0%
00173032198	1998	VENTOLIN 90MCG INH REFILL	93.8%
00173032198	1999	VENTOLIN 90MCG INH REFILL	86.6%
00173032198	2000	VENTOLIN 90MCG INH REFILL	90.3%
00173032198	2001	VENTOLIN 90MCG INH REFILL	93.1%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00173032198	2002	VENTOLIN 90MCG INH REFILL	94.5%
00173032198	2003	VENTOLIN 90MCG INH REFILL	93.7%
00173068200	2002	VENTOLIN HFA 90 MCG INHALER	98.9%
00173068200	2003	VENTOLIN HFA 90 MCG INHALER	97.4%
00173068200	2004	VENTOLIN HFA 90 MCG INHALER	97.6%
00173068200	2005	VENTOLIN HFA 90 MCG INHALER	97.2%
00173038901	1997	VENTOLIN ROTACAPS 200MCG	88.9%
00173038901	1998	VENTOLIN ROTACAPS 200MCG	96.5%
00173038901	1999	VENTOLIN ROTACAPS 200MCG	94.2%
00173038901	2000	VENTOLIN ROTACAPS 200MCG	93.3%
00173038901	2001	VENTOLIN ROTACAPS 200MCG	88.6%
00173038901	2002	VENTOLIN ROTACAPS 200MCG	-50.0%
00173038902	1997	VENTOLIN ROTACAPS 200MCG	92.1%
00173038902	1998	VENTOLIN ROTACAPS 200MCG	97.1%
00173038902	1999	VENTOLIN ROTACAPS 200MCG	96.4%
00173038902	2000	VENTOLIN ROTACAPS 200MCG	97.6%
00173038902	2001	VENTOLIN ROTACAPS 200MCG	96.4%
00173038902	2002	VENTOLIN ROTACAPS 200MCG	-300.0%
00173038903	1997	VENTOLIN ROTACAPS 200MCG	67.0%
00173038903	1998	VENTOLIN ROTACAPS 200MCG	77.0%
00173038903	1999	VENTOLIN ROTACAPS 200MCG	2900.0%
00173038903	2000	VENTOLIN ROTACAPS 200MCG	100.0%
00173017855	1997	WELLBUTRIN 100MG TABLET	80.6%
00173017855	1998	WELLBUTRIN 100MG TABLET	77.3%
00173017855	1999	WELLBUTRIN 100MG TABLET	74.1%
00173017855	2000	WELLBUTRIN 100MG TABLET	63.0%
00173017855	2001	WELLBUTRIN 100MG TABLET	57.2%
00173017855	2002	WELLBUTRIN 100MG TABLET	83.1%
00173017855	2003	WELLBUTRIN 100MG TABLET	82.7%
00173017855	2004	WELLBUTRIN 100MG TABLET	82.3%
00173017855	2005	WELLBUTRIN 100MG TABLET	91.5%
00173017755	1997	WELLBUTRIN 75MG TABLET	78.4%
00173017755	1998	WELLBUTRIN 75MG TABLET	77.1%
00173017755	1999	WELLBUTRIN 75MG TABLET	72.6%
00173017755	2000	WELLBUTRIN 75MG TABLET	59.6%
00173017755	2001	WELLBUTRIN 75MG TABLET	56.6%
00173017755	2002	WELLBUTRIN 75MG TABLET	87.3%
00173017755	2003	WELLBUTRIN 75MG TABLET	88.0%
00173017755	2004	WELLBUTRIN 75MG TABLET	89.2%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00173017755	2005	WELLBUTRIN 75MG TABLET	94.8%
00173094755	1997	WELLBUTRIN SR 100MG TAB SA	96.4%
00173094755	1998	WELLBUTRIN SR 100MG TAB SA	83.6%
00173094755	1999	WELLBUTRIN SR 100MG TAB SA	56.8%
00173094755	2000	WELLBUTRIN SR 100MG TAB SA	78.9%
00173094755	2001	WELLBUTRIN SR 100MG TAB SA	80.4%
00173094755	2002	WELLBUTRIN SR 100MG TAB SA	77.2%
00173094755	2003	WELLBUTRIN SR 100MG TAB SA	71.5%
00173094755	2004	WELLBUTRIN SR 100MG TAB SA	46.1%
00173094755	2005	WELLBUTRIN SR 100MG TAB SA	57.9%
00173013555	1997	WELLBUTRIN SR 150MG TAB SA	95.7%
00173013555	1998	WELLBUTRIN SR 150MG TAB SA	86.3%
00173013555	1999	WELLBUTRIN SR 150MG TAB SA	57.4%
00173013555	2000	WELLBUTRIN SR 150MG TAB SA	79.5%
00173013555	2001	WELLBUTRIN SR 150MG TAB SA	82.2%
00173013555	2002	WELLBUTRIN SR 150MG TAB SA	79.0%
00173013555	2003	WELLBUTRIN SR 150MG TAB SA	78.6%
00173013555	2004	WELLBUTRIN SR 150MG TAB SA	64.0%
00173013555	2005	WELLBUTRIN SR 150MG TAB SA	59.5%
00173072200	2002	WELLBUTRIN SR 200MG TAB SA	91.0%
00173072200	2003	WELLBUTRIN SR 200MG TAB SA	83.2%
00173072200	2004	WELLBUTRIN SR 200MG TAB SA	84.2%
00173072200	2005	WELLBUTRIN SR 200MG TAB SA	85.7%
00173073001	2003	WELLBUTRIN XL 150MG TABLET	96.4%
00173073001	2004	WELLBUTRIN XL 150MG TABLET	86.5%
00173073001	2005	WELLBUTRIN XL 150MG TABLET	84.7%
00173073101	2003	WELLBUTRIN XL 300MG TABLET	93.0%
00173073101	2004	WELLBUTRIN XL 300MG TABLET	86.9%
00173073101	2005	WELLBUTRIN XL 300MG TABLET	84.5%
00173034414	1997	ZANTAC 150MG TABLET	89.5%
00173034414	1998	ZANTAC 150MG TABLET	85.2%
00173034414	1999	ZANTAC 150MG TABLET	81.9%
00173034414	2000	ZANTAC 150MG TABLET	93.4%
00173034414	2001	ZANTAC 150MG TABLET	75.1%
00173034414	2002	ZANTAC 150MG TABLET	89.2%
00173034414	2003	ZANTAC 150MG TABLET	65.4%
00173034414	2004	ZANTAC 150MG TABLET	94.2%
00173034414	2005	ZANTAC 150MG TABLET	92.8%
00173038354	1997	ZANTAC 15MG/ML SYRUP	63.2%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00173038354	1998	ZANTAC 15MG/ML SYRUP	66.6%
00173038354	1999	ZANTAC 15MG/ML SYRUP	67.7%
00173038354	2000	ZANTAC 15MG/ML SYRUP	77.7%
00173038354	2001	ZANTAC 15MG/ML SYRUP	83.4%
00173038354	2002	ZANTAC 15MG/ML SYRUP	86.1%
00173038354	2003	ZANTAC 15MG/ML SYRUP	79.5%
00173038354	2004	ZANTAC 15MG/ML SYRUP	81.1%
00173038354	2005	ZANTAC 15MG/ML SYRUP	89.0%
00173066400	1999	ZIAGEN 20 MG/ML SOLUTION	70.3%
00173066400	2000	ZIAGEN 20 MG/ML SOLUTION	86.7%
00173066400	2001	ZIAGEN 20 MG/ML SOLUTION	88.7%
00173066400	2002	ZIAGEN 20 MG/ML SOLUTION	90.0%
00173066400	2003	ZIAGEN 20 MG/ML SOLUTION	92.5%
00173066400	2004	ZIAGEN 20 MG/ML SOLUTION	90.5%
00173066400	2005	ZIAGEN 20 MG/ML SOLUTION	89.5%
00173066101	1998	ZIAGEN 300MG TABLET	100.0%
00173066101	1999	ZIAGEN 300MG TABLET	58.0%
00173066101	2000	ZIAGEN 300MG TABLET	78.0%
00173066101	2001	ZIAGEN 300MG TABLET	78.2%
00173066101	2002	ZIAGEN 300MG TABLET	75.4%
00173066101	2003	ZIAGEN 300MG TABLET	78.5%
00173066101	2004	ZIAGEN 300MG TABLET	77.3%
00173066101	2005	ZIAGEN 300MG TABLET	75.3%
00173044600	1997	ZOFRAN 4MG TABLET	75.2%
00173044600	1998	ZOFRAN 4MG TABLET	73.2%
00173044600	1999	ZOFRAN 4MG TABLET	50.7%
00173044600	2000	ZOFRAN 4MG TABLET	76.9%
00173044600	2001	ZOFRAN 4MG TABLET	79.8%
00173044600	2002	ZOFRAN 4MG TABLET	78.7%
00173044600	2003	ZOFRAN 4MG TABLET	73.7%
00173044600	2004	ZOFRAN 4MG TABLET	74.8%
00173044600	2005	ZOFRAN 4MG TABLET	80.6%
00173044604	1997	ZOFRAN 4MG TABLET	93.3%
00173044604	1998	ZOFRAN 4MG TABLET	88.7%
00173044604	1999	ZOFRAN 4MG TABLET	68.3%
00173044604	2000	ZOFRAN 4MG TABLET	92.9%
00173044604	2001	ZOFRAN 4MG TABLET	95.2%
00173044604	2002	ZOFRAN 4MG TABLET	94.4%
00173044604	2003	ZOFRAN 4MG TABLET	94.5%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00173044604	2004	ZOFRAN 4MG TABLET	94.1%
00173044604	2005	ZOFRAN 4MG TABLET	95.3%
00173048900	1997	ZOFRAN 4MG/5ML ORAL SOLN	87.6%
00173048900	1998	ZOFRAN 4MG/5ML ORAL SOLN	66.6%
00173048900	1999	ZOFRAN 4MG/5ML ORAL SOLN	42.6%
00173048900	2000	ZOFRAN 4MG/5ML ORAL SOLN	68.3%
00173048900	2001	ZOFRAN 4MG/5ML ORAL SOLN	68.3%
00173048900	2002	ZOFRAN 4MG/5ML ORAL SOLN	71.0%
00173048900	2003	ZOFRAN 4MG/5ML ORAL SOLN	66.9%
00173048900	2004	ZOFRAN 4MG/5ML ORAL SOLN	63.1%
00173048900	2005	ZOFRAN 4MG/5ML ORAL SOLN	68.6%
00173044700	1997	ZOFRAN 8MG TABLET	77.8%
00173044700	1998	ZOFRAN 8MG TABLET	77.2%
00173044700	1999	ZOFRAN 8MG TABLET	55.3%
00173044700	2000	ZOFRAN 8MG TABLET	77.0%
00173044700	2001	ZOFRAN 8MG TABLET	79.4%
00173044700	2002	ZOFRAN 8MG TABLET	77.4%
00173044700	2003	ZOFRAN 8MG TABLET	77.5%
00173044700	2004	ZOFRAN 8MG TABLET	77.6%
00173044700	2005	ZOFRAN 8MG TABLET	80.1%
00173044704	1997	ZOFRAN 8MG TABLET	95.8%
00173044704	1998	ZOFRAN 8MG TABLET	92.1%
00173044704	1999	ZOFRAN 8MG TABLET	71.7%
00173044704	2000	ZOFRAN 8MG TABLET	91.9%
00173044704	2001	ZOFRAN 8MG TABLET	93.6%
00173044704	2002	ZOFRAN 8MG TABLET	93.2%
00173044704	2003	ZOFRAN 8MG TABLET	94.0%
00173044704	2004	ZOFRAN 8MG TABLET	91.4%
00173044704	2005	ZOFRAN 8MG TABLET	95.3%
00173056900	1999	ZOFRAN ODT 4MG TABLET	52.2%
00173056900	2000	ZOFRAN ODT 4MG TABLET	60.1%
00173056900	2001	ZOFRAN ODT 4MG TABLET	69.0%
00173056900	2002	ZOFRAN ODT 4MG TABLET	70.1%
00173056900	2003	ZOFRAN ODT 4MG TABLET	61.4%
00173056900	2004	ZOFRAN ODT 4MG TABLET	72.8%
00173056900	2005	ZOFRAN ODT 4MG TABLET	76.0%
00173057000	1999	ZOFRAN ODT 8MG TABLET	66.5%
00173057000	2000	ZOFRAN ODT 8MG TABLET	71.5%
00173057000	2001	ZOFRAN ODT 8MG TABLET	74.5%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00173057000	2002	ZOFRAN ODT 8MG TABLET	72.4%
00173057000	2003	ZOFRAN ODT 8MG TABLET	78.2%
00173057000	2004	ZOFRAN ODT 8MG TABLET	77.1%
00173057000	2005	ZOFRAN ODT 8MG TABLET	80.1%
00173095396	1997	ZOVIRAX 200MG/5ML SUSP	86.8%
00173095396	1998	ZOVIRAX 200MG/5ML SUSP	80.4%
00173095396	1999	ZOVIRAX 200MG/5ML SUSP	67.1%
00173095396	2000	ZOVIRAX 200MG/5ML SUSP	67.2%
00173095396	2001	ZOVIRAX 200MG/5ML SUSP	59.2%
00173095396	2002	ZOVIRAX 200MG/5ML SUSP	58.6%
00173095396	2003	ZOVIRAX 200MG/5ML SUSP	68.3%
00173095396	2004	ZOVIRAX 200MG/5ML SUSP	41.4%
00173095396	2005	ZOVIRAX 200MG/5ML SUSP	33.6%
00173099394	1997	ZOVIRAX 5% OINTMENT	85.2%
00173099394	1998	ZOVIRAX 5% OINTMENT	87.4%
00173099394	1999	ZOVIRAX 5% OINTMENT	82.4%
00173099394	2000	ZOVIRAX 5% OINTMENT	87.2%
00173099394	2001	ZOVIRAX 5% OINTMENT	83.8%
00173099394	2002	ZOVIRAX 5% OINTMENT	100.0%
00173099394	2003	ZOVIRAX 5% OINTMENT	100.0%
00173099394	2004	ZOVIRAX 5% OINTMENT	-22.2%
00173099394	2005	ZOVIRAX 5% OINTMENT	100.0%
00173055601	1997	ZYBAN 150MG TABLET SA	99.2%
00173055601	1998	ZYBAN 150MG TABLET SA	93.7%
00173055601	1999	ZYBAN 150MG TABLET SA	68.2%
00173055601	2000	ZYBAN 150MG TABLET SA	86.5%
00173055601	2001	ZYBAN 150MG TABLET SA	87.7%
00173055601	2002	ZYBAN 150MG TABLET SA	84.9%
00173055601	2003	ZYBAN 150MG TABLET SA	79.2%
00173055601	2004	ZYBAN 150MG TABLET SA	68.0%
00173055601	2005	ZYBAN 150MG TABLET SA	24.8%
00173055602	1997	ZYBAN 150MG TABLET SA	98.9%
00173055602	1998	ZYBAN 150MG TABLET SA	93.2%
00173055602	1999	ZYBAN 150MG TABLET SA	65.9%
00173055602	2000	ZYBAN 150MG TABLET SA	78.7%
00173055602	2001	ZYBAN 150MG TABLET SA	84.9%
00173055602	2002	ZYBAN 150MG TABLET SA	79.6%
00173055602	2003	ZYBAN 150MG TABLET SA	76.8%
00173055602	2004	ZYBAN 150MG TABLET SA	69.6%

Table F.1 continued

NDC	Year	Drug detail	Percentage of sales units "at or about" WAC
00173055602	2005	ZYBAN 150MG TABLET SA	38.4%

Table F.2: Year-by-year breakdown of refined Devor methodology calculation of GSK NDCs with 50% or less of the units sold during the relevant period “at or about” WAC

NDC	Year	Drug detail	Percentage of sales units “at or about” WAC
00029604420	1999	AMOXIL 200MG TABLET CHEW	94.8%
00029604420	2000	AMOXIL 200MG TABLET CHEW	91.4%
00029604420	2001	AMOXIL 200MG TABLET CHEW	88.8%
00029604420	2002	AMOXIL 200MG TABLET CHEW	20.9%
00029604420	2003	AMOXIL 200MG TABLET CHEW	-56.0%
00029315918	1999	AVANDIA 4MG TABLET	91.8%
00029315918	2000	AVANDIA 4MG TABLET	73.9%
00029315918	2001	AVANDIA 4MG TABLET	61.9%
00029315918	2002	AVANDIA 4MG TABLET	60.9%
00029315918	2003	AVANDIA 4MG TABLET	42.6%
00029315918	2004	AVANDIA 4MG TABLET	-2.4%
00029315918	2005	AVANDIA 4MG TABLET	-58.6%
00173042702	1997	ZANTAC 150MG EFFERDOSE TAB	48.2%
00173042702	1998	ZANTAC 150MG EFFERDOSE TAB	54.5%
00173042702	1999	ZANTAC 150MG EFFERDOSE TAB	48.2%
00173042702	2000	ZANTAC 150MG EFFERDOSE TAB	53.8%
00173042702	2001	ZANTAC 150MG EFFERDOSE TAB	40.2%
00173042702	2002	ZANTAC 150MG EFFERDOSE TAB	51.4%
00173042702	2003	ZANTAC 150MG EFFERDOSE TAB	45.6%
00173042702	2004	ZANTAC 150MG EFFERDOSE TAB	42.2%
00173042702	2005	ZANTAC 150MG EFFERDOSE TAB	64.3%

Attachment G

**Exhibit 24 (Graphic) to the Deposition of David Brown with
Annotations Showing Percentages of GSK's Sales of the Relevant
NDCs into Each Provider Channel**

Ex. 24 to David Brown Deposition
(with annotations)